
<html lang="en"     class="pb-page"  data-request-id="5901b009-2855-4082-bc0e-6ce378a47bf4"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/jm901710h;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2010.53.issue-5;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Identification of Potent Pyrazolo[4,3-h]quinazoline-3-carboxamides as Multi-Cyclin-Dependent Kinase Inhibitors†" /></meta><meta name="dc.Creator" content="Gabriella  Traquandi" /></meta><meta name="dc.Creator" content="Marina  Ciomei" /></meta><meta name="dc.Creator" content="Dario  Ballinari" /></meta><meta name="dc.Creator" content="Elena  Casale" /></meta><meta name="dc.Creator" content="Nicoletta  Colombo" /></meta><meta name="dc.Creator" content="Valter  Croci" /></meta><meta name="dc.Creator" content="Francesco  Fiorentini" /></meta><meta name="dc.Creator" content="Antonella  Isacchi" /></meta><meta name="dc.Creator" content="Antonio  Longo" /></meta><meta name="dc.Creator" content="Ciro  Mercurio" /></meta><meta name="dc.Creator" content="Achille  Panzeri" /></meta><meta name="dc.Creator" content="Wilma  Pastori" /></meta><meta name="dc.Creator" content="Paolo  Pevarello" /></meta><meta name="dc.Creator" content="Daniele  Volpi" /></meta><meta name="dc.Creator" content="Patrick  Roussel" /></meta><meta name="dc.Creator" content="Anna  Vulpetti" /></meta><meta name="dc.Creator" content="Maria Gabriella  Brasca" /></meta><meta name="dc.Description" content="Abnormal proliferation mediated by disruption of the mechanisms that keep the cell cycle under control is a hallmark of virtually all cancer cells. Compounds targeting complexes between cyclin-depe..." /></meta><meta name="Description" content="Abnormal proliferation mediated by disruption of the mechanisms that keep the cell cycle under control is a hallmark of virtually all cancer cells. Compounds targeting complexes between cyclin-depe..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 8, 2010" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm901710h" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2010 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm901710h" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm901710h" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm901710h" /></link>
        
    
    

<title>Identification of Potent Pyrazolo[4,3-h]quinazoline-3-carboxamides as Multi-Cyclin-Dependent Kinase Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm901710h" /></meta><meta property="og:title" content="Identification of Potent Pyrazolo[4,3-h]quinazoline-3-carboxamides as Multi-Cyclin-Dependent Kinase Inhibitors†" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0016.jpeg" /></meta><meta property="og:description" content="Abnormal proliferation mediated by disruption of the mechanisms that keep the cell cycle under control is a hallmark of virtually all cancer cells. Compounds targeting complexes between cyclin-dependent kinases (CDKs) and cyclins (Cy) and inhibiting their activity are regarded as promising antitumor agents to complement the existing therapies. An expansion of pyrazolo[4,3-h]quinazoline chemical class oriented to the development of three points of variability was undertaken leading to a series of compounds able to inhibit CDKs both in vitro and in vivo. Starting from the CDK selective but poorly soluble hit compound 1, we succeeded in obtaining several compounds showing enhanced inhibitory activity both on CDKs and on tumor cells and displaying improved physical properties and pharmacokinetic behavior. Our study led to the identification of compound 59 as a highly potent, orally bioavailable CDK inhibitor that exhibited significant in vivo efficacy on the A2780 ovarian carcinoma xenograft model. The demonstrated mechanisms of action of compound 59 on cancer cell lines and its ability to inhibit tumor growth in vivo render this compound very interesting as potential antineoplastic agent." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm901710h"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm901710h">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm901710h&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm901710h&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm901710h&amp;href=/doi/10.1021/jm901710h" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2010</span><span class="cit-fg-volume">, 53</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 2171-2187</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/53/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm901705h" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm901727j" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Identification of Potent Pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamides as Multi-Cyclin-Dependent Kinase Inhibitors<a class="ref internalNav" href="#fn1" aria-label="†">†</a></span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gabriella++Traquandi">Gabriella Traquandi</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marina++Ciomei">Marina Ciomei</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dario++Ballinari">Dario Ballinari</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Elena++Casale">Elena Casale</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nicoletta++Colombo">Nicoletta Colombo</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Valter++Croci">Valter Croci</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Francesco++Fiorentini">Francesco Fiorentini</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Antonella++Isacchi">Antonella Isacchi</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Antonio++Longo">Antonio Longo</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ciro++Mercurio">Ciro Mercurio</a></span><span class="author-xref-symbol "><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Achille++Panzeri">Achille Panzeri</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wilma++Pastori">Wilma Pastori</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paolo++Pevarello">Paolo Pevarello</a></span><span class="author-xref-symbol "><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniele++Volpi">Daniele Volpi</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Patrick++Roussel">Patrick Roussel</a></span><span class="author-xref-symbol "><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anna++Vulpetti">Anna Vulpetti</a></span><span class="author-xref-symbol "><sup>#</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Maria+Gabriella++Brasca">Maria Gabriella Brasca</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Nerviano Medical Sciences Srl, Business Unit Oncology, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Accelera Srl, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span></div><div class="corresp-fn" id="fn1">†Coordinates of the CDK2 complex with compound 59 have been deposited in the Protein Data Bank under accession code 2WXV, together with the corresponding structure factor files.</div><div class="corresp-info"><strong>*</strong>To whom correspondence should be addressed. Phone: +39-0331-581330. Fax: +39-0331-581347. E-mail: <a href="/cdn-cgi/l/email-protection#8aedebe8f8e3efe6e6eba4fef8ebfbffebe4eee3cae4eff8fce3ebe4e5e7f9a4e9e5e7"><span class="__cf_email__" data-cfemail="82e5e3e0f0ebe7eeeee3acf6f0e3f3f7e3ece6ebc2ece7f0f4ebe3ecedeff1ace1edef">[email protected]</span></a></div><div class="corresp-fn" id="afn2">§Present address: Genextra Group, Milano, Italy.</div><div class="corresp-fn" id="afn3">∥Present address: Newron, Milano, Italy.</div><div class="corresp-fn" id="afn4">⊥Present address: Basilea Pharmaceutica LTD, Switzerland.</div><div class="corresp-fn" id="afn5">#Present address: Novartis Pharma AG, Basel, Switzerland.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm901710h&amp;href=/doi/10.1021%2Fjm901710h" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2010</span></span><span class="cit-volume">, 53</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 2171–2187</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 8, 2010</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>18 November 2009</li><li><span class="item_label"><b>Published</b> online</span>8 February 2010</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 March 2010</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm901710h" title="DOI URL">https://doi.org/10.1021/jm901710h</a></div><div class="article_header-article-copyright"><strong>Copyright © 2010 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2171%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DGabriella%2BTraquandi%252C%2BMarina%2BCiomei%252C%2BDario%2BBallinari%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D53%26issueNum%3D5%26contentID%3Djm901710h%26title%3DIdentification%2Bof%2BPotent%2BPyrazolo%255B4%252C3-h%255Dquinazoline-3-carboxamides%2Bas%2BMulti-Cyclin-Dependent%2BKinase%2BInhibitors%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2187%26publicationDate%3DMarch%2B2010">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm901710h"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2807</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">26</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm901710h" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Identification of Potent Pyrazolo[4,3-h]quinazoline-3-carboxamides as Multi-Cyclin-Dependent Kinase Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Gabriella&quot;,&quot;last_name&quot;:&quot;Traquandi&quot;},{&quot;first_name&quot;:&quot;Marina&quot;,&quot;last_name&quot;:&quot;Ciomei&quot;},{&quot;first_name&quot;:&quot;Dario&quot;,&quot;last_name&quot;:&quot;Ballinari&quot;},{&quot;first_name&quot;:&quot;Elena&quot;,&quot;last_name&quot;:&quot;Casale&quot;},{&quot;first_name&quot;:&quot;Nicoletta&quot;,&quot;last_name&quot;:&quot;Colombo&quot;},{&quot;first_name&quot;:&quot;Valter&quot;,&quot;last_name&quot;:&quot;Croci&quot;},{&quot;first_name&quot;:&quot;Francesco&quot;,&quot;last_name&quot;:&quot;Fiorentini&quot;},{&quot;first_name&quot;:&quot;Antonella&quot;,&quot;last_name&quot;:&quot;Isacchi&quot;},{&quot;first_name&quot;:&quot;Antonio&quot;,&quot;last_name&quot;:&quot;Longo&quot;},{&quot;first_name&quot;:&quot;Ciro&quot;,&quot;last_name&quot;:&quot;Mercurio&quot;},{&quot;first_name&quot;:&quot;Achille&quot;,&quot;last_name&quot;:&quot;Panzeri&quot;},{&quot;first_name&quot;:&quot;Wilma&quot;,&quot;last_name&quot;:&quot;Pastori&quot;},{&quot;first_name&quot;:&quot;Paolo&quot;,&quot;last_name&quot;:&quot;Pevarello&quot;},{&quot;first_name&quot;:&quot;Daniele&quot;,&quot;last_name&quot;:&quot;Volpi&quot;},{&quot;first_name&quot;:&quot;Patrick&quot;,&quot;last_name&quot;:&quot;Roussel&quot;},{&quot;first_name&quot;:&quot;Anna&quot;,&quot;last_name&quot;:&quot;Vulpetti&quot;},{&quot;first_name&quot;:&quot;Maria&quot;,&quot;last_name&quot;:&quot;Gabriella Brasca&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2010&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;08&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;53&quot;,&quot;pages&quot;:&quot;2171-2187&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm901710h&quot;},&quot;abstract&quot;:&quot;Abnormal proliferation mediated by disruption of the mechanisms that keep the cell cycle under control is a hallmark of virtually all cancer cells. Compounds targeting complexes between cyclin-dependent kinases (CDKs) and cyclins (Cy) and inhibiting their activity are regarded as promising antitumor agents to complement the existing therapies. An expansion of pyrazolo[4,3-h]quinazoline chemical class oriented to the development of three points of variability was undertaken leading to a series of compounds able to inhibit CDKs both in vitro and in vivo. Starting from the CDK selective but poorly soluble hit compound 1, we succeeded in obtaining several compounds showing enhanced inhibitory activity both on CDKs and on tumor cells and displaying improved physical properties and pharmacokinetic behavior. Our study led to the identification of compound 59 as a highly potent, orally bioavailable CDK inhibitor that exhibited significant in vivo efficacy on the A2780 ovarian carcinoma xenograft model. The demonstrat&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm901710h&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm901710h" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm901710h&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm901710h" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm901710h&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm901710h" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm901710h&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm901710h&amp;href=/doi/10.1021/jm901710h" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm901710h" /></input><a href="/doi/pdf/10.1021/jm901710h" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm901710h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm901710h%26sid%3Dliteratum%253Aachs%26pmid%3D20141146%26genre%3Darticle%26aulast%3DTraquandi%26date%3D2010%26atitle%3DIdentification%2Bof%2BPotent%2BPyrazolo%255B4%252C3-h%255Dquinazoline-3-carboxamides%2Bas%2BMulti-Cyclin-Dependent%2BKinase%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D53%26issue%3D5%26spage%3D2171%26epage%3D2187%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291305" title="Cell physiology">Cell physiology</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291454" title="Solubility">Solubility</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/53/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/medium/jm-2009-01710h_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901710h&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Abnormal proliferation mediated by disruption of the mechanisms that keep the cell cycle under control is a hallmark of virtually all cancer cells. Compounds targeting complexes between cyclin-dependent kinases (CDKs) and cyclins (Cy) and inhibiting their activity are regarded as promising antitumor agents to complement the existing therapies. An expansion of pyrazolo[4,3-<i>h</i>]quinazoline chemical class oriented to the development of three points of variability was undertaken leading to a series of compounds able to inhibit CDKs both in vitro and in vivo. Starting from the CDK selective but poorly soluble hit compound <b>1</b>, we succeeded in obtaining several compounds showing enhanced inhibitory activity both on CDKs and on tumor cells and displaying improved physical properties and pharmacokinetic behavior. Our study led to the identification of compound <b>59</b> as a highly potent, orally bioavailable CDK inhibitor that exhibited significant in vivo efficacy on the A2780 ovarian carcinoma xenograft model. The demonstrated mechanisms of action of compound <b>59</b> on cancer cell lines and its ability to inhibit tumor growth in vivo render this compound very interesting as potential antineoplastic agent.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22775" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22775" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Progression through the different phases of the eukaryotic cell cycle has been shown to be critically dependent on a family of proteins known as cyclin-dependent kinases (CDKs<a class="ref internalNav" href="#fnabbrev" aria-label="a">a</a>), which specifically form heterodimeric complexes with regulatory subunits named cyclins (Cy).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Different CDK/Cy complexes finely regulate each cell cycle phase transition: CDK2/CyE, CDK4/CyD, and CDK6/CyD primarily regulate passage through the G1 phase and the transition from G1 to S phase, while CDK2/CyA and CDK1/CyA primarily execute their critical function during the S phase and control progression through the G2 phase. CDK1/CyB complex intervenes then as a key initiator of the M phase or mitosis. These CDKs phosphorylate a wide variety of proteins whose function is required over the cell cycle, thereby modulating their activity and consequently affecting cell growth and survival by several mechanisms.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> A second group of CDKs, which include CDK7, CDK8, and CDK9, is involved in transcriptional regulation so that while these CDKs do not directly impinge on the cell cycle, their inhibition can however affect the expression of several cell cycle regulators and mitotic regulatory kinases, as well as of apoptosis mediators. Another member of the family, CDK5, plays a critical role in neuronal and secretory cell function.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Interphase CDK/Cy complexes cooperate in phosphorylating the retinoblastoma protein (pRb), thereby converting it from a repressor to an activator of transcription factors that mediate the transcription of genes required for DNA synthesis.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> pRb function is impaired in most human neoplasms and loss in pRb repressive activity is a consequence of CDK hyperactivation. Aberrant cell proliferation that occurs in the majority of human malignancies can often be attributed to a loss of the correct cell cycle control and in fact a variety of genetic and epigenetic events can cause global overactivation of the cell cycle.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Therefore, the development of agents able to modulate CDK activity may have a strong impact on the prevention and therapy of cancer.<div class="NLM_fn" id="fnabbrev">a<p class="last">Abbreviations: CDK, cyclin-dependent kinase; Cy, cyclin; CDK2/CyA, (cyclin-dependent kinase 2)/(cyclin A); Aur-A, Aurora A; pRb, retinoblastoma protein; CKI, cyclin-dependent kinase inhibitor; GSK-3β, glycogen synthase kinase 3β; ERK2, extracellular signal-regulated kinase 2; ADME, adsorption-distribution-metabolism-excretion; PK, pharmacokinetics; CL, clearance; <i>V</i><sub>ss</sub>, distribution volume; AUC, area under curve; <i>F</i>, oral bioavailability; BrdU, bromodeoxyuridine; EDC, <i>N</i>-(3-dimethylaminopropyl)-<i>N</i>′-ethyl-carbodiimide hydrochloride; HOBT, 1-hydroxybenzotriazole; HOBT·NH<sub>3</sub>, 1-hydroxybenzotriazole ammonium salt; DIPEA, <i>N</i>,<i>N</i>-diisopropyl-<i>N</i>-ethylamine; TGI, tumor growth inhibition; PAMPA, parallel artificial membrane permeability assay; ECACC, european collection of cell cultures; FBS, fetal calf serum; PBS, phosphate buffered saline; RNase A, ribonuclease A.</p></div></div><div class="NLM_p">The cell produces also specific inhibitors of CDKs known as cyclin-dependent kinase inhibitors (CKIs), which directly compete with ATP for binding to the CDK active site.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> In some cancer types, under-expression of these endogenous CKIs has been demonstrated and these findings have solicited the effort of medicinal chemists aimed at replacing CKIs with synthetic small molecule inhibitors. The first CDK inhibitors evaluated in clinical trials were Flavopiridol (L868275)<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> and 7-hydroxystaurosporine (UCN-01).<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> The first one has been granted orphan drug status for the treatment of chronic lymphocytic leukemia. A second generation of CDK inhibitors endowed with higher selectivity have also entered clinical trials, such as Roscovitine (CYC-202)<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and BMS-387032,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> targeting primarily CDK2, but also CDK7 and 9 and PD0332991,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> targeting CDK4 and 6. Recently, several studies have suggested that CDKs and their cyclin partners can substitute and compensate for one another, leading to the notion that the inhibition of more than one CDK might be necessary to sustain the suppression of tumor growth.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> For example, CDK1 is able to replace CDK2 in the case of its absence or inhibition. Indeed, more recent products under clinical study are endowed with a multi-CDK inhibitor activity, such as AT7519<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> (CDK1, 2, 4, and 5 inhibitor), R547<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> (CDK1, 2, and 4 inhibitor), SCH-727965<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> (CDK1, 2, 5, and 9 inhibitor), and AZD5597<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> (CDK1, 2, and 9 inhibitor).</div><div class="NLM_p">We recently reported on a series of pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamides as CDK inhibitors.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17, 18)</a> Previous expansion of this class led to the identification of PHA-848125 as a potent, orally available compound, mainly targeting CDK2 and TRKA, currently undergoing phase II clinical trials. Further exploring this class (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) with the objective to obtain a multi-CDK inhibitor, we identified compound <b>1</b>, endowed with an interesting activity profile: CDK2/CyA IC<sub>50</sub> = 0.051 μM, CDK2/CyE IC<sub>50</sub> = 0.074 μM, CDK1/CyB IC<sub>50</sub> = 0.120 μM, CDK5 IC<sub>50</sub> = 0.049 μM. Compound <b>1</b> presented a significant selectivity when evaluated on a panel of 35 serine-threonine and tyrosine kinases (data not shown) but only a moderate antiproliferative activity in A2780 human ovarian carcinoma cells (IC<sub>50</sub> = 0.933 μM) and very low solubility (<1.0 μM). An expansion program based on the development of three diversity points of the scaffold, R<sup>1</sup>, R<sup>2</sup>, and R<sup>3</sup>, was then undertaken aimed at obtaining more potent compounds both on CDKs and on tumor cells, with improved physical properties and pharmacokinetic profile.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/medium/jm-2009-01710h_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of pyrazolo[4,3-<i>h</i>]quinazoline scaffold and hit compound <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901710h&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00811" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00811" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthetic route to prepare the new pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide series started from compound <b>2</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>), a key intermediate for the development of this chemical class, whose synthesis we have previously described.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17, 18)</a> In a first approach, the pyrimidine moiety was built by condensation of compound <b>2</b> with <i>S</i>-methylisothiourea, affording 2-thiomethylpyrimidino derivative <b>3</b>, that was submitted to ammonolysis to give carboxamide <b>4</b>. The latter was then oxidized with oxone to the corresponding sulfonyl derivative <b>5</b>, suitable for introducing diversity point R<sup>3</sup> by nucleophilic substitution, thus, affording final compounds <b>1</b>, <b>14</b>, <b>19</b>−<b>26</b>, and <b>28</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/medium/jm-2009-01710h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Final Compounds <b>1</b>, <b>14</b>, <b>19</b>−<b>26</b>, and <b>28</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901710h&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>S</i>-methylisothiourea, AcOK, DMF, 90 °C, 74%; (b) NH<sub>4</sub>OH, MeOH-DMF, 80 °C, 52%; (c) oxone, DMF, rt, 80%; (d) R<sup>3</sup>NH<sub>2</sub>, DMSO, 50−120 °C, 40−72%.</p></p></figure><div class="NLM_p">The low solubility of intermediate <b>5</b>, together with the moderate reactivity of the methansulfonyl group toward nucleophilic substitution, prompted us to carry out step d in dimethylsulfoxide at high temperatures. In some cases, partial aromatization of the scaffold central ring occurred in these conditions, lowering yields and complicating the product purification process.</div><div class="NLM_p">An alternative route was also designed to overcome these issues exploiting the trifluoromethanesulfonate moiety, which being a better leaving group than the methansulfonyl group, would have allowed to carry out the reaction more efficiently already at room temperature, thus, avoiding the central ring oxidation side reaction. The synthetic pathway to obtain the proper intermediate entailed the condensation of <b>2</b> with <i>O</i>-methylisourea, providing derivative <b>6</b> (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>), which afforded, through methoxy group hydrolysis, intermediate <b>7</b>. The triflate <b>8</b> was finally obtained by reaction with trifluoromethansulfonic anhydride. Substituted amino groups were introduced in intermediate <b>8</b> by nucleophilic substitution with the proper amine, followed by transformation of the ester group into amide. This step was performed by hydrolysis of the carbetoxy group under basic conditions to the corresponding potassium carboxylate, followed by condensation with <i>N</i>-hydroxy-benzotriazole ammonium salt, as a synthetic equivalent of ammonia, to give the final amides <b>18</b> and <b>29</b>. Alternatively, final compounds were obtained by ammonolysis with ammonium hydroxide (<b>27</b>, <b>48</b>) or by aminolysis with methylamine (<b>30</b>, <b>47</b>, <b>49</b>).</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/medium/jm-2009-01710h_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Final Compounds <b>18</b>, <b>27</b>,<b> 29</b>, <b>30</b>, and <b>47</b>−<b>49</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901710h&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>O</i>-methylisourea, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, reflux, 16 h, 80%; (b) trimethylsilyl chloride, NaI, rt, 8 h, 78%; (c) trifluoromethansulfonic anhydride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, from −78 °C to rt, 5 h, 67%; (d) R<sup>3</sup>NH<sub>2</sub>, dioxane, rt, 70−85%; (e) EtOH, KOH, reflux, 75−80%; HOBT·NH<sub>3</sub>, EDC, DIPEA, DMF-THF, rt, 61−73%; (f) NH<sub>4</sub>OH, MeOH-DMF, 70 °C, 60%; (g) CH<sub>3</sub>NH<sub>2</sub>, EtOH, 60 °C, 50−78%.</p></p></figure><div class="NLM_p">Diversity point R<sup>3</sup> could also be introduced in the scaffold by condensing the versatile intermediate <b>2</b> with guanidine to give compound <b>9</b> (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>) that allowed the preparation of <b>10a</b> and <b>10b</b>, by ammonolysis or by aminolysis with methylamine, respectively. R<sup>3</sup> was introduced either starting from <b>10a</b>, by reductive amination with the suitable arylaldehyde giving final compounds <b>15</b>−<b>17</b>, or starting from <b>10b</b> by reductive amination with the proper cycloalkylketone, thus, affording final compounds <b>51</b>, <b>53</b>, <b>55</b>, <b>57</b>, <b>59</b>, and <b>61</b>.</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/medium/jm-2009-01710h_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Final Compounds <b>15</b>−<b>17</b>, <b>31</b>−<b>36</b>, and <b>50</b>−<b>61</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901710h&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) guanidine hydrochloride, EtONa, EtOH, reflux, 12 h, 85%; (b) NH<sub>4</sub>OH, MeOH-DMF, 70 °C, 50−65%; (c) CH<sub>3</sub>NH<sub>2</sub>, EtOH, 60 °C, 78%; (d) ArCHO, NaBH<sub>3</sub>CN, AcOH−MeOH−H<sub>2</sub>O 1/1/1, rt, 58−62%; (e) cycloalkylketone, NaBH(OAc)<sub>3</sub>, TFA, DMF, rt, 50−73%; (f) KOH, EtOH, reflux; R<sup>1</sup>NH<sub>2</sub>, EDC, HOBT, DIPEA, DMF-THF, rt, 31−51%; (g) KOH, EtOH, reflux; HOBT·NH<sub>3</sub>, EDC, DIPEA, DMF-THF, rt, 43−49%; (h) KOH, EtOH, reflux; (COCl)<sub>2</sub>, R<sup>1</sup>NHOH, rt, 36−62%.</p></p></figure><div class="NLM_p">In some cases, for reactivity reasons, it was profitable to invert the order of the sequence steps so that R<sup>3</sup> was first introduced into the scaffold from intermediate <b>9</b> via reductive amination with the suitable cycloalkylketone, then the R<sup>1</sup> diversity point was constructed by several methodologies. Thus, ammonolysis with ammonium hydroxide afforded compounds <b>54</b> and <b>58</b>, while basic hydrolysis to the corresponding carboxylic acids followed either by condensation with the suitable amine or with HOBT·NH<sub>3</sub> provided compounds <b>31</b>−<b>33</b> and <b>50</b>, <b>52</b>, <b>56</b>, and <b>60</b>, respectively. Alternatively, a sequence of basic hydrolysis, acyl chloride formation and reaction with the proper substituted hydroxylamine afforded compounds <b>34</b>−<b>36</b>.</div><div class="NLM_p">The diversity point R<sup>2</sup> was regioselectively introduced into the pyrazole moiety of the scaffold by condensation of compound <b>11</b>, prepared as previously described,<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17, 18)</a> with the suitable substituted hydrazine, providing intermediates <b>12a</b>−<b>i</b> (Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>); reaction of <b>12a</b>−<b>i</b> with <i>N</i>,<i>N</i>-dimethylformamide di-<i>tert</i>-butyl acetale, followed by condensation with guanidine hydrochloride afforded compounds <b>13a</b>−<b>i</b>. R<sup>3</sup> was then introduced in the scaffold from <b>13a</b>−<b>i</b> by reductive amination with cyclopentyl ketone and R<sup>1</sup> diversity point was finally built by ammonolysis with ammonium hydroxide (<b>37</b>−<b>44</b> and <b>46</b>) or by aminolysis with methylamine (<b>45</b>).</div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/medium/jm-2009-01710h_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Final Compounds <b>37</b>−<b>46</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901710h&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) R<sup>2</sup>NHNH<sub>2</sub>, AcOH, rt, 63−80%; (b) dimethylformamide di-<i>tert</i>-butylacetale, DMF, 60 °C; guanidine hydrochloride, EtONa, EtOH, reflux, 45−72%; (c) cyclopentylketone, NaBH(OAc)<sub>3</sub>, TFA, DMF, rt, 65−80%; (d) NH<sub>4</sub>OH, MeOH-DMF, 70 °C, 75−80%; (e) CH<sub>3</sub>NH<sub>2</sub>, EtOH, 60 °C, 78%.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52320" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52320" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We initially focused our attention on R<sup>3</sup> modifications by pursuing a synthetic strategy that allowed the introduction of this group in a late step, thus, enabling a convenient parallel approach (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). While the unsubstituted compound <b>10a</b> did not show any biological activity, benzyl derivative <b>1</b> showed an interesting activity profile, suggesting that the involved diversity point deserved a more in-depth investigation. In this perspective a series of substituted arylmethyl and heteroarylmethyl derivatives (<b>14</b>−<b>23)</b> were synthesized. Within this series several compounds (<b>14</b>−<b>18</b> and <b>20</b>−<b>23</b>) showed good activity on CDK2/CyA that was used as a sensor of compound activity toward the CDK family and, in several cases, also good selectivity, based on their potency ratio relative to Aur-A being >20×. Indeed, Aur-A, consistently with its similarity to CDK2 in its ATP binding pocket, was the most frequently cross-affected kinase in the selectivity panel used to characterize our compounds and, therefore, in the SAR tables, Aur-A IC<sub>50</sub> will be reported as an index of selectivity. Unfortunately, good activity on CDK2/CyA and good selectivity were generally accompanied by poor solubility (<b>14</b>−<b>17</b>) and low antiproliferative activity on cells, with the exception of compounds <b>16</b>, <b>17</b>, and <b>19</b>, which showed an IC<sub>50</sub> < 1 μM. To improve the solubility, some alkyl derivatives bearing hydrophilic or basic groups were also prepared (<b>24</b>−<b>26</b>), which still displayed, with the exception of <b>26</b>, good inhibitory potency on the enzyme and selectivity versus Aur-A, but their activity on cells was poor. Conversely, exploration of the subclass of cycloalkyl derivatives (<b>27</b>−<b>29</b>) was quite promising. Good solubility was achieved with compound <b>28</b>, but its potency against CDK2/CyA was the lowest in this subclass; instead, derivatives <b>27</b> and <b>29</b>, even though still scarcely soluble, were potent enzyme inhibitors and, in addition, showed a significant improvement in the antiproliferative activity in A2780 human ovarian carcinoma cells and an excellent selectivity. Based on its potency on the enzyme and on cells, we selected compound <b>29</b>, bearing a cyclopentyl group as R<sup>3</sup>, as an interesting hit from which to start further expansion. An investigation of the R<sup>1</sup> and R<sup>2</sup> role on a series of cyclopentyl derivatives was then accomplished (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). We could observe that activity on CDK2/CyA was negatively affected upon increasing R<sup>1</sup> steric hindrance. In fact, secondary amides bearing small substituents such as methyl (<b>30</b>) displayed interesting activity as CDK2/CyA inhibitors, whereas bulkier residues (<b>31</b>−<b>33</b>) caused a marked decrease in activity on the enzyme complex, even though an improvement in the solubility in neutral buffer was observed. Hydroxamate derivatives (<b>34</b>−<b>36</b>) conserved a certain affinity for the enzyme, but poor activity on cells and low solubility were observed for these conpounds.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. R<sup>3</sup> Preliminary Exploration<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/medium/jm-2009-01710h_0010.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table single-image" border="0"><colgroup><col /></col></colgroup><tbody><tr valign="top"><td><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/medium/jm-2009-01710h_0011.gif" alt="" id="fx2" /></img></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Values are the means of two or more experiments.</p></div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. R<sup>2</sup> and R<sup>1</sup> Modification<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/medium/jm-2009-01710h_0012.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table single-image" border="0"><colgroup><col /></col></colgroup><tbody><tr valign="top"><td><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/medium/jm-2009-01710h_0013.gif" alt="" id="fx4" /></img></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Values are the means of two or more experiments.</p></div></div></div><div class="NLM_p">R<sup>2</sup> modulation provided compounds endowed with significant activity on the enzyme (<b>37</b>−<b>46</b>) and also on cells (<b>37</b>−<b>38</b>, <b>40</b>, <b>42</b>−<b>44</b>, and <b>46</b>) and good selectivity versus Aur-A. Some derivatives showed a very poor solubility (<b>37</b>−<b>40</b>, <b>42</b>, and <b>43</b>), while the solubility parameter was improved for compounds bearing hydrophilic or basic substituents (<b>41</b> and <b>44</b>−<b>46</b>). Nevertheless, we observed that R<sup>2</sup> modification caused a general loss of selectivity within the kinase panel (data not shown). We could conclude that a bulky R<sup>2</sup> was tolerated and was suitable to modulate the solubility but could be critical for the selectivity and moreover did not represent a significant advantage with respect to methyl, in terms of atom economy and synthetic complexity. A more focused study of the R<sup>3</sup> substituent role was then undertaken by a further expansion of the cycloalkyl derivative subclass. In this perspective, compounds with R<sup>1</sup> as either hydrogen or methyl and R<sup>2</sup> as methyl (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>) were synthesized. We could observe that secondary methylamides (<b>49</b>, <b>51</b>, <b>53</b>, <b>55</b>, and <b>57</b>), although having good solubility, were less potent than the corresponding primary amides (<b>48</b>, <b>50</b>, <b>52</b>, <b>54</b>, and <b>56</b>) both on enzyme and on cells. Interestingly, compounds <b>58</b>−<b>61</b> showed good activity against CDK2/CyA and in A2780 cell proliferation assay. As far as buffer solubility is concerned, compound <b>59</b>, albeit less potent than compound <b>58</b> on cells, displayed higher solubility. Compounds <b>50</b>, <b>52</b>, and <b>59</b> were then selected for further assessment on the basis of their potency on the enzyme, antiproliferative activity, and preliminary solubility in neutral buffer.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. R<sup>3</sup> and R<sup>1</sup> Optimization<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/medium/jm-2009-01710h_0014.gif" alt="" id="fx5" /></img><div class="scrollable-table-wrap"><table class="table single-image" border="0"><colgroup><col /></col></colgroup><tbody><tr valign="top"><td><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/medium/jm-2009-01710h_0015.gif" alt="" id="fx6" /></img></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Values are the means of two or more experiments.</p></div></div></div><div class="NLM_p">The three selected hits were subsequently screened against a panel of 55 serine-threonine and tyrosine kinases and results are reported in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>. Concerning the members of the CDK family that were part of the panel, compounds <b>50</b>, <b>52</b>, and <b>59</b> turned out to be potent inhibitors of CDK2/CyA, CDK2/CyE, CDK1/CyB, and CDK5/p25, and to inhibit also CDK4/CyD1, although with lower potency. Among all the other enzymes in the panel, only GSK-3β (ratio vs CDK2/CyA of 14×, 16×, and 179×, respectively, for <b>50</b>, <b>52</b>, and <b>59</b>), and ERK2 (106×, 75×, and 311×, respectively) were inhibited in the high nanomolar range, while Aur-A was inhibited in a submicromolar range (ratio vs CDK2/CyA of 223×) only by <b>52</b>. All the other tested kinases were substantially not inhibited (IC<sub>50</sub> > 10 μM).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Selectivity Profile of Compounds <b>50</b>, <b>52</b>, and <b>59</b><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top"><th align="center">kinase</th><th align="center"><b>50</b></th><th align="center"><b>52</b></th><th align="center"><b>59</b></th></tr></thead><tbody><tr valign="top"><td align="left">CDK2/CyA</td><td align="left">0.002</td><td align="left">0.003</td><td align="left">0.002</td></tr><tr valign="top"><td align="left">CDK2/CyE</td><td align="left">0.007</td><td align="left">0.016</td><td align="left">0.008</td></tr><tr valign="top"><td align="left">CDK1/CyB</td><td align="left">0.005</td><td align="left">0.006</td><td align="left">0.006</td></tr><tr valign="top"><td align="left">CDK5/p25</td><td align="left">0.009</td><td align="left">0.010</td><td align="left">0.006</td></tr><tr valign="top"><td align="left">CDK4/CyD1</td><td align="left">nd</td><td align="left">0.350</td><td align="left">0.176</td></tr><tr valign="top"><td align="left">GSK-3β</td><td align="left">0.028</td><td align="left">0.048</td><td align="left">0.358</td></tr><tr valign="top"><td align="left">ERK2</td><td align="left">0.212</td><td align="left">0.226</td><td align="left">0.622</td></tr><tr valign="top"><td align="left">Aur-A</td><td align="left">>10</td><td align="left">0.67</td><td align="left">3.565</td></tr><tr valign="top"><td align="left">other kinases<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td align="left">>10</td><td align="left">>10</td><td align="left">>10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Values are the means of two or more experiments.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">c-ABL, ACK1, ALK, AKT1, Aur-B, BRK, BUB1, CDC7/DBF4, CHK1, CK2, EEF2K, EGFR, FAK, FGFR1, FLT3, IGF1R, IKK1, IKK2, IR, JAK1, JAK3, C-KIT, LCK, LYN, MAPKAPK2, MET, MNK2, MST4, NEK6, NIM, PAK4, PDGFR, PDK1, PERK, PIM1, PIM2, PKAα, PKCβ, PLK1, RET, SYK, SULU1, TYK, TRKA, VEGFR2, VEGFR3, ZAP70.</p></div></div></div><div class="NLM_p">We focused our attention on compound <b>59</b> as the most potent and selective multi-CDK inhibitor in the series. Its distinctive selectivity profile was explained by obtaining the crystal structure of the compound in complex with CDK2/CyA (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). The amino-pyrimidine group is anchored at the hinge region by two hydrogen bonds to the nitrogen and oxygen backbone atoms of Leu83, while the carbonyl oxygen of the amide forms a hydrogen bond with the conserved Lys33. Interaction between the amide nitrogen and the carboxyl group of Asp145 that generally is present for compounds bearing a primary amide (data not shown) is lost for this compound because the secondary amide adopts a CIS conformation. This conformation can explain the experimental data indicating that amide steric hindrance tends to negatively affect activity on CDK2. The methansulfonyl group of the piperidine ring makes a hydrogen bond with backbone nitrogen of Asp86 and an additional weak interaction with Lys89, which is solvent exposed and very flexible. Interestingly, the piperidine ring or more generally a cycloalkyl ring is detrimental for activity against Aur-A and therefore crucial for compound selectivity. This moiety occupies the solvent accessible region, a part of the ATP pocket where Aur-A and CDK2 are structurally different for the presence of an inserted glycine (Gly216) in Aur-A that is absent in CDK2.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> This additional residue in Aur-A induces a different protein conformation between the hinge region and the beginning of the C-terminal domain, which in combination with the presence of Leu139 (CDK2 Ile10) and Thr217 (CDK2 Asp86), tends to render the accommodation of nonplanar groups less favorable. In contrast, the CDK2 pocket, probably due to a better shape complementarity, can well tolerate a cycloalkyl ring.</div><figure id="fig2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/medium/jm-2009-01710h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Crystal structure of selected compound <b>59</b> in complex with CDK2/CyA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901710h&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The pharmacological profile of compound <b>59</b> was then characterized in depth.</div><div class="NLM_p">The effects of compound <b>59</b> on the cell cycle progression and DNA synthesis were analyzed using flow cytometry analysis and BrdU incorporation, respectively, on A2780 ovarian carcinoma cells in exponential growth in the presence or absence of compound, for 24 h, at 1 and 3 μM. Compound <b>59</b> modulates cell cycle with an increase in G2/M phase and a reduction in S phase as expected for an inhibitor able to block both CDK2 and CDK1 activity. The reduction of S phase population was linked to a strong reduction of the percentage of BrdU incorporating cells, meaning that DNA synthesis in these cells was impaired (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). In addition, the effect on the phosphorylation status of a known CDK substrate such as pRb was analyzed in cells treated with compound <b>59</b> at 1 and 3 μM. A clear reduction of the hyperphosphorylated form of pRb was observed in the extracts of treated cells in comparison with the untreated cells, confirming the inhibitory effect exerted by the compound on the activity of CDK2 (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>).</div><figure id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/medium/jm-2009-01710h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effects of compound <b>59</b> on cell cycle progression and DNA synthesis after 24 h treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901710h&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/medium/jm-2009-01710h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Decrease of pRb phosphorylation induced by compound <b>59</b> in cells after 24 h treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901710h&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Analysis of the cell cycle profile, DNA synthesis, and CDK2 substrate phosphorylation status were consistent with an antiproliferative effect mediated by multi-CDK inhibition.</div><div class="NLM_p">A preliminary in vitro ADME study (solubility in 5% dextrose, stability to human CYP4503A4, plasma protein binding, or PPB) was accomplished and in vivo pharmacokinetic data were determined as key-parameters. As reported in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>, compound <b>59</b> revealed high metabolic stability to human CYP4503A4 (88% remaining), good plasma protein binding (69% bound), good solubility (4.0 mg/mL in 5% dextrose as hydrochloric salt), and good permeability (PAMPA and Caco2 cells).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. In Vitro ADME for Selected Compound <b>59</b><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="justify" /></col><col align="justify" /></col><col align="left" /></col><col align="justify" /></col><col align="justify" /></col><col align="justify" /></col></colgroup><thead><tr valign="top"><th colspan="6" align="center">preliminary in vitro ADME</th></tr><tr valign="top"><th align="center">CL<sub>intr</sub> hepatocytes mL/min/kg</th><th align="center">PAMPA permeability 10<sup>−6</sup> cm/sec</th><th align="center">Caco2 cells permeability</th><th align="center">solubility 5% dextrose (mg/mL)</th><th align="center">CYP4503A4 (% remaining)</th><th align="center">PPB (%)</th></tr></thead><tbody><tr valign="top"><td align="justify">5</td><td align="justify">11.9</td><td align="left">high</td><td align="justify">4.0</td><td align="justify">88</td><td align="justify">69</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Dosed in 5% dextrose as hydrochloride salt.</p></div></div></div><div class="NLM_p">The compound, after intravenous administration, showed a low clearance (CL), which accounted for approximately 15% of the hepatic blood flow. The volume of distribution (<i>V</i><sub>ss</sub> 2-fold of the total body water) suggested a good tissue distribution. The terminal half-life was 1.7 h. After oral administration at a dose of 10 mg/kg, compound <b>59</b> showed high oral bioavailability (55%) with an AUC of 15.31 μM·h, <i>C</i><sub>max</sub> of 2.87 μM, and half-life of 3.4 h (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). Overall, compound <b>59</b> showed low clearance, suitable volume of distribution, and high oral bioavailability in the experimental conditions used in the study.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. In Vivo Pharmacokinetic Parameters for Selected Compound <b>59</b><a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="justify" /></col><col align="justify" /></col><col align="justify" /></col><col align="justify" /></col><col align="justify" /></col><col align="justify" /></col><col align="justify" /></col></colgroup><thead><tr valign="top"><th colspan="3" align="center">in vivo PK (mouse) 10 mg/kg iv</th><th colspan="4" align="center">in vivo PK (mouse) 10 mg/kg os</th></tr><tr valign="top"><th align="center"><i>t</i><sub>1/2</sub> (h)</th><th align="center">CL (mL/h/kg)</th><th align="center"><i>V</i><sub>ss</sub> (mL/kg)</th><th align="center"><i>t</i><sub>1/2</sub> (h)</th><th align="center"><i>C</i><sub>max</sub> (μM)</th><th align="center">AUC (os; μM·h)</th><th align="center"><i>F</i> (%)</th></tr></thead><tbody><tr valign="top"><td align="justify">1.7</td><td align="justify">814.2</td><td align="justify">1390.2</td><td align="justify">3.4</td><td align="justify">2.87</td><td align="justify">15.31</td><td align="justify">55.4</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Dosed in 5% dextrose as hydrochloride salt.</p></div></div></div><div class="NLM_p">On the basis of the data presented above, compound <b>59</b> proceeded to further in vivo characterization in the human A2780 xenograft mouse model. The doses of 5, 10, and 20 mg/kg were selected and administered orally twice a day, for 10 consecutive days (on days 8−17 from tumor cell injection). A pharmacokinetic analysis was also performed in a satellite group of three mice after the last oral administration at 20 mg/kg twice a day, for 10 consecutive days, and confirmed the good and dose-proportional exposure obtained with the compound <b>59</b> (AUC = 56.21 μM·h; <i>C</i><sub>max</sub> of 6.40 μM). Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a> illustrates the results from this study. Compound <b>59</b> caused a dose-dependent inhibition of A2780 tumor growth up to 75% at the dose of 20 mg/kg on day 18 (<i>P</i> < 0.0001 vs control group, Mann−Whitney U-test) and a corresponding tumor growth delay of 6.4 days.</div><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/medium/jm-2009-01710h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>59</b> shows 38, 46, and 75% tumor growth inhibition (TGI) against a human ovarian cancer model (A2780) transplanted into nude mice when orally administered respectively at doses of 5 (square), 10 (triangle), and 20 (cross) mg/kg bid for 10 consecutive days. Vehicle-treated (control) curve is reported with open circles.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901710h&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76430" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76430" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Exploration of the pyrazoloquinazoline class focused on R<sup>1</sup>, R<sup>2</sup>, and R<sup>3</sup> modifications afforded several compounds that showed good potency as multi-CDK inhibitors, good selectivity when tested on a panel of serine-threonine and tyrosine kinases, and antiproliferative activity in A2780 human ovarian carcinoma cells. Optimization of the physical properties and pharmacokinetic profile led to the identification of the highly potent, orally available compound <b>59</b>. Analysis of the cell cycle profile, DNA synthesis, and CDK2 substrate phosphorylation status were consistent with an antiproliferative effect mediated by multi-CDK inhibition. The compound exhibited good efficacy in vivo on A2780 xenograft model when orally administered at dose of 20 mg/kg bid for 10 consecutive days. The complete pharmacological profile of compound <b>59</b> will be reported in a separate paper.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77028" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77028" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Chemistry</h3><div class="NLM_p last">All solvents and reagents, unless otherwise stated, were commercially available, of the best grade, and were used without further purification. All experiments dealing with moisture-sensitive compounds were conducted under dry nitrogen or argon. Organic solutions were evaporated using a Heidolph WB 2001 rotary evaporator at 15−20 mmHg. Thin-layer chromatography was performed on Merck silica gel 60 F<sub>254</sub> precoated plates. Column chromatography was conducted either under medium pressure on silica (Merck silica gel 40−63 μm) or on prepacked silica gel cartridges (Biotage). Components were visualized by UV light (λ: 254 nm) and by iodine vapor. <sup>1</sup>H NMR spectra were recorded at a constant temperature of 28 °C on a Varian INOVA 400 spectrometer operating at 400.45 MHz and equipped with a 5 mm Indirect Detection PFG Probe (<sup>1</sup>H{<sup>1</sup>5N−<sup>31</sup>P}). Chemical shifts were referenced with respect to the residual solvent signals (DMSO-<i>d</i><sub>6</sub>: 2.50 ppm for <sup>1</sup>H). Data are reported as follows: chemical shift (δ), multiplicity (s = singlet, bs = broad signal, d = doublet, t = triplet, q = quartet, quin = quintet, sxt = sixtet, dd = doublet of doublets, ddd = doublet of doublet of doublets, dt = doublet of triplets, td = triplet of doublets, m = multiplet), coupling constants (Hz), and number of protons. Electrospray (ESI) mass spectra were obtained on a Finnigan LCQ ion trap. Unless otherwise specified, all final compounds were homogeneous (purity of not less than 95%), as determined by high-performance liquid chromatography (HPLC). HPLC-UV-MS analyses, used to assess compound purity, were carried out combining the ion trap MS instrument with HPLC system SSP4000 (Thermo Separation Products) equipped with an autosampler LC Pal (CTC Analytics) and UV6000LP diode array detector (UV detection 215−400 nm). Instrument control, data acquisition and processing were performed by using Xcalibur 1.2 software (Finnigan). HPLC chromatography was run at room temperature, and 1 mL/min flow rate, using a Waters X Terra RP 18 column (4.6 × 50 mm; 3.5 μm). Mobile phase A was ammonium acetate 5 mM buffer (pH 5.5 with acetic acid)/acetonitrile 90:10, and mobile phase B was ammonium acetate 5 mM buffer (pH 5.5 with acetic acid)/acetonitrile 10:90; the gradient was from 0 to 100% B in 7 min then hold 100% B for 2 min before re-equilibration. ESI(+) high resolution mass spectra (HRMS) were obtained on a Waters Q-Tof Ultima directly connected with micro-HPLC 1100 Agilent as previously described.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Elemental analyses were performed on a Carlo Erba 1110 instrument, and C, H, and N results were within ±0.4% of theoretical values unless specified. All reactants were commercially available or were prepared as previously described.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Ethyl 1-Methyl-8-(methylsulfanyl)-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxylate (<b>3</b>)</h3><div class="NLM_p last">To a solution of ethyl (6<i>E</i>)-6-[(dimethylamino)methylidene]-1-methyl-7-oxo-4,5,6,7-tetrahydro-1<i>H</i>-indazole-3-carboxylate <b>2</b> (9.0 g, 69 mmol, prepared according to ref <a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">17</a>) in dry DMF (350 mL), dry potassium acetate (13.4 g, 138 mmol), and <i>S</i>-methylisothiourea sulfate (19.18 g, 69 mmol) were added. The mixture was maintained at 90 °C under stirring for 8 h. The solvent was then evaporated, the residue dissolved with dichloromethane and washed with water. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. The crude was finally triturated with diethyl ether and collected by filtration to give <b>3</b> (15.5 g, 74%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.31 (t, <i>J</i> = 7.1 Hz, 3H), 2.56 (s, 3H), 2.91 (m, 2H), 3.00 (m, 2H), 4.29 (d, <i>J</i> = 7.1 Hz, 2H), 4.33 (s, 3H), 8.55 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 305 (M + H)<sup>+</sup>.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> 1-Methyl-8-(methylsulfanyl)-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>4</b>)</h3><div class="NLM_p last">A suspension of <b>3</b> (13.0 g, 0.043 mol) in a mixture of methanol (200 mL), DMF (200 mL), and 33% NH<sub>4</sub>OH (200 mL) was stirred at 65 °C in a closed bottle for about 8 h. The solvent was then evaporated to dryness, the residue dissolved with dichloromethane and washed with water. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. The crude was purified by flash chromatography on a silica gel column (cyclohexane/ethyl acetate, 8/2), giving <b>4</b> (6.16 g, 52%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 2.56 (s, 3H), 2.88 (m, 2H), 3.01 (m, 2H), 4.30 (s, 3H), 7.27 (bs, 1H), 7.36−7.69 (m, 1H), 8.53 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 276 (M + H)<sup>+</sup>.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> 1-Methyl-8-(methylsulfonyl)-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>5</b>)</h3><div class="NLM_p last">A solution of <b>4</b> (6.0 g, 0.022 mol) in DMF (1000 mL) and potassium monopersulfate triple salt (oxone, 40.57 g, 0.066 mol) was stirred at room temperature for 16 h. Water and ethyl acetate were then added and the layers separated. The organic phase was finally dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. The residue was triturated with diethyl ether and <b>5</b> (5.40 g, 80%) was collected by filtration. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 3.08 (s, 4H), 3.45 (s, 3H), 4.31 (s, 3H), 7.33 (bs, 1H), 7.55 (bs, 1H), 8.93 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 308 (M + H)<sup>+</sup>.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> 8-(Benzylamino)-1-methyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>1</b>)</h3><div class="NLM_p">To a solution of <b>5</b> (400 mg, 1.30 mmol) in dry DMSO (20 mL), benzylamine (0.28 mL, 2.60 mmol) was added. After 6 h at 95 °C under nitrogen atmosphere, the solvent was evaporated. The residue was then dissolved with dichloromethane and washed with water. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated to dryness. By chromatography on a silica gel column (dichloromethane/acetone, 9/1) <b>1</b> was obtained (304 mg, 70%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 2.68−2.76 (m, 2H), 2.84−2.99 (m, 2H), 4.16 (bs, 3H), 4.53 (d, <i>J</i> = 6.2 Hz, 2H), 7.15−7.23 (m, 2H), 7.25−7.35 (m, 4H), 7.40 (bs, 1H), 7.68 (bs, 1H), 8.21 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 335 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>18</sub>H<sub>18</sub>N<sub>6</sub>O + H<sup>+</sup>, 335.1615; found, 335.1610; Anal. (C<sub>18</sub>H<sub>18</sub>N<sub>6</sub>O) C, H, N.</div><div class="NLM_p last">Compounds <b>14</b>, <b>19</b>−<b>26</b>, and <b>28</b>. By employment of the above-described procedure, starting from <b>5</b> and using the suitable amine, compounds <b>14</b>, <b>19</b>−<b>26</b>, and <b>28</b> were prepared.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> 8-[(3-Methoxybenzyl)amino]-1-methyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>14</b>)</h3><div class="NLM_p last">Yield, 72%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 2.71 (t, <i>J</i> = 7.6 Hz, 2H), 2.92 (t, <i>J</i> = 7.6 Hz, 2H), 3.71 (s, 3H), 4.17 (s, 3H), 4.49 (d, <i>J</i> = 6.3 Hz, 2H), 6.73−6.80 (m, 1H), 6.89 (d, <i>J</i> = 1.3 Hz, 1H), 6.89−6.92 (m, 1H), 7.15−7.28 (m, 2H), 7.39 (s, 1H), 7.66 (t, <i>J</i> = 6.6 Hz, 1H), 8.21 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 365 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>19</sub>H<sub>20</sub>N<sub>6</sub>O<sub>2</sub> + H<sup>+</sup>, 365.1721; found, 365.1725; Anal. (C<sub>19</sub>H<sub>20</sub>N<sub>6</sub>O<sub>2</sub> C, H, N.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 1-Methyl-8-{[3-(4-methylpiperazin-1-yl)benzyl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>19</b>)</h3><div class="NLM_p last">Yield, 66%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 2.21 (s, 3H), 2.43 (m, 4H), 2.67−2.75 (m, 2H), 2.86−2.97 (m, 2H), 3.05−3.12 (m, 4H), 4.19 (s, 3H), 4.46 (d, <i>J</i> = 6.2 Hz, 2H), 6.72−6.80 (m, 2H), 6.89−6.96 (m, 1H), 7.08−7.16 (m, 1H), 7.21 (s, 1H), 7.40 (s, 1H), 7.62 (s, 1H), 8.21 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 433 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>23</sub>H<sub>28</sub>N<sub>8</sub>O + H<sup>+</sup>, 433.2459; found, 433.2454; Anal. (C<sub>23</sub>H<sub>28</sub>N<sub>8</sub>O) C, H, N.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 1-Methyl-8-{[4-(4-methylpiperazin-1-yl)benzyl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>20</b>)</h3><div class="NLM_p last">Yield, 68%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 2.26 (bs, 3H), 2.43−2.56 (m, 4H), 2.71 (m, 2H), 2.92 (m, 2H), 3.09 (s, 4H), 4.21 (s, 3H), 4.42 (d, <i>J</i> = 6.2 Hz, 2H), 6.86 (d, <i>J</i> = 8.7 Hz, 2H), 7.18 (d, <i>J</i> = 8.7 Hz, 2H), 7.21 (s, 1H), 7.40 (t, 1H), 7.56 (t, <i>J</i> = 6.1 Hz, 1H), 8.20 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 433 (M + H)<sup>+</sup>; Anal. (C<sub>23</sub>H<sub>28</sub>N<sub>8</sub>O) C, H, N.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 1-Methyl-8-[(pyridin-4-ylmethyl)amino]-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>21</b>)</h3><div class="NLM_p last">Yield, 45%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 2.68−2.78 (m, 2H), 2.86−2.98 (m, 2H), 4.07 (bs, 3H), 4.54 (d, <i>J</i> = 6.2 Hz, 2H), 7.21 (bs, 1H), 7.27−7.34 (m, 2H), 7.40 (bs, 1H), 7.78 (t, <i>J</i> = 6.8 Hz, 1H), 8.22 (s, 1H), 8.38−8.54 (m, 2H); LCMS (ESI) <i>m</i>/<i>z</i> 336 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>17</sub>H<sub>17</sub>N<sub>7</sub>O + H<sup>+</sup>, 336.1568; found, 336.1572; Anal. (C<sub>17</sub>H<sub>17</sub>N<sub>7</sub>O) C, H, N.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 1-Methyl-8-[(pyridin-3-ylmethyl)amino]-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>22</b>)</h3><div class="NLM_p last">Yield, 40%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 2.68−2.97 (m, 4H), 4.16 (s, 3H), 4.55 (d, <i>J</i> = 6.2 Hz, 2H), 7.21 (s, 1H), 7.32 (dd, <i>J</i> = 7.8, 4.7 Hz, 1H), 7.40 (s, 1H), 7.63−7.81 (m, 1H), 7.72 (dt, <i>J</i> = 7.7, 1.8 Hz, 1H), 8.23 (s, 1H), 8.42 (dd, <i>J</i> = 4.7, 1.5 Hz, 1H), 8.55 (d, <i>J</i> = 1.8 Hz, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 342 (M + H)<sup>+</sup>; Anal. (C<sub>17</sub>H<sub>17</sub>N<sub>7</sub>O) C, H, N.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 1-Methyl-8-[(pyridin-2-ylmethyl)amino]-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>23</b>)</h3><div class="NLM_p last">Yield, 42%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 2.68−2.76 (m, 2H), 2.92 (m, 2H), 4.04 (bs, 3H), 4.60 (d, <i>J</i> = 6.1 Hz, 2H), 7.10−7.28 (m, 2H), 7.31 (d, <i>J</i> = 7.8 Hz, 1H), 7.39 (bs, 1H), 7.71 (td, <i>J</i> = 7.6, 1.83 Hz, 2H), 8.22 (s, 1H), 8.47−8.50 (m, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 336 (M + H)<sup>+</sup>; Anal. (C<sub>17</sub>H<sub>17</sub>N<sub>7</sub>O) C, H, N.</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 1-Methyl-8-{[2-(morpholin-4-yl)ethyl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-h]quinazoline-3-carboxamide (<b>24</b>)</h3><div class="NLM_p last">Yield, 46%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 2.41 (m, 4H), 2.67−2.77 (m, 2H), 2.88−3.02 (m, 2H), 3.43 (q, <i>J</i> = 6.5 Hz, 2H), 3.57 (m, 4H), 4.30 (s, 3H), 6.92 (t, <i>J</i> = 5.9 Hz, 1H), 7.22 (bs, 1H), 7.41 (bs, 1H), 8.20 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 358 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>17</sub>H<sub>23</sub>N<sub>7</sub>O<sub>2</sub> + H<sup>+</sup>, 358.1986; found, 358.1971; Anal. (C<sub>17</sub>H<sub>23</sub>N<sub>7</sub>O<sub>2</sub>) C, H, N.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 8-[(2-Hydroxyethyl)amino]-1-methyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>25</b>)</h3><div class="NLM_p last">Yield, 48%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 2.67−2.98 (m, 4H), 3.34−3.60 (m, 4H), 4.29 (s, 3H), 4.65 (s, 1H), 6.95 (t, <i>J</i> = 5.7 Hz, 1H), 7.22 (s, 1H), 7.41 (s, 1H), 8.19 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 289 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>13</sub>H<sub>16</sub>N<sub>6</sub>O<sub>2</sub> + H<sup>+</sup>, 289.1408; found, 289.1410; Anal. (C<sub>13</sub>H<sub>16</sub>N<sub>6</sub>O<sub>2</sub>) C, H, N.</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 1-Methyl-8-{[2-(piperidin-1-yl)ethyl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>26</b>)</h3><div class="NLM_p last">Yield, 40%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.38 (m, 2H), 1.44−1.58 (m, 4H), 2.38 (bs, 4H), 2.46 (bs, 2H), 2.72 (m, 2H), 2.93 (m, 2H), 3.41 (q, <i>J</i> = 6.3 Hz, 2H), 4.30 (s, 3H), 6.86 (bs, 1H), 7.22 (bs, 1H), 7.41 (bs, 1H), 8.20 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 356 (M + H)<sup>+</sup>; Anal. (C<sub>18</sub>H<sub>25</sub>N<sub>7</sub>O) C, H, N.</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 8-[(1-Ethylpiperidin-4-yl)amino]-1-methyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>28</b>)</h3><div class="NLM_p last">Yield, 63%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.00 (t, <i>J</i> = 7.2 Hz, 3H), 1.42−1.57 (m, 2H), 1.86−1.93 (m, 2H), 1.93−2.02 (m, 2H), 2.33 (q, <i>J</i> = 7.2 Hz, 2H), 2.71 (t, <i>J</i> = 7.6 Hz, 2H), 2.87 (m, 2H), 2.93 (t, <i>J</i> = 7.62 Hz, 2H), 3.57−3.76 (m, 1H), 4.29 (s, 3H), 6.98 (d, <i>J</i> = 7.9 Hz, 1H), 7.21 (s, 1H), 7.42 (s, 1H), 8.19 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 356 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>18</sub>H<sub>25</sub>N<sub>7</sub>O M + H<sup>+</sup>, 356.2193; found, 356.2184.</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Ethyl 8-Methoxy-1-methyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxylate (<b>6</b>)</h3><div class="NLM_p last">To a solution of <b>2</b> (2.0 g, 7.2 mmol) in acetonitrile (200 mL), <i>O-</i>methylisourea sulfate (17.4 g, 70.6 mmol) and potassium carbonate (10.0 g, 72.4 mmol) were added. The reaction mixture was stirred at reflux for 16 h. The solvent was then evaporated, and the residue was dissolved with dichloromethane and washed with water. The organic layer was dried over dry Na<sub>2</sub>SO<sub>4</sub> and concentrated. After flash chromatography on a silica gel column (dichloromethane) <b>6</b> was obtained (1.7 g, 80%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.31 (t, <i>J</i> = 7.1 Hz, 3H), 2.87−2.93 (m, 2H), 2.99 (m, 2H), 3.95 (s, 3H), 4.29 (q, <i>J</i> = 7.1 Hz, 2H), 4.33 (s, 3H), 8.52 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 289 (M + H)<sup>+</sup>.</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Ethyl 8-Hydroxy-1-methyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxylate (<b>7</b>)</h3><div class="NLM_p last">To a solution of <b>6</b> (1.5 g, 5.2 mmol) in acetonitrile (90 mL), sodium iodide (1.6 g, 10.6 mmol), and trimethylsilylchloride (1.5 mL, 12 mmol) were added in sequence. After 24 h under stirring and nitrogen atmosphere at room temperature, the solvent was evaporated, and the residue was dissolved with a mixture dichloromethane/methanol 4/1 and washed with a saturated aqueous solution of sodium thiosulfate. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated to dryness. The residue was crystallized from methanol leading <b>7</b> (1.1 g, 78%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.30 (t, <i>J</i> = 7.1 Hz, 3H), 2.71 (m, 1H), 2.93 (m, 1H), 4.29 (q, <i>J</i> = 7.1 Hz, 2H), 4.27 (s, 3H), 7.85 (s, 1H), 11.69 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 275 (M + H)<sup>+</sup>; HPLC purity 80%.</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Ethyl 1-Methyl-8-{[(trifluoromethyl)sulfonyl]oxy}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxylate (<b>8</b>)</h3><div class="NLM_p last">A solution of <b>7</b> (0.60 g, 2.19 mmol) and triethylamine (0.31 mL, 2.19 mmol) in dichloromethane (60 mL) was stirred at −78 °C for 5 h. After this time, trifluoromethansulfonic anhydride (0.72 mL, 2.19 mmol) was added. The reaction was stirred overnight and allowed to come to room temperature, washed with aqueous NaHCO<sub>3</sub>, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated to dryness. The residue was triturated with diethyl ether/acetone and <b>8</b> was collected by filtration (0.60 g, 67%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.31 (t, <i>J</i> = 7.1 Hz, 3H), 3.07 (s, 4H), 4.27 (s, 3H), 4.31 (q, <i>J</i> = 7.1 Hz, 2H), 8.84 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 407 (M + H)<sup>+</sup>.</div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 1-Methyl-8-{[4-(methylsulfonyl)benzyl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>18</b>)</h3><div class="NLM_p last">A solution of <b>8</b> (1.5 g, 3.69 mmol) and 4-methylsulfonyl benzylamine hydrochloride (1.6 g, 7.38 mmol) in dry 1,4-dioxane (100 mL) was stirred at room temperature for 6 h, then the solvent was removed in vacuo. The residue was taken up with dichloromethane and washed with aqueous NaHCO<sub>3</sub>. The organic layer was then dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. The crude was triturated with diethyl ether and filtered, giving ethyl 1-methyl-8-{[4-(methylsulfonyl)benzyl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxylate (2.3 g, 70%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.29 (t, <i>J</i> = 7.1 Hz, 3H), 2.75 (t, <i>J</i> = 7.6 Hz, 2H), 2.91 (t, <i>J</i> = 7.6 Hz, 2H), 3.16 (s, 3H), 4.08 (s, 3H), 4.27 (q, <i>J</i> = 7.1 Hz, 2H), 4.62 (d, <i>J</i> = 6.2 Hz, 2H), 7.58 (d, <i>J</i> = 8.5 Hz, 2H), 7.86 (m, 3H), 8.24 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 442 (M + H)<sup>+</sup>. HRMS (ESI) calcd for C<sub>21</sub>H<sub>23</sub>N<sub>5</sub>O<sub>4</sub>S + H<sup>+</sup>, 442.1543; found, 442.1543. A suspension of the above-described ethyl carboxylate (2.0 g, 4.54 mmol) in dry ethanol (40 mL) was treated with a 1.5 M solution of KOH in ethanol (9.10 mL, 13.62 mmol) at reflux temperature for 2 h. After cooling in an ice bath, the resulting precipitate was collected by filtration to give potassium 1-methyl-8-{[4-(methylsulfonyl)benzyl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxylate (1.54 g, 75%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 2.63 (t, <i>J</i> = 7.6 Hz, 2H), 2.87 (t, <i>J</i> = 7.6 Hz, 2H), 3.16 (s, 3H), 3.97 (s, 3H), 4.60 (d, <i>J</i> = 6.1 Hz, 2H), 7.58 (d, <i>J</i> = 8.4 Hz, 2H), 7.67 (t, <i>J</i> = 6.3 Hz, 1H), 7.85 (d, <i>J</i> = 8.4 Hz, 2H), 8.13 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 414 (M + H)<sup>+</sup>. HRMS (ESI): calcd for C<sub>19</sub>H<sub>19</sub>N<sub>5</sub>O<sub>4</sub>S + H<sup>+</sup>, 414.1231; found, 414.1234. A solution of the above-described carboxylic acid potassium salt (298 mg, 0.66 mmol) was dissolved in a mixture of dry DMF (5 mL) and dry THF (5 mL). After cooling to 0 °C, <i>N</i>,<i>N</i>-diisopropyl-<i>N</i>′-ethylamine (DIPEA; 0.46 mL, 2.64 mmol) and <i>N</i>-(3-dimethylaminopropyl)-<i>N</i>′-ethylcarbodiimide hydrochloride (EDC; 380 mg, 1.98 mmol) were added in sequence to the solution. The reaction mixture was maintained at the same temperature for 30 min and then <i>N</i>-hydroxybenzotriazole ammonium salt (HOBT·NH<sub>3</sub>; 300 mg, 1.98 mmol) was added under stirring. The mixture was warmed to room temperature and kept at this temperature overnight. The solvent was then evaporated and the residue taken up with dichloromethane and washed with aqueous NaHCO<sub>3</sub>. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and the solvent removed in vacuo. After trituration with diethyl ether, <b>18</b> (167 mg, 61%) was collected by filtration. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 2.72 (m, 2H), 2.92 (m, 2H), 3.16 (s, 3H), 4.07 (bs, 3H), 4.62 (d, <i>J</i> = 6.2 Hz, 2H), 7.21 (bs, 1H), 7.39 (bs, 1H), 7.58 (d, <i>J</i> = 8.5 Hz, 2H), 7.79−7.84 (m, 1H), 7.86 (d, <i>J</i> = 8.5 Hz, 2H), 8.22 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 413 (M + H)<sup>+</sup>; HPLC purity 90%.</div></div><div id="sec5_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 8-(Cyclopentylamino)-1-methyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>29</b>)</h3><div class="NLM_p last">By employment of the above-described procedure, starting from <b>8</b>, and using cyclopentylamine, compound <b>29</b> was prepared. Yield, 55%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.47−1.78 (m, 6H), 1.86−1.99 (m, 2H), 2.71 (m, 2H), 2.93 (t, <i>J</i> = 7.6 Hz, 2H), 4.08−4.20 (m, 1H), 4.31 (s, 3H), 7.06 (d, <i>J</i> = 6.8 Hz, 1H), 7.22 (s, 1H), 7.41 (s, 1H), 8.19 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 313 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>16</sub>H<sub>20</sub>N<sub>6</sub>O + H<sup>+</sup>, 313.1772; found, 313.1774.</div></div><div id="sec5_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 8-(Cyclohexylamino)-1-methyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>27</b>)</h3><div class="NLM_p last">A solution of <b>8</b> (1.5 g, 3.69 mmol) and cyclohexylamine (0.84 mL, 7.33 mmol) in dry 1,4-dioxane (100 mL) was stirred at room temperature for 6 h, and then the solvent was removed in vacuo. The residue was taken up with dichloromethane and washed with aqueous NaHCO<sub>3</sub>. The organic layer was then dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. The crude was triturated with diethyl ether and filtered, giving ethyl 8-(cyclohexylamino)-1-methyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxylate (1.07 g, 82%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.06−1.35 (m, 5H), 1.30 (t, <i>J</i> = 7.1 Hz, 3H), 1.53−1.64 (m, 1H), 1.68−1.78 (m, 2H), 1.85−2.01 (m, 2H), 2.74 (t, <i>J</i> = 7.6 Hz, 2H), 2.92 (t, <i>J</i> = 7.6 Hz, 2H), 3.60−3.75 (m, 1H), 4.28 (q, <i>J</i> = 7.1 Hz, 2H), 4.32 (s, 3H), 6.96 (d, <i>J</i> = 5.4 Hz, 1H), 8.19 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 356 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>19</sub>H<sub>25</sub>N<sub>5</sub>O<sub>2</sub> + H<sup>+</sup>, 356.2081; found, 356.2081. A solution of the above-described ethyl carboxylate (250 mg, 0.70 mmol) in a mixture of methanol (10 mL), DMF (10 mL), and 33% NH<sub>4</sub>OH (5 mL) was stirred at 70 °C in a closed bottle for 8 h. The solvent was removed under reduced pressure and the residue dissolved with dichloromethane and washed with water. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. The crude was purified by flash chromatography on a silica gel column (dichloromethane/methanol) affording <b>27</b> (137 mg, 60%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.05−1.42 (m, 5H), 1.54−1.99 (m, 5H), 2.71 (t, <i>J</i> = 7.6 Hz, 2H), 2.93 (t, <i>J</i> = 7.6 Hz, 2H), 3.61−3.78 (m, 1H), 4.29 (s, 3H), 6.93 (d, <i>J</i> = 6.9 Hz, 1H), 7.21 (s, 1H), 7.42 (s, 1H), 8.18 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 327 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>17</sub>H<sub>22</sub>N<sub>6</sub>O + H<sup>+</sup>, 327.1928; found, 327.1928; Anal. (C<sub>17</sub>H<sub>22</sub>N<sub>6</sub>O) C, H, N.</div></div><div id="sec5_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 1-Methyl-8-[(1-methylpiperidin-4-yl)amino]-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>48</b>)</h3><div class="NLM_p last">By employment of the above-described procedure, starting from <b>8</b>, and using 1-methylpiperidin-4-yl-amine, compound <b>48</b> was prepared. Yield, 50%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.44−1.64 (m, 2H), 1.89 (m, 2H), 1.96−2.08 (m, 2H), 2.20 (s, 3H), 2.71 (t, <i>J</i> = 7.6 Hz, 2H), 2.79 (m, 2H), 2.93 (t, <i>J</i> = 7.6 Hz, 2H), 3.58−3.73 (m, 1H), 4.29 (s, 3H), 6.99 (d, <i>J</i> = 6.3 Hz, 1H), 7.21 (s, 1H), 7.42 (s, 1H), 8.19 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 342 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>17</sub>H<sub>23</sub>N<sub>7</sub>O<sub>4</sub> + H<sup>+</sup>, 342.2037; found, 342.2024.</div></div><div id="sec5_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 8-(Cyclohexylamino)-<i>N</i>-1-dimethyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>47</b>)</h3><div class="NLM_p">A solution of ethyl 8-(cyclohexylamino)-1-methyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxylate (200 mg, 0.56 mmol), prepared as described for the synthesis of compound <b>27</b> in a mixture of ethanol (30 mL) and 33 wt % methylamine (10 mL) in absolute ethanol, was stirred at 60 °C in a closed bottle for 8 h. The solvent was then removed in vacuo and the crude purified by flash chromatography on a silica gel column (dichloromethane/methanol/triethylamine 95/5/5) affording <b>47</b> (149 mg, 78%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.24 (m, 4H), 1.61 (m, 2H), 1.75 (m, 2H), 1.94 (m, 2H), 2.70−2.74 (m, 2H), 2.75 (d, <i>J</i> = 4.7 Hz, 3H), 2.95 (m, 2H), 3.69 (m, 1H), 4.31 (s, 3H), 6.94 (d, <i>J</i> = 5.6 Hz, 1H), 8.06 (q, <i>J</i> = 4.7 Hz, 1H), 8.20 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 341 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>18</sub>H<sub>24</sub>N<sub>6</sub>O + H<sup>+</sup>, 341.2084; found, 341.2089.</div><div class="NLM_p last">By employment of the above-described procedure, starting from <b>8</b>, and using the suitable amine, compounds <b>30</b> and <b>49</b> were prepared.</div></div><div id="sec5_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 8-(Cyclopentylamino)-<i>N</i>-1-dimethyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>30</b>)</h3><div class="NLM_p last">Yield, 51%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.43−1.79 (m, 6H), 1.87−2.03 (m, 2H), 2.74 (d, <i>J</i> = 4.7 Hz, 3H), 2.77 (t, <i>J</i> = 7.6 Hz, 2H), 2.98 (t, <i>J</i> = 7.6 Hz, 2H), 4.19 (s, 1H), 4.30 (s, 3H), 7.67−7.90 (m, 1H), 8.10 (q, <i>J</i> = 4.7 Hz, 1H), 8.22 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 327 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>17</sub>H<sub>22</sub>N<sub>6</sub>O + H<sup>+</sup>, 327.1928; found, 327.1933; HPLC purity 95%.</div></div><div id="sec5_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> <i>N</i>-1-Dimethyl-8-[(1-methylpiperidin-4-yl)amino]-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>49</b>)</h3><div class="NLM_p last">Yield, 50%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.46−1.60 (m, 2H), 1.88 (m, 2H), 1.98−2.07 (m, 2H), 2.20 (s, 3H), 2.68−2.75 (m, 2H), 2.73 (d, <i>J</i> = 4.7 Hz, 3H), 2.76−2.82 (m, 2H), 2.93 (t, <i>J</i> = 7.6 Hz, 2H), 3.61−3.73 (m, 1H), 4.29 (s, 3H), 6.99 (d, <i>J</i> = 7.6 Hz, 1H), 8.04 (q, <i>J</i> = 4.7 Hz, 1H), 8.19 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 356 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>18</sub>H<sub>25</sub>N<sub>7</sub>O + H<sup>+</sup>, 356.2193; found, 356.2176; HPLC purity 95%.</div></div><div id="sec5_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Ethyl 8-Amino-1-methyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxylate (<b>9</b>)</h3><div class="NLM_p last">To a solution of <b>2</b> (16.0 g, 0.06 mol) in ethanol (600 mL), sodium ethylate (3.90 g, 0.06 mol) and guanidine hydrochloride (5.44 g, 0.06 mol) were added in sequence. The mixture was stirred under reflux for 12 h. The solvent was then evaporated, the residue taken up with dichloromethane and washed with water. The organic layer was then dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was triturated with diethyl ether and <b>9</b> was collected by filtration (13.9 g, 85%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.30 (t, <i>J</i> = 7.1 Hz, 3H), 2.74 (m, 2H), 2.92 (m, 2H), 4.28 (q, <i>J</i> = 7.1 Hz, 2H), 4.32 (s, 3H), 6.56 (s, 2H), 8.18 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 274 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>13</sub>H<sub>15</sub>N<sub>5</sub>O<sub>2</sub> + H<sup>+</sup>, 274.1298; found, 274.1299.</div></div><div id="sec5_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 8-Amino-1-methyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>10a</b>)</h3><div class="NLM_p last">A suspension of <b>9</b> (300 mg, 1.1 mmol) in a mixture of 33% NH<sub>4</sub>OH (20 mL), methanol (20 mL), and DMF (10 mL) was stirred at 65 °C for 16 h in a closed bottle. The solvent was evaporated in vacuo, and the residue was taken up with dichloromethane and washed with aqueous NaHCO<sub>3</sub> The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated, giving <b>10a</b> (135 mg, 50%) after trituration with diethyl ether. <sup>1</sup>H NMR (401 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 2.71 (t, <i>J</i> = 7.6 Hz, 2H), 2.92 (m, 2H), 4.29 (s, 3H), 6.52 (s, 2H), 7.21 (bs, 1H), 7.41 (bs, 1H), 8.16 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 245 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>11</sub>H<sub>12</sub>N<sub>6</sub>O + H<sup>+</sup>, 245.1146; found, 245.1143.</div></div><div id="sec5_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 8-[(4-Methoxybenzyl)amino]-1-methyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>15</b>)</h3><div class="NLM_p">To a solution of <b>10a</b> (244 mg, 1.0 mmol) in a mixture of glacial acetic acid/methanol/water 1/1/1 (30 mL) in a round-bottom flask, <i>p</i>-methoxybenzaldehyde (0.88 mL, 6.0 mmol) and then 85% sodium cyanoborohydride (420 mg, 4.0 mmol) were added. The solution was stirred at room temperature overnight. The reaction mixture was then poured into ice-water (200 mL), the pH was adjusted to 10 by addition of saturated aqueous Na<sub>2</sub>CO<sub>3</sub>, and the solution was extracted with ethyl acetate. The collected organic extracts were washed with brine until neutral, washed with water, and dried over Na<sub>2</sub>SO<sub>4</sub>. Evaporation of the solvent under reduced pressure left a yellow solid residue that was purified by flash chromatography on silica gel (dichloromethane/methanol, 95/5) to yield a yellow compound. Crystallization from methanol afforded crystalline <b>15</b> (225 mg, 62%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 2.71 (m, 2H), 2.92 (m, 2H), 3.71 (s, 3H), 4.20 (bs, 3H), 4.45 (s, 2H), 6.86 (d, <i>J</i> = 8.8 Hz, 2H), 7.21 (bs, 1H), 7.25 (d, <i>J</i> = 8.8 Hz, 2H), 7.40 (bs, 1H), 7.62 (bs, 1H), 8.20 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 365 (M + H)<sup>+</sup>.</div><div class="NLM_p last">By employment of the above-described procedure, starting from <b>10a</b> and using the suitable aldehyde, compounds <b>16</b> and <b>17</b> were prepared.</div></div><div id="sec5_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 8-[(4-Bromobenzyl)amino]-1-methyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>16</b>)</h3><div class="NLM_p last">Yield, 60%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 2.68−3.00 (m, 4H), 4.15 (s, 3H), 4.49 (d, <i>J</i> = 6.3 Hz, 2H), 7.21 (s, 1H), 7.29 (d, <i>J</i> = 8.5 Hz, 2H), 7.40 (s, 1H), 7.49 (d, <i>J</i> = 8.5 Hz, 2H), 7.65−7.77 (m, 1H), 8.21 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 413 (M + H)<sup>+</sup>.</div></div><div id="sec5_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 8-{[4-(Acetylamino)benzyl]amino}-1-methyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>17</b>)</h3><div class="NLM_p last">Yield, 58%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 2.00 (s, 3H), 2.71 (t, <i>J</i> = 7.7 Hz, 2H), 2.92 (t, <i>J</i> = 7.7 Hz, 2H), 4.18 (s, 1H), 4.46 (d, <i>J</i> = 6.2 Hz, 1H), 7.21 (s, 1H), 7.24 (d, <i>J</i> = 8.5 Hz, 2H), 7.40 (s, 1H), 7.48 (d, <i>J</i> = 8.5 Hz, 2H), 7.56−7.68 (m, 1H), 8.21 (s, 1H), 9.80 (none, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 392 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>20</sub>H<sub>21</sub>N<sub>7</sub>O<sub>2</sub> + H<sup>+</sup>, 392.183; found, 392.1835; Anal. (C<sub>20</sub>H<sub>21</sub>N<sub>7</sub>O<sub>2</sub>) C, H, N.</div></div><div id="sec5_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 8-Amino-<i>N</i>-1-dimethyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>10b</b>)</h3><div class="NLM_p last">A solution of <b>9</b> (200 mg, 0.73 mmol) in a mixture of ethanol (10 mL) and 33 wt % methylamine in absolute ethanol (30 mL) was stirred at 60 °C in a closed bottle for 8 h. The solvent was then removed in vacuo and the crude was purified by flash chromatography on a silica gel column (dichloromethane/methanol/triethylamine, 95/5/5) affording <b>10b</b> (147 mg, 78%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 2.68−2.73 (m, 2H), 2.73 (d, <i>J</i> = 4.8 Hz, 3H), 2.93 (t, <i>J</i> = 7.6 Hz, 2H), 4.29 (s, 3H), 6.52 (s, 2H), 7.97−8.06 (m, 1H), 8.16 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 259 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>12</sub>H<sub>14</sub>N<sub>6</sub>O + H<sup>+</sup>, 259.1302; found, 259.1300.</div></div><div id="sec5_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 8-[(1-Acetylpiperidin-4-yl)amino]-<i>N</i>,1-dimethyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>51</b>)</h3><div class="NLM_p">To a suspension of <b>10b</b> (490 mg, 1.9 mmol) in dry DMF (12 mL), 1-acetyl-4-piperidone (470 μL, 3.8 mmol), trifluoroacetic acid (1 mL, 12.8 mmol), and sodium triacetoxyborohydride (886 mg, 4.2 mmol) were added. After 18 h, 0.33 N NaOH (80 mL, 26.4 mmol) was added dropwise to the mixture. The precipitate was filtered, washed with water, and dried in an oven to dryness to give <b>51</b> (509 mg, 70%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.84 (m, 4H), 2.03 (s, 3H), 2.76 (d, <i>J</i> = 4.8, 3H), 2.84 (m, 2H), 3.17 (m, 2H), 4.21 (m, 1H), 4.24 (s, 3H), 7.28 (s, 1H), 8.19 (s, 1H), 9.10 (q, <i>J</i> = 4.8 Hz, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 384 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>19</sub>H<sub>25</sub>N<sub>7</sub>O<sub>2</sub> + H<sup>+</sup>, 384.2142; found, 384.2145.</div><div class="NLM_p last">By employment of the above-described procedure, starting from <b>10b</b> and using the suitable cycloalkylketone, compounds <b>53</b>, <b>55</b>, <b>59</b>, and <b>61</b> were prepared.</div></div><div id="sec5_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> <i>N</i>-1-Dimethyl-8-{[1-(phenylcarbonyl)piperidin-4-yl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>53</b>)</h3><div class="NLM_p last">Yield, 70%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.50 (s, 2H), 1.97 (s, 2H), 2.73 (d, <i>J</i> = 4.7 Hz, 3H), 2.76 (m, 2H), 2.96 (t, <i>J</i> = 7.7 Hz, 2H), 3.05−3.77 (m, 3H), 4.03 (m, 1H), 4.29 (s, 3H), 4.39 (m, 1H), 7.35−7.41 (m, 2H), 7.43−7.47 (m, 3H), 7.58 (s, 1H), 8.08 (q, <i>J</i> = 4.7 Hz, 1H), 8.24 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 891 (2M + H)<sup>+</sup>; HRMS (ESI) calcd for 2.C<sub>24</sub>H<sub>27</sub>N<sub>7</sub>O<sub>2</sub> + H<sup>+</sup>, 891.4525; found, 891.4491.</div></div><div id="sec5_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> <i>N</i>-1-Dimethyl-8-({1-[(4-methylpiperazin-1-yl)carbonyl]piperidin-4-yl}amino)-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>55</b>)</h3><div class="NLM_p last">Yield, 50%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.41−1.50 (m, 2H), 1.90 (m, 2H), 2.19 (s, 3H), 2.31 (s, 4H), 2.69−2.75 (m, 2H), 2.73 (d, <i>J</i> = 4.7 Hz, 3H), 2.80−2.89 (m, 2H), 2.94 (t, <i>J</i> = 7.6 Hz, 2H), 3.10−3.17 (m, 4H), 3.58 (dt, <i>J</i> = 13.3, 3.3 Hz, 2H), 3.78−3.93 (m, 1H), 4.29 (s, 3H), 7.07 (s, 1H), 8.04 (q, <i>J</i> = 4.7 Hz, 1H), 8.20 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 468 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>23</sub>H<sub>33</sub>N<sub>9</sub>O<sub>2</sub> + H<sup>+</sup>, 468.2830; found, 468.2831.</div></div><div id="sec5_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> Ethyl 4-{[1-Methyl-3-(methylcarbamoyl)-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazolin-8-yl]amino}piperidine-1-carboxylate (<b>57</b>)</h3><div class="NLM_p last">Yield, 60%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.18 (t, <i>J</i> = 7.1 Hz, 3H), 1.32−1.49 (m, 2H), 1.90 (m, 2H), 2.70−2.75 (m, 1H), 2.73 (d, <i>J</i> = 4.7 Hz, 1H), 2.94 (t, <i>J</i> = 7.7 Hz, 1H), 2.94 (t, <i>J</i> = 7.7 Hz, 1H), 3.84−3.93 (m, 1H), 3.92−3.98 (m, 1H), 4.04 (q, <i>J</i> = 7.1 Hz, 2H), 4.29 (s, 3H), 7.08 (d, <i>J</i> = 5.9 Hz, 1H), 8.04 (q, <i>J</i> = 4.7 Hz, 1H), 8.21 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 414 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>20</sub>H<sub>27</sub>N<sub>7</sub>O<sub>3</sub> + H<sup>+</sup>, 414.2248; found, 414.2263.</div></div><div id="sec5_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> <i>N</i>-1-Dimethyl-8-{[1-(methylsulfonyl)piperidin-4-yl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>59</b>)</h3><div class="NLM_p last">Yield, 72%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.59 (m, 2H), 2.02 (m, 2H), 2.73 (m, 2H), 2.75 (d, <i>J</i> = 4.7 Hz, 3H), 2.86 (m, 2H), 2.88 (s, 3H), 2.96 (t, <i>J</i> = 7.6 Hz, 2H), 3.56 (m, 2H), 3.87 (m, 1H), 4.29 (s, 3H), 7.43 (m, 1H), 8.08 (m, 1H), 8.23 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 420 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>18</sub>H<sub>25</sub>N<sub>7</sub>O<sub>3</sub>S + H<sup>+</sup>, 420.1812; found, 420.1814; Anal. (C<sub>18</sub>H<sub>25</sub>N<sub>7</sub>O<sub>3</sub>S) C, H, N, S.</div></div><div id="sec5_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> <i>N</i>-1-Dimethyl-8-{[1-(phenylsulfonyl)piperidin-4-yl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>61</b>)</h3><div class="NLM_p last">Yield, 68%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.59 (m, 2H), 1.98 (m, 2H), 2.56 (m, 2H), 2.74 (m, 2H), 2.72 (d, <i>J</i> = 4.8 Hz, 3H), 2.94 (t, <i>J</i> = 7.6 Hz, 2H), 3.58 (m, 2H), 3.74 (m, 1H), 4.22 (s, 3H), 7.53 (s, 1H), 7.66 (m, 2H), 7.74 (m, 1H), 7.74−7.76 (m, 2H), 8.06 (q, <i>J</i> = 4.8 Hz, 1H), 8.20 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 482 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>23</sub>H<sub>27</sub>N<sub>7</sub>O<sub>3</sub>S + H<sup>+</sup>, 482.1969; found, 482.1959.</div></div><div id="sec5_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> 1-Methyl-8-({1-[(4-methylpiperazin-1-yl)carbonyl]piperidin-4-yl}amino)-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>54</b>)</h3><div class="NLM_p last">To a suspension of <b>9</b> (355 mg, 1.30 mmol) in dry DMF (10 mL), 1-[(4-methylpiperazin-1-yl)carbonyl]piperidin-4-one dihydrochloride (562 mg, 2.50 mmol, prepared as described in ref <a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">17</a>, trifluoroacetic acid (1.3 mL, 16.64 mmol), and sodium triacetoxyborohydride (528 mg, 2.50 mmol) were added. After 18 h, the mixture was poured into a solution of potassium carbonate (500 mg in 100 mL of water) and extracted with dichloromethane. The organic layer was concentrated and the residue purified by flash chromatography on a silica gel column (dichloromethane/ethanol 9/1) affording ethyl 1-methyl-8-({1-[(4-methylpiperazin-1-yl)carbonyl]piperidin-4-yl}amino)-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxylate (315 mg, 50%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.30 (t, <i>J</i> = 7.1 Hz, 3H), 1.45 (m, 2H), 1.89 (m, 2H), 2.18 (s, 3H), 2.37 (m, 4H), 2.75 (t, <i>J</i> = 7.7 Hz, 2H), 2.85 (m, 2H), 2.93 (t, <i>J</i> = 7.6 Hz, 2H), 3.13 (m, 4H), 3.57 (m, 2H), 3.87 (m, 1H), 4.28 (q, <i>J</i> = 7.1 Hz, 2H), 4.31 (s, 3H), 7.11 (s, 1H), 8.22 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 483 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>24</sub>H<sub>34</sub>N<sub>8</sub>O<sub>3</sub> + H<sup>+</sup>, 483.2827; found, 483.2820. A suspension of the above-described ethyl carboxylate (300 mg, 0.62 mmol) in a mixture of 33% NH<sub>4</sub>OH (10 mL), methanol (5 mL), and DMF (5 mL) was stirred at 65 °C in a closed bottle for 16 h. After that time, the solvent was removed and the residue was partitioned between dichloromethane and aqueous NaHCO<sub>3</sub>. The organic layer was then dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated affording <b>54</b> (170 mg, 61%), after purification by flash chromatography (dichloromethane/ethanol/33% NH<sub>4</sub>OH, 90/9/1). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.87 (m, 4H), 2.44(s, 3H), 2.49 (m, 4H), 2.86 (m, 2H), 3.13 (m, 2H), 3.39 (m, 2H), 3.50 (m, 2H), 3.80 (m, 2H), 4.05 (m, 1H), 4.24 (s, 3H), 7.28 (s, 1H), 7.27 (bs, 1H), 7.45 (bs, 1H), 8.18 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 454 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>22</sub>H<sub>31</sub>N<sub>9</sub>O<sub>2</sub> + H<sup>+</sup>, 454.2673; found, 454.2687.</div></div><div id="sec5_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 1-Methyl-8-{[1-(methylsulfonyl)piperidin-4-yl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>58</b>)</h3><div class="NLM_p last">By employment of the above-described procedure, compound <b>58</b> was prepared. Yield, 52%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.50−1.66 (m, 2H), 2.02 (m, 2H), 2.74 (t, <i>J</i> = 7.7 Hz, 2H), 2.84−2.92 (m, 2H), 2.88 (s, 3H), 2.95 (t, <i>J</i> = 7.6 Hz, 2H), 3.52−3.61 (m, 2H), 3.80−3.92 (m, 1H), 4.29 (s, 3H), 7.24 (s, 1H), 7.34 (s, 1H), 7.44 (s, 1H), 8.23 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 406 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>17</sub>H<sub>23</sub>N<sub>7</sub>O<sub>3</sub>S + H<sup>+</sup>, 406.1656; found, 406.1653.</div></div><div id="sec5_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 8-(Cyclopentylamino)-<i>N</i>-[1-(dimethylamino)propan-2-yl]-1-methyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>31</b>)</h3><div class="NLM_p">A suspension of <b>9</b> (546 mg, 2 mmol) in dry DMF (10 mL) was treated with cyclopentanone (212 μL, 2.4 mmol), trifluoroacetic acid (1 mL, 12.8 mmol), and sodium triacetoxyborohydride (632 mg, 3 mmol). After 16 h, 0.5 N NaOH (60 mL, 30 mmol) was added dropwise to the mixture. The precipitate was filtered, washed with water, and dried. The residue was then purified by flash chromatography on a silica gel column (dichloromethane/methanol, 99/1) affording ethyl 8-(cyclopentylamino)-1-methyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxylate (500 mg, 73%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.30 (t, <i>J</i> = 7.1 Hz, 3H), 1.44−1.61 (m, 4H), 1.63−1.73 (m, 2H), 1.92 (m, 2H), 2.75 (m, 2H), 2.92 (m, 2H), 4.15 (m, 1H), 4.28 (q, <i>J</i> = 7.1 Hz, 2H), 4.33 (s, 3H), 7.08 (d, <i>J</i> = 5.6 Hz, 1H), 8.20 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 342 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>18</sub>H<sub>23</sub>N<sub>5</sub>O<sub>2</sub> + H<sup>+</sup>, 342.1924; found, 342.1924. A suspension of the above-described ethyl carboxylate (230 mg, 0.67 mmol) was suspended in dry ethanol (5 mL) and treated with a 1.5 M solution of KOH in ethanol (1.33 mL, 2.01 mmol) at reflux temperature for 1.5 h. After cooling in an ice bath, the resulting precipitate was collected by filtration to give potassium 8-(cyclopentylamino)-1-methyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxylate (210 mg, 89%) as a crystalline solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.39−1.76 (m, 6H), 1.80−1.99 (m, 2H), 2.63 (t, <i>J</i> = 7.7 Hz, 2H), 2.88 (t, <i>J</i> = 7.7 Hz, 2H), 4.09−4.17 (m, 1H), 4.18 (s, 3H), 6.87 (d, <i>J</i> = 6.8 Hz, 1H), 8.10 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 314 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>16</sub>H<sub>19</sub>N<sub>5</sub>O<sub>2</sub> + H<sup>+</sup>, 314.1611; found, 314.1615. To a suspension of the above-described carboxylic acid potassium salt (210 mg, 0.58 mmol) in DMF (4 mL), 1-hydroxybenzotriazole (HOBT, 101 mg, 0.75 mmol) and EDC (144 mg, 0.75 mmol) were added in sequence. The mixture was stirred at room temperature for 30 min, then <i>N</i><sup>1</sup>,<i>N</i><sup>1</sup>-dimethylpropane-1,2-diamine (130 μL, 1 mmol)) was added. After 20 h the reaction mixture was poured into water and extracted with dichloromethane. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The crude was then purified by flash chromatography on a silica gel column (dichloromethane/ethanol/33% NH<sub>4</sub>OH, 94/5.5/0.5). The residue was triturated with diethyl ether and <b>31</b> was collected by filtration (81 mg, 35%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.10 (d, <i>J</i> = 6.6 Hz, 3H), 1.60 (m, 4H), 1.84 (m, 2H), 2.07 (m, 2H), 2.27 (s, 6H), 2.30 (m, 2H), 2.85 (m, 2H), 3.11 (m, 2H), 4.12 (m, 1H), 4.24 (s, 3H), 4.57 (quin, <i>J</i> = 8.0 Hz, 1H), 7.28 (s, 1H), 8.02 (s, 1H), 8.20 (d, <i>J</i> = 7.9 Hz, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 398 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>21</sub>H<sub>31</sub>N<sub>7</sub>O + H<sup>+</sup>, 398.2663; found, 398.2671.</div><div class="NLM_p last">By employment of the above-described procedure, starting from <b>9</b> and using the suitable amine, compounds <b>32</b> and <b>33</b> were prepared.</div></div><div id="sec5_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> 8-(Cyclopentylamino)-<i>N</i>-[2-(dimethylamino)ethyl]-<i>N</i>-1-dimethyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>32</b>)</h3><div class="NLM_p last">Yield, 45%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.64 (m, 4H), 1.84. (m, 4H), 2.03 (m, 2H), 2.27 (s, 6H), 2.41 (t, <i>J</i> = 6.5 Hz, 2H), 2.87 (m, 2H), 2.92 (s, 3H), 2.98 (m, 2H), 3.70 (t, <i>J</i> = 6.5 Hz, 2H), 4.23 (s, 3H), 4.57 (quin, <i>J</i> = 8.0 Hz, 1H), 7.28 (s, 1H), 8.18 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 398 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>21</sub>H<sub>31</sub>N<sub>7</sub>O + H<sup>+</sup>, 398.2663; found, 398.2676.</div></div><div id="sec5_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> [8-(Cyclopentylamino)-1-methyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazolin-3-yl](4-methylpiperazin-1-yl)methanone (<b>33</b>)</h3><div class="NLM_p last">Yield, 51%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.64 (m, 4H), 1.86. (m, 2H), 2.08 (m, 2H), 2.47 (s, 3H), 2.55 (m, 4H), 2.89 (m, 2H), 3.03 (m, 2H), 3.64 (m, 2H), 3.71 (m, 2H), 4.22 (s, 3H), 4.57 (quin, <i>J</i> = 8.0 Hz, 1H), 7.28 (s, 1H), 8.20 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 396 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>21</sub>H<sub>29</sub>N<sub>7</sub>O + H<sup>+</sup>, 396.2506; found, 396.2518.</div></div><div id="sec5_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> 8-[(1-Acetylpiperidin-4-yl)amino]-1-methyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>50</b>)</h3><div class="NLM_p">To a suspension of <b>9</b> (5.187 g, 19 mmol) in dry DMF (120 mL), 1-acetyl-4-piperidone (4.7 mL, 38 mmol), trifluoroacetic acid (10 mL, 128 mmol), and sodium triacetoxyborohydride (8.862 g, 42 mmol) were added. After 18 h, 0.33 N NaOH (800 mL, 264 mmol) was added dropwise to the mixture. The precipitate was filtered, washed with water, and dried in oven to dryness to give of ethyl 8-[(1-acetylpiperidin-4-yl)amino]-1-methyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxylate (5.3 g, 70%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.30 (t, <i>J</i> = 7.1 Hz, 3H), 1.43 (m, 2H), 1.94 (m, 2H), 2.01 (s, 3H), 2.76 (m, 3H), 2.93 (t, <i>J</i> = 7.8 Hz, 2H), 3.15 (m, 1H), 3.33 (m, 1H), 3.81 (m, 1H), 3.94 (m, 1H), 4.28 (q, <i>J</i> = 7.1 Hz, 2H), 4.32 (s, 3H), 7.13 (d, <i>J</i> = 7.2 Hz, 1H), 8.23 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 399 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>20</sub>H<sub>26</sub>N<sub>6</sub>O<sub>3</sub> + H<sup>+</sup>, 399.2139; found, 399.2140. A suspension of the above-described ethyl carboxylate (1.0 g, 2.50 mmol) in anhydrous ethanol (20 mL) was treated with a 1.5 M solution of KOH in ethanol (5 mL, 7.5 mmol) at reflux temperature for 1.5 h. After cooling in ice bath, the resulting precipitate was collected by filtration to give potassium 8-[(1-acetylpiperidin-4-yl)amino]-1-methyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxylate (836 mg, 82%) as a crystalline solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.38 (m, 2H), 1.79−1.99 (m, 2H), 2.00 (s, 3H), 2.64 (m, 2H), 2.74 (td, <i>J</i> = 12.78, 3.1 Hz, 1H), 2.89 (m, 2H), 2.96 (m, 1H), 3.14 (m, 2H), 3.81 (m, 1H), 3.86−3.99 (m, 1H), 4.17 (s, 3H), 4.23−4.32 (m, 1H), 6.93 (d, <i>J</i> = 7.3 Hz, 1H), 8.12 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 371 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>18</sub>H<sub>22</sub>N<sub>6</sub>O<sub>3</sub> + H<sup>+</sup>, 371.1826; found, 371.1825. A suspension of the above-described carboxylic acid potassium salt (500 mg, 1.23 mmol) in a mixture of dry DMF (10 mL) and dry THF (10 mL) was cooled to 0 °C, then DIPEA (0.86 mL, 4.92 mmol) and EDC (708 mg, 3.69 mmol) were added in sequence. After stirring at the same temperature for 30 min, HOBT·NH<sub>3</sub> (560 mg, 3.69 mmol) was added. The mixture was then maintained at room temperature overnight and then the solvent was removed under reduced pressure. The residue was taken up with dichloromethane and washed with aqueous NaHCO<sub>3</sub>. The organic layer was finally dried over Na<sub>2</sub>SO<sub>4</sub> and the solvent was evaporated. After trituration with diethyl ether, <b>50</b> (272 mg, 60%) was collected by filtration. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.16−1.52 (m, 3H), 1.83−1.99 (m, 2H), 2.01 (s, 3H), 2.72 (m, 2H), 2.93 (m, 2H), 3.16 (m, 2H), 3.81 (m, 2H), 3.87−4.02 (m, 2H), 4.27 (bs, 2H), 4.29 (s, 3H), 7.10 (bs, 1H), 7.22 (bs, 1H), 7.42 (bs, 1H), 8.21 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 370 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>18</sub>H<sub>23</sub>N<sub>7</sub>O<sub>2</sub> + H<sup>+</sup>, 370.1986; found, 370.1982.</div><div class="NLM_p last">By employment of the above-described procedure, compounds <b>52</b>, <b>56</b>, and <b>60</b> were prepared.</div></div><div id="sec5_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> 1-Methyl-8-{[1-(phenylcarbonyl)piperidin-4-yl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>52</b>)</h3><div class="NLM_p last">Yield, 45%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.91 (m, 4H), 2.86 (m, 4H), 3.08 (m, 2H), 3.61 (m, 4H), 4.02 (m, 1H), 4.24 (s, 3H), 7.26 (bs, 1H), 7.28 (bs, 1H), 7.47 (bs, 1H), 7.55 (m, 3H), 7.78 (m, 2H), 8.20 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 432 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>23</sub>H<sub>25</sub>N<sub>7</sub>O<sub>2</sub> + H<sup>+</sup>, 432.2142; found, 432.2135.</div></div><div id="sec5_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> Ethyl 4-[(3-Carbamoyl-1-methyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazolin-8-yl)amino]piperidine-1-carboxylate (<b>56</b>)</h3><div class="NLM_p last">Yield, 50%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.18 (t, <i>J</i> = 7.1 Hz, 3H), 1.39 (m, 2H), 1.91 (m, 2H), 2.69−2.76 (m, 2H), 2.94 (m, 4H), 3.88 (m, 1H), 3.91−3.98 (m, 2H), 4.04 (q, <i>J</i> = 7.1 Hz, 2H), 4.28 (s, 3H), 7.07 (bs, 1H), 7.22 (bs, 1H), 7.42 (bs, 1H), 8.21 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 400 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>19</sub>H<sub>25</sub>N<sub>7</sub>O<sub>3</sub> + H<sup>+</sup>, 400.2092; found, 400.2095; Anal. (C<sub>19</sub>H<sub>25</sub>N<sub>7</sub>O<sub>3</sub>) C, H, N.</div></div><div id="sec5_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> 1-Methyl-8-{[1-(phenylsulfonyl)piperidin-4-yl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>60</b>)</h3><div class="NLM_p last">Yield, 43%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.60 (m, 2H), 1.99 (m, 2H), 2.55 (m, 2H), 2.71 (t, <i>J</i> = 7.6 Hz, 2H), 2.93 (m, 2H), 3.59 (m, 2H), 3.72 (m, 1H), 4.24 (s, 3H), 7.10 (d, <i>J</i> = 7.3 Hz, 1H), 7.23 (s, 1H), 7.41 (s, 1H), 7.62 (m, 2H), 7.75 (m, 1H), 7.77 (m, 2H), 8.19 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 468 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>22</sub>H<sub>25</sub>N<sub>7</sub>O<sub>3</sub>S + H<sup>+</sup>, 468.1813; found, 468.1808.</div></div><div id="sec5_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> 8-(Cyclopentylamino)-<i>N</i>-hydroxy-<i>N</i>,1-dimethyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>34</b>)</h3><div class="NLM_p">To a suspension of potassium 8-(cyclopentylamino)-1-methyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxylate (300 mg, 0.85 mmol, prepared as described for the preparation of compound <b>31</b>) in dry dichloromethane (60 mL) and a few drops of dry DMF, oxalyl chloride (85 μL, 1 mmol) was added at 0 °C. The mixture was stirred at room temperature for 6 h and then evaporated, dissolved in dry dichloromethane, and dropped into a solution of methylhydroxylamine hydrochloride (141 mg, 1.70 mmol) and triethylamine (490 μL, 3.40 mmol) in the same solvent (20 mL), cooled to 0 °C. After 4 h the mixture was washed with a saturated solution of NaHCO<sub>3</sub>, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated to dryness. The residue was triturated with diethyl ether and filtered to give <b>34</b> (175 mg, 60%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.53 (m, 4H), 1.66 (m, 2H), 1.93 (m, 2H), 2.65−2.87 (m, 4H), 3.33 (s, 3H), 4.15 (m, 1H), 4.29 (s, 3H), 7.04 (d, <i>J</i> = 6.6 Hz, 1H), 8.19 (s, 1H), 9.87 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 343 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>17</sub>H<sub>22</sub>N<sub>6</sub>O<sub>2</sub> + H<sup>+</sup>, 343.1877; found, 343.1884; Anal. (C<sub>17</sub>H<sub>22</sub>N<sub>6</sub>O<sub>2</sub>) C, H, N.</div><div class="NLM_p last">By employment of the above-mentioned procedure and using the suitable substituted hydroxylamine, compounds <b>35</b> and <b>36</b> were prepared.</div></div><div id="sec5_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> <i>N</i>-Cyclohexyl-8-(cyclopentylamino)-<i>N</i>-hydroxy-1-methyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>35</b>)</h3><div class="NLM_p last">Yield, 55%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.16−1.36 (m, 2H), 1.46−1.80 (m, 12H), 1.84−1.99 (m, 2H), 2.65−2.79 (m, 4H), 4.16 (m, 1H), 4.29 (s, 3H), 4.33 (m, 1H), 7.04 (d, <i>J</i> = 6.8 Hz, 1H), 8.18 (s, 1H), 9.44 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 411 (M + H)<sup>+</sup>; Anal. (C<sub>22</sub>H<sub>30</sub>N<sub>6</sub>O<sub>2</sub>) C, H, N.</div></div><div id="sec5_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> <i>N</i>-Benzyl-8-(cyclopentylamino)-<i>N</i>-hydroxy-1-methyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>36</b>)</h3><div class="NLM_p last">Yield, 62%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.52 (m, 4H), 1.69 (m, 2H), 1.89 (m, 2H), 2.76 (m, 4H), 4.16 (m, 1H), 4.29 (s, 3H), 4.99 (s, 2H), 7.05 (d, <i>J</i> = 6.6 Hz, 1H), 7.20−7.41 (m, 5H), 8.19 (s, 1H), 9.87 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 419 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>23</sub>H<sub>26</sub>N<sub>6</sub>O<sub>2</sub> + H<sup>+</sup>, 419.2190; found, 419.2201.</div></div><div id="sec5_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Ethyl 1-Benzyl-7-oxo-4,5,6,7-tetrahydro-1<i>H</i>-indazole-3-carboxylate (<b>12a</b>)</h3><div class="NLM_p">Ethyl (3-ethoxy-2-oxocyclohex-3-en-1-yl)(oxo)acetate <b>11</b> (3.0 g, 12.5 mmol, prepared as described in ref <a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">17</a>) was dissolved in glacial acetic acid (15 mL) and benzylhydrazine dihydrochloride (2.44 g, 12.5 mmol) was added. The mixture was stirred at room temperature for 6 h. The solvent was evaporated and the crude dissolved with water, the solution made basic with 33% NH<sub>4</sub>OH and extracted with dichloromethane. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was chromatographed on a silica gel column (<i>n</i>-hexane/ethylacetate, 7/3) and triturated with a mixture <i>n</i>-hexane/diethyl ether to give <b>12a</b> (2.34 g, 63%). <sup>1</sup>H NMR (401 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.30 (t, <i>J</i> = 7.1 Hz, 3H), 2.06 (quin, <i>J</i> = 6.3 Hz, 1H), 2.56 (dd, <i>J</i> = 7.3, 5.7 Hz, 2H), 2.95 (t, <i>J</i> = 6.1 Hz, 2H), 4.29 (q, <i>J</i> = 7.1 Hz, 2H), 5.72 (s, 2H), 7.19 (dd, <i>J</i> = 7.8, 1.6 Hz, 2H); LCMS (ESI) <i>m</i>/<i>z</i> 299 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>17</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub> + H<sup>+</sup>, 299.1390; found, 299.1404.</div><div class="NLM_p last">By employment of the above-described procedure, starting from <b>11</b> and using the suitable substituted hydrazine, compounds <b>12b</b>−<b>i</b> were prepared.</div></div><div id="sec5_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> Ethyl 7-Oxo-1-phenyl-4,5,6,7-tetrahydro-1<i>H</i>-indazole-3-carboxylate (<b>12b</b>)</h3><div class="NLM_p last">Yield, 80%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.32 (t, <i>J</i> = 7.1 Hz, 3H), 2.08−2.17 (m, 2H), 2.56 (dd, <i>J</i> = 7.4, 5.5 Hz, 2H), 3.03 (t, <i>J</i> = 6.1 Hz, 2H), 4.34 (q, <i>J</i> = 7.1 Hz, 2H), 7.51 (s, 5H); LCMS (ESI) <i>m</i>/<i>z</i> 285 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>16</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub> + H<sup>+</sup>, 285.1234; found, 285.1236.</div></div><div id="sec5_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> Ethyl 1-(4-Methoxyphenyl)-7-oxo-4,5,6,7-tetrahydro-1<i>H</i>-indazole-3-carboxylate (<b>12c</b>)</h3><div class="NLM_p last">Yield, 72%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.32 (t, <i>J</i> = 7.1 Hz, 3H), 2.03−2.15 (m, 2H), 2.54 (dd, <i>J</i> = 7.3, 5.5 Hz, 2H), 3.01 (t, <i>J</i> = 6.1 Hz, 2H), 3.83 (s, 3H), 4.33 (q, <i>J</i> = 7.1 Hz, 2H), 7.03 (d, <i>J</i> = 9.0 Hz, 2H), 7.42 (d, <i>J</i> = 9.0 Hz, 2H); LCMS (ESI) <i>m</i>/<i>z</i> 315 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>17</sub>H<sub>18</sub>N<sub>2</sub>O<sub>4</sub> + H<sup>+</sup>, 315.1339; found, 315.1345.</div></div><div id="sec5_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> Ethyl 7-Oxo-1-(4-sulfamoylphenyl)-4,5,6,7-tetrahydro-1<i>H</i>-indazole-3-carboxylate (<b>12d</b>)</h3><div class="NLM_p last">Yield, 70%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.32 (t, <i>J</i> = 7.1 Hz, 3H), 2.08−2.17 (m, 2H), 2.55−2.61 (m, 2H), 3.03 (t, <i>J</i> = 6.1 Hz, 2H), 4.35 (q, <i>J</i> = 7.1 Hz, 2H), 7.53 (s, 2H), 7.75 (d, <i>J</i> = 8.8 Hz, 2H), 7.94 (d, <i>J</i> = 8.8 Hz, 2H); LCMS (ESI) <i>m</i>/<i>z</i> 364 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>16</sub>H<sub>17</sub>N<sub>3</sub>O<sub>5</sub>S + H<sup>+</sup>, 364.0962; found, 364.0961.</div></div><div id="sec5_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> Ethyl 7-Oxo-1-(pyridin-2-yl)-4,5,6,7-tetrahydro-1<i>H</i>-indazole-3-carboxylate (<b>12e</b>)</h3><div class="NLM_p last">Yield, 75%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.32 (t, <i>J</i> = 7.1 Hz, 3H), 2.08−2.19 (m, 2H), 2.57 (dd, <i>J</i> = 7.3, 5.6 Hz, 2H), 3.03 (t, <i>J</i> = 6.2 Hz, 2H), 4.34 (q, <i>J</i> = 7.1 Hz, 2H), 7.60 (ddd, <i>J</i> = 7.4, 4.7, 1.0 Hz, 1H), 7.62 (dt, <i>J</i> = 7.9, 0.9 Hz, 1H), 8.06 (td, <i>J</i> = 7.7, 1.8 Hz, 1H), 8.56 (ddd, <i>J</i> = 4.7, 1.8, 0.8 Hz, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 286 (M + H)<sup>+</sup>.</div></div><div id="sec5_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> Ethyl 1-(2-Hydroxyethyl)-7-oxo-4,5,6,7-tetrahydro-1<i>H</i>-indazole-3-carboxylate (<b>12f</b>)</h3><div class="NLM_p last">Yield, 72%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.30 (t, <i>J</i> = 7.1 Hz, 3H), 1.99−2.09 (m, 2H), 2.51−2.56 (m, 2H), 2.93 (t, <i>J</i> = 6.1 Hz, 2H), 3.72 (t, <i>J</i> = 5.8 Hz, 2H), 4.25−4.34 (m, 2H), 4.54 (t, <i>J</i> = 5.8 Hz, 2H), 4.85 (bs, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 253 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>12</sub>H<sub>16</sub>N<sub>2</sub>O<sub>4</sub> + H<sup>+</sup>, 253.1183; found, 253.1187.</div></div><div id="sec5_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Ethyl 7-Oxo-1-(2,2,2-trifluoroethyl)-4,5,6,7-tetrahydro-1<i>H</i>-indazole-3-carboxylate (<b>12g</b>)</h3><div class="NLM_p last">Yield, 68%; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.31 (t, <i>J</i> = 7.2 Hz, 3H), 2.07 (dt, <i>J</i> = 12.5, 6.26 Hz, 2H), 2.59 (dd, <i>J</i> = 7.2, 5.9 Hz, 2H), 2.96 (t, <i>J</i> = 6.1 Hz, 2H), 4.32 (q, <i>J</i> = 7.2 Hz, 2H), 5.48 (q, <i>J</i> = 8.7 Hz, 2H); LCMS (ESI) <i>m</i>/<i>z</i> 291 (M + H)<sup>+</sup>.</div></div><div id="sec5_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> Ethyl 1-(1-Methylpiperidin-4-yl)-7-oxo-4,5,6,7-tetrahydro-1<i>H</i>-indazole-3-carboxylate (<b>12h</b>)</h3><div class="NLM_p last">Yield, 79%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.30 (t, <i>J</i> = 7.1 Hz, 3H), 1.82−2.10 (m, 6H), 2.26 (s, 3H), 2.46−2.51 (m, 2H), 2.50−2.58 (m, 2H), 2.89−2.98 (m, 2H), 2.93 (t, <i>J</i> = 6.2 Hz, 2H), 4.30 (q, <i>J</i> = 7.1 Hz, 2H), 4.92−5.10 (m, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 306 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>16</sub>H<sub>23</sub>N<sub>3</sub>O<sub>3</sub> + H<sup>+</sup>, 306.1812; found, 306.1801.</div></div><div id="sec5_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Ethyl 1-(1-Acetylpiperidin-4-yl)-7-oxo-4,5,6,7-tetrahydro-1<i>H</i>-indazole-3-carboxylate (<b>12i</b>)</h3><div class="NLM_p last">Yield, 76% yield); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.30 (t, <i>J</i> = 7.1 Hz, 3H), 1.73 (m, 1H), 1.95 (m, 3H), 2.00−2.08 (m, 2H), 2.04 (s, 3H), 2.56 (dd, <i>J</i> = 7.2, 5.6 Hz, 2H), 2.64−2.76 (m, 1H), 2.93 (t, <i>J</i> = 6.1 Hz, 2H), 3.20 (m, 2H), 3.87−3.99 (m, 1H), 4.29 (q, <i>J</i> = 7.1 Hz, 2H), 4.48 (m, 1H), 5.27 (m, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 334 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>17</sub>H<sub>23</sub>N<sub>3</sub>O<sub>4</sub> + H<sup>+</sup>, 334.1762; found, 334.1757.</div></div><div id="sec5_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> Ethyl 8-Amino-1-benzyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxylate (<b>13a</b>)</h3><div class="NLM_p">To a solution of <b>12a</b> (500 mg, 1.67 mmol) in dry DMF (12 mL), <i>N</i>,<i>N</i>-dimethylformamide di-<i>tert</i>-butylacetale (4 mL, 16.3 mmol) was added. The mixture was stirred at 60 °C for 8 h. The solvent was then evaporated and the residue triturated with diethyl ether to give ethyl (6<i>E</i>)-1-benzyl-6-[(dimethylamino)methylidene]-7-oxo-4,5,6,7-tetrahydro-1<i>H</i>-indazole-3-carboxylate (501 mg, 85%). <sup>1</sup>H NMR (401 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.29 (t, <i>J</i> = 7.1 Hz, 3H), 2.80−2.87 (m, 2H), 2.87−2.96 (m, 2H), 3.12 (s, 6H), 4.26 (q, <i>J</i> = 7.1 Hz, 2H), 5.80 (s, 2H), 7.18−7.22 (m, 2H), 7.23−7.34 (m, 2H), 7.51 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 354 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>20</sub>H<sub>23</sub>N<sub>3</sub>O<sub>3</sub> + H<sup>+</sup>, 354.1812; found, 354.1804. To a solution of the above-described ethyl carboxylate (450 mg, 1.27 mmol) in ethanol (20 mL), sodium ethylate (86 mg, 1.27 mmol) and guanidine hydrochloride (121 mg, 1.27 mmol) were added in sequence. The solution was stirred at reflux for 12 h. The solvent was then evaporated, the residue taken up with dichloromethane and washed with water. The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was triturated with diethyl ether and collected by filtration, giving <b>13a</b> (377 mg, 85%). <sup>1</sup>H NMR (401 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.30 (t, <i>J</i> = 7.1 Hz, 3H), 2.75 (t, <i>J</i> = 7.7 Hz, 2H), 2.94 (t, <i>J</i> = 7.7 Hz, 2H), 4.28 (q, <i>J</i> = 7.1 Hz, 2H), 6.07 (s, 2H), 6.63 (bs, 2H), 7.22−7.38 (m, 5H), 8.17 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 350 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>19</sub>H<sub>19</sub>N<sub>5</sub>O<sub>2</sub> + H<sup>+</sup>, 350.1612; found, 350.1618.</div><div class="NLM_p last">By employment of the above-described procedure, starting from intermediates <b>12b</b>−<b>i</b>, compounds <b>13b</b>−<b>i</b> were prepared.</div></div><div id="sec5_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Ethyl 8-Amino-1-phenyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxylate (<b>13b</b>)</h3><div class="NLM_p last">Yield, 56%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.32 (t, <i>J</i> = 7.1 Hz, 3H), 2.80 (m, 2H), 2.99 (m, 2H), 4.33 (q, <i>J</i> = 7.1 Hz, 2H), 6.04 (bs, 2H), 7.50 (m, 3H), 7.56 (m, 2H), 8.20 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 336 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>18</sub>H<sub>17</sub>N<sub>5</sub>O<sub>2</sub> + H<sup>+</sup>, 336.1455; found, 336.1449.</div></div><div id="sec5_61" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> Ethyl 8-Amino-1-(4-methoxyphenyl)-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxylate (<b>13c</b>)</h3><div class="NLM_p last">Yield, 52%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.32 (t, <i>J</i> = 7.1 Hz, 3H), 2.79 (t, <i>J</i> = 7.5 Hz, 2H), 2.98 (t, <i>J</i> = 7.4 Hz, 2H), 3.84 (s, 3H), 4.32 (q, <i>J</i> = 7.1 Hz, 2H), 6.08 (s, 2H), 7.0 (d, <i>J</i> = 9.0 Hz, 2H), 7.48 (d, <i>J</i> = 9.0 Hz, 2H), 8.19 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 366 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>19</sub>H<sub>19</sub>N<sub>5</sub>O<sub>3</sub> + H<sup>+</sup>, 366.1561; found, 366.1564; HPLC purity 85%.</div></div><div id="sec5_62" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> Ethyl 8-Amino-1-(4-sulfamoylphenyl)-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxylate (<b>13d</b>)</h3><div class="NLM_p last">Yield, 60%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.33 (t, <i>J</i> = 7.1 Hz, 3H), 2.82 (t, <i>J</i> = 7.5 Hz, 2H), 3.00 (t, <i>J</i> = 7.4 Hz, 2H), 4.34 (q, <i>J</i> = 7.1 Hz, 2H), 6.12 (s, 2H), 7.43 (s, 2H), 7.81 (d, <i>J</i> = 8.8 Hz, 2H), 7.90−7.97 (m, 2H), 8.23 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 415 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>18</sub>H<sub>18</sub>N<sub>6</sub>O<sub>4</sub>S + H<sup>+</sup>, 415.1183; found, 415.1174.</div></div><div id="sec5_63" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> Ethyl 8-Amino-1-(pyridin-2-yl)-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxylate (<b>13e</b>)</h3><div class="NLM_p last">Yield, 58%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.33 (t, <i>J</i> = 7.1 Hz, 3H), 2.81 (t, <i>J</i> = 7.5 Hz, 2H), 2.99 (t, <i>J</i> = 7.5 Hz, 2H), 4.34 (q, <i>J</i> = 7.1 Hz, 2H), 6.00 (s, 2H), 7.56 (ddd, <i>J</i> = 7.5, 4.8, 1.0 Hz, 1H), 7.67 (dt, <i>J</i> = 7.9, 0.9 Hz, 1H), 8.04 (td, <i>J</i> = 7.7, 1.9 Hz, 1H), 8.20 (s, 1H), 8.51 (ddd, <i>J</i> = 4.8, 1.9, 0.9 Hz, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 337 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>17</sub>H<sub>16</sub>N<sub>6</sub>O<sub>2</sub> + H<sup>+</sup>, 337.1407; found, 337.1394.</div></div><div id="sec5_64" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> Ethyl 8-Amino-1-(2-hydroxyethyl)-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxylate (<b>13f</b>)</h3><div class="NLM_p last">Yield, 70%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.31 (t, <i>J</i> = 7.1 Hz, 3H), 2.74 (t, <i>J</i> = 7.6 Hz, 2H), 2.92 (t, <i>J</i> = 7.5 Hz, 2H), 3.77−3.86 (m, 2H), 4.29 (q, <i>J</i> = 7.1 Hz, 2H), 4.78 (t, <i>J</i> = 5.8 Hz, 1H), 4.82 (t, <i>J</i> = 5.9 Hz, 2H), 6.53 (s, 2H), 8.17 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 304 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>14</sub>H<sub>17</sub>N<sub>5</sub>O<sub>3</sub> + H<sup>+</sup>, 304.1404; found, 304.1412; HPLC purity 80%.</div></div><div id="sec5_65" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> Ethyl 8-Amino-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxylate (<b>13g</b>)</h3><div class="NLM_p last">Yield, 45%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.33 (t, <i>J</i> = 7.1 Hz, 3H), 2.77 (t, <i>J</i> = 7.8 Hz, 2H), 2.97 (t, <i>J</i> = 7.8 Hz, 2H), 4.32 (q, <i>J</i> = 7.1 Hz, 2H), 5.82 (q, <i>J</i> = 8.9 Hz, 2H), 6.65 (s, 2H), 8.22 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 342 (M + H)<sup>+</sup>.</div></div><div id="sec5_66" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> Ethyl 8-Amino-1-(1-methylpiperidin-4-yl)-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxylate (<b>13h</b>)</h3><div class="NLM_p last">Yield, 68%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.31 (t, <i>J</i> = 7.1 Hz, 3H), 1.93 (m, 2H), 2.04 (m, 2H), 2.14−2.24 (m, 4H), 2.25 (s, 3H), 2.72 (m, 2H), 2.87 (bs, 2H), 2.91 (m, 2H), 4.29 (q, <i>J</i> = 7.1 Hz, 2H), 5.55 (tt, <i>J</i> = 11.3, 4.2 Hz, 1H), 6.53 (s, 2H), 6.73−6.74 (m, 1H), 6.77−6.79 (m, 1H), 8.18 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 357 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>18</sub>H<sub>24</sub>N<sub>6</sub>O<sub>2</sub> + H<sup>+</sup>, 357.2033; found, 357.2033.</div></div><div id="sec5_67" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> Ethyl 1-(1-Acetylpiperidin-4-yl)-8-amino-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxylate (<b>13i</b>)</h3><div class="NLM_p last">Yield, 79%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.30 (t, <i>J</i> = 7.1 Hz, 3H), 1.72−2.05 (m, 4H), 2.07 (s, 3H), 2.71−2.76 (m, 2H), 2.73−2.85 (m, 1H), 2.92 (t, <i>J</i> = 7.6 Hz, 2H), 3.26−3.35 (m, 1H), 3.89−4.03 (m, 1H), 4.28 (q, <i>J</i> = 7.1 Hz, 2H), 4.46−4.57 (m, 1H), 5.77−5.95 (m, 1H), 6.60 (s, 2H), 8.19 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 385 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>19</sub>H<sub>24</sub>N<sub>6</sub>O<sub>3</sub> + H<sup>+</sup>, 385.1983; found, 385.1983.</div></div><div id="sec5_68" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> 1-Benzyl-8-(cyclopentylamino)-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>37</b>)</h3><div class="NLM_p">To a suspension of <b>13a</b> (450 mg, 1.29 mmol) in dry DMF (10 mL), cyclopentanone (0.23 mL, 2.58 mmol), sodium triacetoxyborohydride (600 mg, 2.84 mmol), and trifluoroacetic acid (0.7 mL, 9 mmol) were added in sequence. The mixture was stirred at room temperature overnight. After this time, 0.33 N NaOH (54 mL, 18 mmol) was added dropwise to the mixture. The precipitate was filtered, washed with water, and dried in an oven to dryness to give ethyl 1-benzyl-8-(cyclopentylamino)-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxylate (430 mg, 80%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.29 (t, <i>J</i> = 7.1 Hz, 3H), 1.42 (bs, 4H), 1.53−1.65 (m, 2H), 1.75 (bs, 2H), 2.77 (m, 2H), 2.97 (m, 2H), 4.00 (bs, 1H), 4.28 (q, <i>J</i> = 7.1 Hz, 2H), 6.10 (s, 2H), 7.09 (d, <i>J</i> = 7.2 Hz, 1H), 7.17 (m, 2H), 7.25 (m, 1H), 7.31 (m, 2H), 8.21 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 418 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>24</sub>H<sub>27</sub>N<sub>5</sub>O<sub>2</sub> + H<sup>+</sup>, 418.2238; found, 418.2236. A solution of the above-described ethyl carboxylate (300 mg, 0.72 mmol) in a mixture of methanol (10 mL), DMF (10 mL), and 33% NH<sub>4</sub>OH (5 mL) was stirred at 70 °C in a close bottle for 8 h. The solvent was then removed under reduced pressure and the residue dissolved with dichloromethane and washed with water. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. The crude was purified by flash chromatography on a silica gel column (dicloromethane/methanol, 98/2) affording <b>37</b> (223 mg, 80%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.36−1.52 (m, 4H), 1.58−1.83 (m, 4H), 2.79 (t, <i>J</i> = 7.6 Hz, 2H), 3.02 (t, <i>J</i> = 7.6 Hz, 2H), 3.98 (s, 1H), 6.04 (s, 2H), 7.09−7.34 (m, 7H), 7.49 (s, 1H), 7.70 (s, 1H), 8.22 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 389 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>22</sub>H<sub>24</sub>N<sub>6</sub>O + H<sup>+</sup>, 389.2085; found, 389.2090.</div><div class="NLM_p last">By employment of the above-described procedure, starting from intermediates <b>13b</b>−<b>i</b>, compounds <b>38</b>−<b>44</b> and <b>46</b> were prepared.</div></div><div id="sec5_69" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> 8-(Cyclopentylamino)-1-phenyl-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>38</b>)</h3><div class="NLM_p last">Yield, 55%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.01−1.62 (m, 8H), 2.79 (t, <i>J</i> = 7.62 Hz, 2H), 3.02 (t, <i>J</i> = 7.62 Hz, 2H), 3.25−3.31 (m, 1H), 6.75 (s, 1H), 7.32 (s, 1H), 7.43−7.56 (m, 5H), 7.59 (s, 1H), 8.16 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 375 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>21</sub>H<sub>22</sub>N<sub>6</sub>O + H<sup>+</sup>, 375.1928; found, 375.1933.</div></div><div id="sec5_70" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> 8-(Cyclopentylamino)-1-(pyridin-2-yl)-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>39</b>)</h3><div class="NLM_p last">Yield, 50%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.04−1.63 (m, 8H), 2.80 (t, <i>J</i> = 7.7 Hz, 2H), 3.02 (t, <i>J</i> = 7.7 Hz, 2H), 3.11−3.61 (m, 1H), 6.77 (s, 1H), 7.35 (s, 1H), 7.56 (ddd, <i>J</i> = 7.5, 4.8, 1.1 Hz, 1H), 7.63 (s, 1H), 7.66 (dt, <i>J</i> = 7.9, 0.9 Hz, 1H), 8.02−8.08 (m, 1H), 8.17 (s, 1H), 8.56 (ddd, <i>J</i> = 4.8, 1.8, 0.9 Hz, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 376 (M + H)<sup>+</sup>.</div></div><div id="sec5_71" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> 8-(Cyclopentylamino)-1-(4-methoxyphenyl)-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>40</b>)</h3><div class="NLM_p last">Yield, 52%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 0.98−1.66 (m, 8H), 2.77 (t, <i>J</i> = 7.6 Hz, 2H), 3.01 (t, <i>J</i> = 7.6 Hz, 2H), 3.20−3.42 (m, 1H), 3.80 (s, 3H), 6.77 (d, <i>J</i> = 5.8 Hz, 1H), 7.02 (d, <i>J</i> = 9.0 Hz, 2H), 7.29 (s, 1H), 7.44 (d, <i>J</i> = 8.9 Hz, 2H), 7.56 (s, 1H), 8.14 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 405 (M + H)<sup>+</sup>; Anal. (C<sub>22</sub>H<sub>24</sub>N<sub>6</sub>O<sub>2</sub>) C, H, N.</div></div><div id="sec5_72" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> 8-(Cyclopentylamino)-1-(4-sulfamoylphenyl)-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>41</b>)</h3><div class="NLM_p last">Yield, 48%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.07−1.66 (m, 8H), 2.85 (t, <i>J</i> = 7.4 Hz, 2H), 3.06 (t, <i>J</i> = 7.4 Hz, 2H), 3.27−3.55 (m, 1H), 7.45 (s, 4H), 7.69 (s, 1H), 7.81 (d, <i>J</i> = 8.6 Hz, 2H), 7.93 (d, <i>J</i> = 8.6 Hz, 2H), 8.23 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 454 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>21</sub>H<sub>23</sub>N<sub>7</sub>O<sub>3</sub>S + H<sup>+</sup>, 454.1656; found, 454.1651; Anal. (C<sub>21</sub>H<sub>23</sub>N<sub>7</sub>O<sub>3</sub>S) C, H, N, S.</div></div><div id="sec5_73" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> 8-(Cyclopentylamino)-1-(2-hydroxyethyl)-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>42</b>)</h3><div class="NLM_p last">Yield, 51%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.39−1.76 (m, 6H), 1.83−1.99 (m, 2H), 2.71 (t, <i>J</i> = 7.7 Hz, 2H), 2.93 (t, <i>J</i> = 7.6 Hz, 2H), 3.84 (t, <i>J</i> = 6.1 Hz, 2H), 4.07−4.24 (m, 1H), 4.71−4.88 (m, 1H), 4.80 (t, <i>J</i> = 6.2 Hz, 2H), 7.03 (d, <i>J</i> = 6.0 Hz, 1H), 7.22 (s, 1H), 7.41 (s, 1H), 8.19 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 343 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>17</sub>H<sub>22</sub>N<sub>6</sub>O<sub>2</sub> + H<sup>+</sup>, 343.1877; found, 343.1876.</div></div><div id="sec5_74" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> 8-(Cyclopentylamino)-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>43</b>)</h3><div class="NLM_p last">Yield, 53%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.40−1.76 (m, 6H), 1.82−1.98 (m, 2H), 2.76 (t, <i>J</i> = 7.7 Hz, 2H), 2.97 (t, <i>J</i> = 7.7 Hz, 2H), 4.00−4.18 (m, 1H), 5.79 (q, <i>J</i> = 8.8 Hz, 2H), 7.20 (d, <i>J</i> = 6.9 Hz, 1H), 7.39 (s, 1H), 7.44 (s, 1H), 8.24 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 381 (M + H)<sup>+</sup>; Anal. (C<sub>17</sub>H<sub>19</sub>F<sub>3</sub>N<sub>6</sub>O) C, H, N.</div></div><div id="sec5_75" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> 8-(Cyclopentylamino)-1-(1-methylpiperidin-4-yl)-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>44</b>)</h3><div class="NLM_p last">Yield, 58%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.4−1.63 (m, 4H), 1.68−1.79 (m, 2H), 1.83−2.11 (m, 4H), 2.09−2.32 (m, 6H), 2.67−2.73 (m, 2H), 2.92 (t, <i>J</i> = 7.7 Hz, 2H), 2.98 (bs, 2H), 4.17 (sxt, <i>J</i> = 7.0 Hz, 1H), 5.58 (bs, 1H), 7.08 (bs, 1H), 7.24 (bs, 1H), 7.33 (bs, 1H), 8.19 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 396 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>21</sub>H<sub>29</sub>N<sub>7</sub>O + H<sup>+</sup>, 396.2507; found, 396.2507.</div></div><div id="sec5_76" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> 1-(1-Acetylpiperidin-4-yl)-8-(cyclopentylamino)-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>46</b>)</h3><div class="NLM_p last">Yield, 49%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.43−1.60 (m, 4H), 1.71 (m, 2H), 1.89−2.04 (m, 6H), 2.06 (s, 3H), 2.65 (bs, 1H), 2.71 (t, <i>J</i> = 7.7 Hz, 2H), 2.85−2.99 (m, 2H), 3.07−3.21 (m, 1H), 4.02 (m, 1H), 4.16 (m, 1H), 4.55 (m, 1H), 5.81 (m, 1H), 7.07 (bs, 1H), 7.21 (s, 1H), 7.41 (s, 1H), 8.20 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 424 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>22</sub>H<sub>29</sub>N<sub>7</sub>O<sub>2</sub> + H<sup>+</sup>, 424.2456; found, 424.2457.</div></div><div id="sec5_77" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> 8-(Cyclopentylamino)-<i>N</i>-methyl-1-(1-methylpiperidin-4-yl)-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (<b>45</b>)</h3><div class="NLM_p last">To a suspension of <b>13h</b> (1.0 g, 2.80 mmol) in dry DMF (20 mL), cyclopentanone (0.5 mL, 5.6 mmol), trifluoroacetic acid (1.53 mL, 19.6 mmol), and sodium triacetoxyborohydride (1.3 g, 6.16 mmol) were added. After 18 h, 0.33 N NaOH (119 mL, 39.2 mmol) was added dropwise to the mixture. The precipitate was filtered and dried in oven to give ethyl 8-(cyclopentylamino)-1-(1-methylpiperidin-4-yl)-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxylate (949 mg, 80%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.31 (t, <i>J</i> = 7.1 Hz, 3H), 1.44−1.64 (m, 4H), 1.73 (m, 2H), 1.90−2.02 (m, 6H), 2.13 (m, 2H), 2.25 (bs, 3H), 2.73 (m, 2H), 2.92 (m, 2H), 2.99 (bs, 2H), 4.17 (m, 1H), 4.29 (q, <i>J</i> = 7.1 Hz, 2H), 5.63 (m, 1H), 7.12 (bs, 1H), 8.21 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 425 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>23</sub>H<sub>32</sub>N<sub>6</sub>O<sub>2</sub> + H<sup>+</sup>, 425.2660; found, 425.2658. To a solution of the above-described ethyl carboxylate (800 mg, 1.89 mmol) in ethanol (50 mL) was added 33 wt % methylamine in absolute ethanol (15 mL). The solution was stirred at 60 °C in a closed bottle for 8 h. The solvent was then removed under reduced pressure and the crude purified by flash chromatography on a silica gel column (dichloromethane/methanol/triethylamine, 95/5/5) affording <b>45</b> (603 mg, 78%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.43−1.62 (m, 4H), 1.74 (m, 2H), 1.87−2.06 (m, 6H), 2.13−2.20 (m, 2H), 2.21 (s, 3H), 2.67−2.73 (m, 2H), 2.75 (d, <i>J</i> = 4.8 Hz, 3H), 2.92 (t, <i>J</i> = 7.7 Hz, 2H), 2.96 (bs, 2H), 4.17 (sxt, <i>J</i> = 7.2 Hz, 1H), 5.57 (tt, <i>J</i> = 11.4, 3.9 Hz, 1H), 7.09 (bs, 1H), 7.93 (m, 1H), 8.19 (s, 1H); LCMS (ESI) <i>m</i>/<i>z</i> 410 (M + H)<sup>+</sup>; HRMS (ESI) calcd for C<sub>22</sub>H<sub>31</sub>N<sub>7</sub>O + H<sup>+</sup>, 410.2663; found, 410.2668.</div></div><div id="sec5_78" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> Crystallographic Methods</h3><div class="NLM_p last">Expression, purification, crystallization, and soaking procedures of the CDK2/cyclin A complexes were carried out as previously described.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div></div><div id="sec5_79" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> Kinase Assays</h3><div class="NLM_p last">Kinase assays were performed as previously described.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The panel includes the following: c-ABL, ACK1, ALK, AKT1, Aur-A, Aur-B, BRK, BUB1, CDC7/DBF4, CDK2/CyA, CDK2/CyE, CDK1/CyB, CDK5/p25, CDK4/CyD1, GSK-3β, CHK1, CK2, EEF2K, EGFR, ERK2, FAK, FGFR1, FLT3, IGF1R, IKK1, IKK2, IR, JAK1, JAK3, C-KIT, LCK, LYN, MAPKAPK2, MET, MNK2, MST4, NEK6, NIM, PAK4, PDGFR, PDK1, PERK, PIM1, PIM2, PKAα, PKCβ, PLK1, RET, SYK, SULU1, TYK, TRKA, VEGFR2, VEGFR3, and ZAP70.</div></div><div id="sec5_80" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> In Vitro Pharmacology. A2780 Cells Proliferation Assay</h3><div class="NLM_p last">This cell line was selected for the screening of compounds active against CDKs because it has a high proliferation rate (doubling time of 21 h). Cells were seeded into 96 or 384 wells plates at final concentration ranging from 10000 to 30000 cells per cm<sup>2</sup> in appropriate medium plus 10% FCS. After 24 h, cells were treated with scalar doses of test compounds in two replicates. Compound dilutions were prepared in 100% DMSO at 1000-fold concentration, and then diluted in the culture medium to have in the wells the desired compound dose with a final DMSO concentration of 0.1% that does not interfere with cell proliferation. A total of 72 h after the treatment, the cell number was evaluated using the Cell Titer_Glo Assay (Promega). IC<sub>50</sub>s were calculated using a Sygmoidal fitting (Symyx Assay Explorer). Experiments were replicated at least two times.</div></div><div id="sec5_81" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> Flow Cytometry Analysis, Immunoblot, and BrdU Incorporation</h3><div class="NLM_p last">A2780 cells (human ovary adenocarcinoma, from ECACC), were seeded in T-75 tissue culture flasks, 25000 cells/cm<sup>2</sup> in RPMI 1640, pH 7.4, 10% FBS, 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine, 1× penicillin-streptomycin, and maintained in 5% CO<sub>2</sub> at 37 °C with 96% relative humidity. After 24 h, cells were treated with the compound at 1 and 3 μM for 24 h, approximately 3- and 10-fold the IC<sub>50</sub> measured in 72 h proliferation study. Both detached and adherent cells were collected using 0.25% trypsin, 0.02% EDTA, washed in PBS, and divided into three samples for flow cytometry analysis, immunoblot, and BrdU incorporation as previously described.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> In particular, the sample for cell cycle analysis was fixed in ethanol 70% in PBS for at least 12 h. DNA staining was performed using a solution of propidium iodide 25 μg/mL in sodium citrate 1% containing RNase A (2 μg/mL) and 0.002% NP-40 (Sigma). After 1 h at room temperature, samples were acquired and analyzed using a FACS-Calibur flow cytometer (Beckton Dickinson). The DNA histograms were analyzed by Modfit 3.0 (Verity Software House).</div></div><div id="sec5_82" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> In Vivo Pharmacology</h3><div class="NLM_p last">All animal studies were carried out in compliance with Italian Legislative Decree No. 116, dated January 27, 1992, and the European Communities Council Directive No. 86/609/EEC concerning the protection of animals for experimental purposes and according to institutional policy regarding the care and use of laboratory animals. Female nu/nu mice (Harlan), 5−6 weeks age (average weight 20−22 g) were used. A2780 human ovarian carcinoma cells were transplanted s.c. in athymic mice. Mice bearing a palpable tumor were selected and randomized into vehicle and treated groups (Mean: 180 mg). Treatments started the day after randomization. Compound <b>59</b> was dissolved in 5% dextrose. Treatments were administered twice a day for 10 consecutive days. Dimensions of the tumors were measured regularly using Vernier calipers for all the duration of the experiment and tumor masses and tumor growth inhibition were calculated as described.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The effectiveness of the anticancer treatment was also determined as the delay in the onset of the exponential growth of the tumor according to the criteria of Bissery et al.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Tumor growth delay was defined as the difference between the treatment and the control group in the median time (in days) to reach the predetermined size of 1 g.</div></div><div id="sec5_83" class="NLM_sec NLM_sec_level_2"><div id="ac_i98" class="anchor-spacer"></div><h3 class="article-section__title" id="_i98"> High-Throughput Solubility</h3><div class="NLM_p last">Solubility at pH 7 was evaluated as previously described.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div></div><div id="sec5_84" class="NLM_sec NLM_sec_level_2"><div id="ac_i99" class="anchor-spacer"></div><h3 class="article-section__title" id="_i99"> Metabolic Stability</h3><div class="NLM_p last">Compound was dissolved in DMSO at 10 μM concentration. Human cDNA expressed cytochrome P450 isoforms (supersomes) were purchased from Gentest (Woburn, MA). All chemicals were of analytical grade and commercially available. The potential inhibitory effect was investigated against cDNA expressed human CYP4503A4 supersome using typical substrates incubated at their respective Km concentration. The reference inhibitor ketoconazole was included to check the inhibition response. Analysis of both substrate and metabolite was done by LC/MS/MS.</div></div><div id="sec5_85" class="NLM_sec NLM_sec_level_2"><div id="ac_i100" class="anchor-spacer"></div><h3 class="article-section__title" id="_i100"> Plasma Protein Binding</h3><div class="NLM_p last">Plasma protein binding was evaluated as previously described.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div></div><div id="sec5_86" class="NLM_sec NLM_sec_level_2"><div id="ac_i101" class="anchor-spacer"></div><h3 class="article-section__title" id="_i101"> In Vivo Pharmacokinetics</h3><div class="NLM_p last">The pharmacokinetic profile of the compounds was investigated in overnight fasted male Nu/Nu mice following a single dose given intravenously (iv) or orally (po). The vehicle used was 5% dextrose solution. A total of six mice were treated (three for each leg). Pharmacokinetic analysis was also repeated in three A2780 tumor bearing female Balb nu/nu mice the last day of treatment with 20 mg/kg twice a day orally for 10 consecutive days. Blood samples of each mouse were collected from the saphenous vein at predose, 0.083, 0.5, 1, 6, and 24 h postdosing following iv dosing, and at predose, 0.25, 0.5, 1, 6, and 24 h following oral dosing. Samples were centrifuged at 10000 g for 3 min at 4 °C and the plasma was stored at −80 °C until analysis. Samples were analyzed by LC/MS/MS technique.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i103"><a href="/doi/suppl/10.1021/jm901710h">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45124" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45124" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">X-ray crystallographic studies of compound <b>59</b>; Elemental analysis results of compounds <b>1</b>, <b>14</b>, <b>17</b>, <b>19</b>−<b>27</b>, <b>34</b>, <b>35</b>, <b>40</b>, <b>41</b>, <b>43</b>, <b>56</b>, and <b>59</b>. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm901710h/suppl_file/jm901710h_si_001.pdf">jm901710h_si_001.pdf (133.24 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm901710h" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21730" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21730" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gabriella Traquandi</span> - <span class="hlFld-Affiliation affiliation">Nerviano Medical Sciences Srl, Business Unit Oncology, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Accelera Srl, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#0d6a6c6f7f646861616c23797f6c7c786c6369644d63687f7b646c6362607e236e6260"><span class="__cf_email__" data-cfemail="385f595a4a515d545459164c4a59494d59565c5178565d4a4e51595657554b165b5755">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marina Ciomei</span> - <span class="hlFld-Affiliation affiliation">Nerviano Medical Sciences Srl, Business Unit Oncology, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Accelera Srl, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dario Ballinari</span> - <span class="hlFld-Affiliation affiliation">Nerviano Medical Sciences Srl, Business Unit Oncology, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Accelera Srl, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elena Casale</span> - <span class="hlFld-Affiliation affiliation">Nerviano Medical Sciences Srl, Business Unit Oncology, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Accelera Srl, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicoletta Colombo</span> - <span class="hlFld-Affiliation affiliation">Nerviano Medical Sciences Srl, Business Unit Oncology, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Accelera Srl, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Valter Croci</span> - <span class="hlFld-Affiliation affiliation">Nerviano Medical Sciences Srl, Business Unit Oncology, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Accelera Srl, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Francesco Fiorentini</span> - <span class="hlFld-Affiliation affiliation">Accelera Srl, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Antonella Isacchi</span> - <span class="hlFld-Affiliation affiliation">Nerviano Medical Sciences Srl, Business Unit Oncology, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Accelera Srl, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Antonio Longo</span> - <span class="hlFld-Affiliation affiliation">Nerviano Medical Sciences Srl, Business Unit Oncology, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Accelera Srl, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ciro Mercurio</span> - <span class="hlFld-Affiliation affiliation">Nerviano Medical Sciences Srl, Business Unit Oncology, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Accelera Srl, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Achille Panzeri</span> - <span class="hlFld-Affiliation affiliation">Nerviano Medical Sciences Srl, Business Unit Oncology, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Accelera Srl, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wilma Pastori</span> - <span class="hlFld-Affiliation affiliation">Nerviano Medical Sciences Srl, Business Unit Oncology, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Accelera Srl, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paolo Pevarello</span> - <span class="hlFld-Affiliation affiliation">Nerviano Medical Sciences Srl, Business Unit Oncology, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Accelera Srl, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniele Volpi</span> - <span class="hlFld-Affiliation affiliation">Nerviano Medical Sciences Srl, Business Unit Oncology, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Accelera Srl, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patrick Roussel</span> - <span class="hlFld-Affiliation affiliation">Nerviano Medical Sciences Srl, Business Unit Oncology, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Accelera Srl, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anna Vulpetti</span> - <span class="hlFld-Affiliation affiliation">Nerviano Medical Sciences Srl, Business Unit Oncology, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Accelera Srl, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maria Gabriella Brasca</span> - <span class="hlFld-Affiliation affiliation">Nerviano Medical Sciences Srl, Business Unit Oncology, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Accelera Srl, Viale Pasteur 10, 20014 Nerviano (MI), Italy</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="ack"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i102">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30026" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30026" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Walter Moretti and Piero Sansonna for their skilled synthetic chemistry support. We thank Maristella Colombo and Federico Riccardi Sirtori for skillful assistance in MS spectra recording and interpretation, and Clara Albanese for her support in flow cytometry analysis. We are also grateful to Nilla Avanzi and the group of Assay Development and to Marcella Nesi and Luisa Rusconi for their enlightening advices.</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i104">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14566" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14566" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 22 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Massagué, J.</span><span> </span><span class="NLM_article-title">G1 cell cycle and cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">432</span><span class="NLM_x">, </span> <span class="NLM_fpage">298</span><span class="NLM_x">–</span> <span class="NLM_lpage">306</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=432&publication_year=2004&pages=298-306&author=J.+Massagu%C3%A9&title=G1+cell+cycle+and+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMassagu%25C3%25A9%26aufirst%3DJ.%26atitle%3DG1%2520cell%2520cycle%2520and%2520cancer%26jtitle%3DNature%26date%3D2004%26volume%3D432%26spage%3D298%26epage%3D306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Grana, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span> </span><span class="NLM_article-title">Cell cycle control in mammalian cells: role of cyclins, cyclin-dependent kinases (CDKs), growth suppressor genes, and cyclin-dependent kinase inhibitors (CKIs)</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1995&pages=211-219&author=X.+Granaauthor=E.+P.+Reddy&title=Cell+cycle+control+in+mammalian+cells%3A+role+of+cyclins%2C+cyclin-dependent+kinases+%28CDKs%29%2C+growth+suppressor+genes%2C+and+cyclin-dependent+kinase+inhibitors+%28CKIs%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGrana%26aufirst%3DX.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DCell%2520cycle%2520control%2520in%2520mammalian%2520cells%253A%2520role%2520of%2520cyclins%252C%2520cyclin-dependent%2520kinases%2520%2528CDKs%2529%252C%2520growth%2520suppressor%2520genes%252C%2520and%2520cyclin-dependent%2520kinase%2520inhibitors%2520%2528CKIs%2529%26jtitle%3DOncogene%26date%3D1995%26volume%3D11%26spage%3D211%26epage%3D219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Morgan, D. O.</span><span> </span><span class="NLM_article-title">Principles of CDK regulation</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">374</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">134</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Fjm901710h&amp;key=10.1038%2F374131a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Fjm901710h&amp;key=7877684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Fjm901710h&amp;key=1%3ACAS%3A528%3ADyaK2MXkt1yju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=1995&pages=131-134&author=D.+O.+Morgan&title=Principles+of+CDK+regulation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Principles of CDK regulation</span></div><div class="casAuthors">Morgan, David O.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">6518</span>),
    <span class="NLM_cas:pages">131-4</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">A review with 77 refs.  As key regulators of the cell cycle, the cyclin-dependent kinases (CDKs) must be tightly regulated by extra- and intracellular signals.  The activity of cyclin-dependent kinases is controlled by four highly conserved biochem. mechanisms, forming a web of regulatory pathways unmatched in its elegance and intricacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrQWC7U9kpj7Vg90H21EOLACvtfcHk0lhW30myAK6txQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXkt1yju7s%253D&md5=3dafa23aec02e4887757b100abb52d89</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1038%2F374131a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F374131a0%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DD.%2BO.%26atitle%3DPrinciples%2520of%2520CDK%2520regulation%26jtitle%3DNature%26date%3D1995%26volume%3D374%26spage%3D131%26epage%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Dynlacht, B.</span><span> </span><span class="NLM_article-title">Regulation of transcription during the cell cycle</span> <span class="citation_source-journal">Transcription Factors</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_fpage">85</span><span class="NLM_x">–</span> <span class="NLM_lpage">112</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Fjm901710h&amp;key=1%3ACAS%3A528%3ADC%252BD3cXovFWgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&pages=85-112&author=B.+Dynlacht&title=Regulation+of+transcription+during+the+cell+cycle"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of transcription during the cell cycle</span></div><div class="casAuthors">Dynlacht, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Transcription Factors</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">85-112</span>CODEN:
                <span class="NLM_cas:coden">69ATCS</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">BIOS Scientific Publishers Ltd.</span>)
        </div><div class="casAbstract">A review with 198 refs emphasizing recent advances in understanding of factors regulating transcription during cell-cycle progression in mammalian cells.  Studies in this system are providing a unified view of the regulatory controls based on the sequential activation of CDKs during G1 phase and S phase entry.  These kinases progressively inhibit the retinoblastoma (pRB) tumor-sup- pressor protein and initially promote, and then inhibit, E2F, a transcription factor that displays the properties of an oncogene and tumor suppressor.  This leads to the timely activation of genes required for cell-cycle progression.  Similarly, cyclin B/Cdc2 activity inhibits a no. of transcriptional regulators during M phase.  Two other CDK complexes that have less clear roles in cell-cycle regulation, cyclin H/Cdk7 and cyclin C/Cdk8, modify pol II thereby regulating the initiation and progression of transcription.  Recent results further suggest intriguing parallels between the mechanisms that regulate transcription by all three RNA polymerases during the cell cycle and conservation of transcriptional controls between yeast and mammalian cells.  Thus, an intricate balance of transcriptional and post-translational controls govern the activity of transcription factors that propel the cell cycle in a unidirectional manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6rja6WN4tk7Vg90H21EOLACvtfcHk0lhW30myAK6txQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXovFWgtL4%253D&md5=f98c23b9cec17dd2a25ddcf84d3a9b56</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDynlacht%26aufirst%3DB.%26atitle%3DRegulation%2520of%2520transcription%2520during%2520the%2520cell%2520cycle%26jtitle%3DTranscription%2520Factors%26date%3D2001%26spage%3D85%26epage%3D112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">De Falco, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, A.</span><span> </span><span class="NLM_article-title">CDK9: from basal transcription to cancer and AIDS</span> <span class="citation_source-journal">Cancer Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">342</span><span class="NLM_x">–</span> <span class="NLM_lpage">347</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Fjm901710h&amp;key=12432243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Fjm901710h&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlsFygsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=342-347&author=G.+De+Falcoauthor=A.+Giordano&title=CDK9%3A+from+basal+transcription+to+cancer+and+AIDS"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">CDK9: from basal transcription to cancer and AIDS</span></div><div class="casAuthors">De Falco, Giulia; Giordano, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">342-347</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  Cdk9 is a member of the Cdc2-like family of kinases.  Its cyclin partners are members of the family of cyclin T (T1, T2a and T2b) and cyclin K.  The Cdk9/cyclin T complexes appear to be involved in regulating several physiol. processes.  Cdk9/cyclin T1 belongs to the P-TEFb complex, and is responsible for the phosphorylation of the carboxyl-terminal domain (CTD) of the RNA Polymerase II, thus promoting general elongation.  Cdk9 has also been described as the kinase of the TAK complex, which is homologous to the P-TEFb complex and involved in HIV replication.  Cdk9 also appears to be involved in the differentiation program of several cell types, such as muscle cells, monocytes and neurons, suggesting that it may have a function in controlling specific differentiative pathways.  In addn., Cdk9 seems to have an anti-apoptotic function in monocytes, that may be related to its control over differentiation of monocytes.  This data suggests the involvement of Cdk9 in several physiol. processes in the cell, the deregulation of which may be related to the genesis of transforming events, that may in turn lead to the onset of cancer.  In addn., since the complex Cdk9/cyclin T1 is able to bind to the HIV-1 product Tat, the study of the functions of Cdk9/cyclin T may be of interest in understanding the basal mechanisms that regulate HIV replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-K3Ihi8BcqLVg90H21EOLACvtfcHk0lhW30myAK6txQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlsFygsQ%253D%253D&md5=27ca2c40fa916694ef9d8e8dadfc7bf9</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BFalco%26aufirst%3DG.%26aulast%3DGiordano%26aufirst%3DA.%26atitle%3DCDK9%253A%2520from%2520basal%2520transcription%2520to%2520cancer%2520and%2520AIDS%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2002%26volume%3D1%26spage%3D342%26epage%3D347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Cruz, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, L. A.</span><span> </span><span class="NLM_article-title">Jekyll and Hyde kinase: roles for Cdk5 in brain development and disease</span> <span class="citation_source-journal">Curr. Opin. Neurobiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">390</span><span class="NLM_x">–</span> <span class="NLM_lpage">394</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=390-394&author=J.+C.+Cruzauthor=L.+A.+Tsai&title=Jekyll+and+Hyde+kinase%3A+roles+for+Cdk5+in+brain+development+and+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCruz%26aufirst%3DJ.%2BC.%26aulast%3DTsai%26aufirst%3DL.%2BA.%26atitle%3DJekyll%2520and%2520Hyde%2520kinase%253A%2520roles%2520for%2520Cdk5%2520in%2520brain%2520development%2520and%2520disease%26jtitle%3DCurr.%2520Opin.%2520Neurobiol.%26date%3D2004%26volume%3D14%26spage%3D390%26epage%3D394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span> </span><span class="NLM_article-title">Cyclin-dependent kinase pathways as targets for cancer treatment</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1770</span><span class="NLM_x">–</span> <span class="NLM_lpage">1783</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Fjm901710h&amp;key=10.1200%2FJCO.2005.03.7689" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Fjm901710h&amp;key=16603719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Fjm901710h&amp;key=1%3ACAS%3A528%3ADC%252BD28XksVKgtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=1770-1783&author=G.+I.+Shapiro&title=Cyclin-dependent+kinase+pathways+as+targets+for+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase pathways as targets for cancer treatment</span></div><div class="casAuthors">Shapiro, Geoffrey I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1770-1783</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Cyclin-dependent kinases (cdks) are crit. regulators of cell cycle progression and RNA transcription.  A variety of genetic and epigenetic events cause universal overactivity of the cell cycle cdks in human cancer, and their inhibition can lead to both cell cycle arrest and apoptosis.  However, built-in redundancy may limit the effects of highly selective cdk inhibition.  Cdk4/6 inhibition has been shown to induce potent G1 arrest in vitro and tumor regression in vivo; cdk2/1 inhibition has the most potent effects during the S and G2 phases and induces E2F transcription factor-dependent cell death.  Modulation of cdk2 and cdk1 activities also affects survival checkpoint responses after exposure to DNA-damaging and microtubule-stabilizing agents.  The transcriptional cdks phosphorylate the carboxy-terminal domain of RNA polymerase II, facilitating efficient transcriptional initiation and elongation.  Inhibition of these cdks primarily affects the accumulation of transcripts with short half-lives, including those encoding antiapoptosis family members, cell cycle regulators, as well as p53 and nuclear factor-kappa B-responsive gene targets.  These effects may account for apoptosis induced by cdk9 inhibitors, esp. in malignant hematopoietic cells, and may also potentiate cytotoxicity mediated by disruption of a variety of pathways in many transformed cell types.  Current work is focusing on overcoming pharmacokinetic barriers that hindered development of flavopiridol, a pan-cdk inhibitor, as well as assessing novel classes of compds. potently targeting groups of cell cycle cdks (cdk4/6 or cdk2/1) with variable effects on the transcriptional cdks 7 and 9.  These efforts will establish whether the strategy of cdk inhibition is able to produce therapeutic benefit in the majority of human tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYfmCpSfvpTbVg90H21EOLACvtfcHk0lgKcG8_lT4OFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksVKgtbg%253D&md5=420a31b47f6600625f7d499a4b8a5fc9</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.03.7689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.03.7689%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DCyclin-dependent%2520kinase%2520pathways%2520as%2520targets%2520for%2520cancer%2520treatment%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D1770%26epage%3D1783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Dyson, N.</span><span> </span><span class="NLM_article-title">The regulation of E2F by pRb-family proteins</span> <span class="citation_source-journal">Gene Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2245</span><span class="NLM_x">–</span> <span class="NLM_lpage">2262</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Fjm901710h&amp;key=10.1101%2Fgad.12.15.2245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Fjm901710h&amp;key=9694791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Fjm901710h&amp;key=1%3ACAS%3A528%3ADyaK1cXltlagu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1998&pages=2245-2262&author=N.+Dyson&title=The+regulation+of+E2F+by+pRb-family+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">The regulation of E2F by pRB-family proteins</span></div><div class="casAuthors">Dyson, Nicholas</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2245-2262</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">A review with over 100 refs.  Topics include: Introduction to the families of E2F and DP proteins (free E2F, complexed E2F), E2F-binding sites mediate both transcriptional activation and repression (E2F as a transcriptional activator, E2F-mediated repression), Activation of E2F-dependent transcription (phosphorylation of pRB-family members, phosphorylation of E2F-1, changes in the subcellular localization of specific E2F complexes, synthesis of new E2Fs), Inactivation of E2F (E2F/DP phosphorylation, degrdn. of free E2F, E2F-repressors), Consequences of elevated E2F activity-ectopic S-phase entry and apoptosis, Is E2F required for S-phase entry, What are the key targets of E2F activity, What is the role of pRB in E2F regulation, Is the ability of pRB to bind E2F important for pRB's role as a tumor suppressor, and How can E2F-1 be both an oncogene and a tumor suppressor gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeXAl9aLvm5bVg90H21EOLACvtfcHk0lgKcG8_lT4OFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXltlagu74%253D&md5=755af21d258487f59a09899698e860e8</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1101%2Fgad.12.15.2245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.12.15.2245%26sid%3Dliteratum%253Aachs%26aulast%3DDyson%26aufirst%3DN.%26atitle%3DThe%2520regulation%2520of%2520E2F%2520by%2520pRb-family%2520proteins%26jtitle%3DGene%2520Dev.%26date%3D1998%26volume%3D12%26spage%3D2245%26epage%3D2262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hanahan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, R. A.</span><span> </span><span class="NLM_article-title">The hallmarks of cancer</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">–</span> <span class="NLM_lpage">70</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Fjm901710h&amp;key=10.1016%2FS0092-8674%2800%2981683-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Fjm901710h&amp;key=10647931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Fjm901710h&amp;key=1%3ACAS%3A528%3ADC%252BD3cXks1CktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2000&pages=57-70&author=D.+Hanahanauthor=R.+A.+Weinberg&title=The+hallmarks+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">The hallmarks of cancer</span></div><div class="casAuthors">Hanahan, Douglas; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-70</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review is given with many refs. on principles governing the transformation of normal human cells into malignant cancers.  The authors suggest that research over the past decades has revealed a small no. of mol., biochem., and cellular traits (acquired capabilities) shared by most and perhaps all types of cancer.  Topics included are the acquired capabilities self-sufficiency in growth signals, insensitivity to antigrowth signals, evading apoptosis, limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis followed by genome instability as an enabling characteristic and alternative pathways to cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooXmGqKjM1C7Vg90H21EOLACvtfcHk0lgKcG8_lT4OFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXks1CktA%253D%253D&md5=1d23c4400dad34c7f32d4a0c41890349</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981683-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981683-9%26sid%3Dliteratum%253Aachs%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DThe%2520hallmarks%2520of%2520cancer%26jtitle%3DCell%26date%3D2000%26volume%3D100%26spage%3D57%26epage%3D70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Malumbres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span> </span><span class="NLM_article-title">Cell cycle, CDKs and cancer: a changing paradigm</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">166</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Fjm901710h&amp;key=10.1038%2Fnrc2602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Fjm901710h&amp;key=19238148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Fjm901710h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=153-166&author=M.+Malumbresauthor=M.+Barbacid&title=Cell+cycle%2C+CDKs+and+cancer%3A+a+changing+paradigm"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle, CDKs and cancer: a changing paradigm</span></div><div class="casAuthors">Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">153-166</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor-assocd. cell cycle defects are often mediated by alterations in cyclin-dependent kinase (CDK) activity.  Misregulated CDKs induce unscheduled proliferation as well as genomic and chromosomal instability.  According to current models, mammalian CDKs are essential for driving each cell cycle phase, so therapeutic strategies that block CDK activity are unlikely to selectively target tumor cells.  However, recent genetic evidence has revealed that, whereas CDK1 is required for the cell cycle, interphase CDKs are only essential for proliferation of specialized cells.  Emerging evidence suggests that tumor cells may also require specific interphase CDKs for proliferation.  Thus, selective CDK inhibition may provide therapeutic benefit against certain human neoplasias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzlIKlbCPWnLVg90H21EOLACvtfcHk0lgKcG8_lT4OFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D&md5=2a7eb34b2381e288b3f43ec1bffc0aec</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1038%2Fnrc2602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2602%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DCell%2520cycle%252C%2520CDKs%2520and%2520cancer%253A%2520a%2520changing%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D153%26epage%3D166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Malumbres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span> </span><span class="NLM_article-title">Milestones in cell division: to cycle or not to cycle: a critical decision in cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">222</span><span class="NLM_x">–</span> <span class="NLM_lpage">231</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=16&amp;doi=10.1021%2Fjm901710h&amp;key=10.1038%2F35106065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=8&amp;doi=10.1021%2Fjm901710h&amp;key=11902577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=32&amp;doi=10.1021%2Fjm901710h&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvF2qtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=222-231&author=M.+Malumbresauthor=M.+Barbacid&title=Milestones+in+cell+division%3A+to+cycle+or+not+to+cycle%3A+a+critical+decision+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5cR"><div class="casContent"><span class="casTitleNuber">5c</span><div class="casTitle"><span class="NLM_cas:atitle">Milestones in cell division: to cycle or not to cycle: a critical decision in cancer</span></div><div class="casAuthors">Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">222-231</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor cells undergo uncontrolled proliferation, yet tumors most often originate from adult tissues, in which most cells are quiescent.  So, the proliferative advantage of tumor cells arises from their ability to bypass quiescence.  This can be due to increased mitogenic signaling and/or alterations that lower the threshold required for cell-cycle commitment.  Understanding the mol. mechanisms that underlie this commitment should provide important insights into how normal cells become tumorigenic and how new anticancer strategies can be devised.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI2EOLFB2ULbVg90H21EOLACvtfcHk0li9135P51kHgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvF2qtrg%253D&md5=2bd8961854332a30c814f8ac2f9bd6f4</span></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=10.1038%2F35106065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35106065%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DMilestones%2520in%2520cell%2520division%253A%2520to%2520cycle%2520or%2520not%2520to%2520cycle%253A%2520a%2520critical%2520decision%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2001%26volume%3D1%26spage%3D222%26epage%3D231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sherr, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, J. M.</span><span> </span><span class="NLM_article-title">Inhibitors of mammalian G1 cyclin-dependent kinases</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1149</span><span class="NLM_x">–</span> <span class="NLM_lpage">1163</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1995&pages=1149-1163&author=C.+J.+Sherrauthor=J.+M.+Robert&title=Inhibitors+of+mammalian+G1+cyclin-dependent+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSherr%26aufirst%3DC.%2BJ.%26aulast%3DRobert%26aufirst%3DJ.%2BM.%26atitle%3DInhibitors%2520of%2520mammalian%2520G1%2520cyclin-dependent%2520kinases%26jtitle%3DGenes%2520Dev.%26date%3D1995%26volume%3D9%26spage%3D1149%26epage%3D1163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sherr, C. J.</span><span> </span><span class="NLM_article-title">Cancer cell cycles</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">274</span><span class="NLM_x">, </span> <span class="NLM_fpage">1672</span><span class="NLM_x">–</span> <span class="NLM_lpage">1677</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1996&pages=1672-1677&author=C.+J.+Sherr&title=Cancer+cell+cycles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSherr%26aufirst%3DC.%2BJ.%26atitle%3DCancer%2520cell%2520cycles%26jtitle%3DScience%26date%3D1996%26volume%3D274%26spage%3D1672%26epage%3D1677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, G.</span><span> </span><span class="NLM_article-title">Genetic alterations of cyclins, cyclin-dependent kinases and Cdk inhibitors in human cancer</span> <span class="citation_source-journal">Adv. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">67</span><span class="NLM_x">–</span> <span class="NLM_lpage">108</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=1996&pages=67-108&author=M.+Hallauthor=G.+Peters&title=Genetic+alterations+of+cyclins%2C+cyclin-dependent+kinases+and+Cdk+inhibitors+in+human+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DM.%26aulast%3DPeters%26aufirst%3DG.%26atitle%3DGenetic%2520alterations%2520of%2520cyclins%252C%2520cyclin-dependent%2520kinases%2520and%2520Cdk%2520inhibitors%2520in%2520human%2520cancer%26jtitle%3DAdv.%2520Cancer%2520Res.%26date%3D1996%26volume%3D68%26spage%3D67%26epage%3D108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Christian, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grever, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrd, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T. S.</span><span> </span><span class="NLM_article-title">Flavopiridol in the treatment of chronic lymphocytic leukemia</span> <span class="citation_source-journal">Curr. Opin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">573</span><span class="NLM_x">–</span> <span class="NLM_lpage">578</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm901710h&amp;key=10.1097%2FCCO.0b013e3282efb9da" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm901710h&amp;key=17906454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm901710h&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSnu7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2007&pages=573-578&author=B.+A.+Christianauthor=M.+R.+Greverauthor=J.+C.+Byrdauthor=T.+S.+Lin&title=Flavopiridol+in+the+treatment+of+chronic+lymphocytic+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Flavopiridol in the treatment of chronic lymphocytic leukemia</span></div><div class="casAuthors">Christian, Beth A.; Grever, Michael R.; Byrd, John C.; Lin, Thomas S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">573-578</span>CODEN:
                <span class="NLM_cas:coden">CUOOE8</span>;
        ISSN:<span class="NLM_cas:issn">1040-8746</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: The synthetic flavone flavopiridol induces apoptosis of chronic lymphocytic leukemia cells in vitro; however, initial studies administering flavopiridol by a 24- to 72-h continuous i.v. infusion demonstrated no clin. activity.  This review focuses on a novel dosing regimen that has achieved significant clin. activity in relapsed, poor-risk chronic lymphocytic leukemia.  Recent findings: Binding to human plasma proteins reduces free flavopiridol concn. and makes continuous i.v. infusion dosing ineffective.  Pharmacokinetic modeling indicated that administering flavopiridol by a 30-min i.v. bolus followed by a 4-h continuous i.v. infusion would achieve serum concns. necessary to induce in-vivo apoptosis.  Our institution conducted a phase I study in relapsed chronic lymphocytic leukemia.  Dose-limiting toxicity was acute tumor lysis syndrome resulting in fatal hyperkalemia.  Careful monitoring and aggressive intervention for hyperkalemia, including hemodialysis if necessary, allowed flavopiridol to be given safely.  Nineteen of 42 patients responded (45%), including five of 12 patients (42%) with del(17p13) and 13 of 18 patients (72%) with del(11q22).  Summary: Flavopiridol, when administered by a 30-min i.v. bolus followed by a 4-h continuous i.v. infusion, is active in high-risk, refractory chronic lymphocytic leukemia.  Careful monitoring and aggressive intervention for tumor lysis syndrome and hyperkalemia is necessary for safe drug administration.  Further studies to optimize the dose and schedule of administration, and to study this drug in other hematol. malignancies, are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6YGpEb0iAxLVg90H21EOLACvtfcHk0li9135P51kHgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSnu7zL&md5=9682028742de790c116d8e99a9aa60c5</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1097%2FCCO.0b013e3282efb9da&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCCO.0b013e3282efb9da%26sid%3Dliteratum%253Aachs%26aulast%3DChristian%26aufirst%3DB.%2BA.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DLin%26aufirst%3DT.%2BS.%26atitle%3DFlavopiridol%2520in%2520the%2520treatment%2520of%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DCurr.%2520Opin.%2520Oncol.%26date%3D2007%26volume%3D19%26spage%3D573%26epage%3D578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Fuse, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuwabara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sparreboom, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sausville, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figg, W. D.</span><span> </span><span class="NLM_article-title">Review of UCN-01 development: A lesson in the importance of clinical pharmacology</span> <span class="citation_source-journal">J. Clin. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">394</span><span class="NLM_x">–</span> <span class="NLM_lpage">403</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm901710h&amp;key=10.1177%2F0091270005274549" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm901710h&amp;key=15778420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm901710h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXksFyhtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2005&pages=394-403&author=E.+Fuseauthor=T.+Kuwabaraauthor=A.+Sparreboomauthor=E.+A.+Sausvilleauthor=W.+D.+Figg&title=Review+of+UCN-01+development%3A+A+lesson+in+the+importance+of+clinical+pharmacology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Review of UCN-01 development: A lesson in the importance of clinical pharmacology</span></div><div class="casAuthors">Fuse, Eiichi; Kuwabara, Takashi; Sparreboom, Alex; Sausville, Edward A.; Figg, William D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">394-403</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  UCN-01 is a protein kinase inhibitor under development as a novel anticancer drug.  The initial pharmacol. features in patients were not predicted from preclin. expts.  The distribution vol. and the systemic clearance were much lower than those in exptl. animals (mice, rats, and dogs), and the elimination half-life was unusually long (> 200 h).  The unbound fraction in human plasma was also much smaller than that in dogs, rats and mice, as was the binding of UCN-01 to human alpha-1 acid glycoprotein much stronger than that to human serum albumin or human γ-globulin.  The assocn. consts. for alpha-1 acid glycoprotein and human plasma were approx. 8 × 108 (mol/L)-1, indicating extremely high affinity.  In this review article, the authors discuss the pharmacol. features of UCN-01 across species and provide a perspective on how this information could be applied prospectively to the future development of this agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn8zC_DOvaOrVg90H21EOLACvtfcHk0ljvY94zneMBsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXksFyhtL8%253D&md5=094cb6a7f568b8f74a05356c6b2d15d6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1177%2F0091270005274549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270005274549%26sid%3Dliteratum%253Aachs%26aulast%3DFuse%26aufirst%3DE.%26aulast%3DKuwabara%26aufirst%3DT.%26aulast%3DSparreboom%26aufirst%3DA.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DFigg%26aufirst%3DW.%2BD.%26atitle%3DReview%2520of%2520UCN-01%2520development%253A%2520A%2520lesson%2520in%2520the%2520importance%2520of%2520clinical%2520pharmacology%26jtitle%3DJ.%2520Clin.%2520Pharm.%26date%3D2005%26volume%3D45%26spage%3D394%26epage%3D403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Meijer, L.; Bettayeb, K.; Galons, H.</span><span> </span><span class="NLM_article-title">(<i>R</i>)-Roscovitine (CYC202, Seliciclib)</span>.  <span class="citation_source-book">Inhibitors of Cyclin-Dependent Kinases as Anti-Tumor Agents</span>; <span class="NLM_publisher-name">CRC</span>: <span class="NLM_publisher-loc">Boca Raton, FL</span>,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">187</span>− <span class="NLM_lpage">225</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&pages=187-225&author=L.+Meijer&author=K.+Bettayeb&author=H.+Galons&title=Inhibitors+of+Cyclin-Dependent+Kinases+as+Anti-Tumor+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMeijer%26aufirst%3DL.%26atitle%3D%2528R%2529-Roscovitine%2520%2528CYC202%252C%2520Seliciclib%2529%26btitle%3DInhibitors%2520of%2520Cyclin-Dependent%2520Kinases%2520as%2520Anti-Tumor%2520Agents%26pub%3DCRC%26date%3D2007%26spage%3D187%26epage%3D225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Misra, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rawlins, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, S. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bednarz, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kellar, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulheron, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batorsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roongta, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranadive, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavletich, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimball, S. D.</span><span> </span><span class="NLM_article-title"><i>N</i>-(Cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. <i>N</i>-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1719</span><span class="NLM_x">–</span> <span class="NLM_lpage">1728</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0305568" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1719-1728&author=R.+N.+Misraauthor=H.+Xiaoauthor=K.+S.+Kimauthor=S.+Luauthor=W.+Hanauthor=S.+A.+Barbosaauthor=J.+T.+Huntauthor=D.+B.+Rawlinsauthor=W.+Shanauthor=S.+Z.+Ahmedauthor=L.+Qianauthor=B.+Chenauthor=R.+Zhaoauthor=M.+S.+Bednarzauthor=K.+A.+Kellarauthor=J.+G.+Mulheronauthor=R.+Batorskyauthor=U.+Roongtaauthor=A.+Kamathauthor=P.+Maratheauthor=S.+A.+Ranadiveauthor=J.+S.+Sackauthor=J.+S.+Tokarskiauthor=N.+P.+Pavletichauthor=F.+Y.+F.+Leeauthor=K.+R.+Websterauthor=S.+D.+Kimball&title=N-%28Cycloalkylamino%29acyl-2-aminothiazole+inhibitors+of+cyclin-dependent+kinase+2.+N-%5B5-%5B%5B%5B5-%281%2C1-Dimethylethyl%29-2-oxazolyl%5Dmethyl%5Dthio%5D-2-thiazolyl%5D-4-piperidinecarboxamide+%28BMS-387032%29%2C+a+highly+efficacious+and+selective+antitumor+agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm0305568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0305568%26sid%3Dliteratum%253Aachs%26aulast%3DMisra%26aufirst%3DR.%2BN.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DK.%2BS.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DHan%26aufirst%3DW.%26aulast%3DBarbosa%26aufirst%3DS.%2BA.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DRawlins%26aufirst%3DD.%2BB.%26aulast%3DShan%26aufirst%3DW.%26aulast%3DAhmed%26aufirst%3DS.%2BZ.%26aulast%3DQian%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DBednarz%26aufirst%3DM.%2BS.%26aulast%3DKellar%26aufirst%3DK.%2BA.%26aulast%3DMulheron%26aufirst%3DJ.%2BG.%26aulast%3DBatorsky%26aufirst%3DR.%26aulast%3DRoongta%26aufirst%3DU.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DRanadive%26aufirst%3DS.%2BA.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26aulast%3DLee%26aufirst%3DF.%2BY.%2BF.%26aulast%3DWebster%26aufirst%3DK.%2BR.%26aulast%3DKimball%26aufirst%3DS.%2BD.%26atitle%3DN-%2528Cycloalkylamino%2529acyl-2-aminothiazole%2520inhibitors%2520of%2520cyclin-dependent%2520kinase%25202.%2520N-%255B5-%255B%255B%255B5-%25281%252C1-Dimethylethyl%2529-2-oxazolyl%255Dmethyl%255Dthio%255D-2-thiazolyl%255D-4-piperidinecarboxamide%2520%2528BMS-387032%2529%252C%2520a%2520highly%2520efficacious%2520and%2520selective%2520antitumor%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1719%26epage%3D1728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Toogood, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Repine, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehan, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VanderWel, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodfuehrer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barvian, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span> </span><span class="NLM_article-title">Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">2388</span><span class="NLM_x">–</span> <span class="NLM_lpage">2406</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049354h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm901710h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVGisL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2388-2406&author=P.+L.+Toogoodauthor=P.+J.+Harveyauthor=J.+T.+Repineauthor=D.+J.+Sheehanauthor=S.+N.+VanderWelauthor=H.+Zhouauthor=P.+R.+Kellerauthor=D.+J.+McNamaraauthor=D.+Sherryauthor=T.+Zhuauthor=J.+Brodfuehrerauthor=C.+Choiauthor=M.+R.+Barvianauthor=D.+W.+Fry&title=Discovery+of+a+potent+and+selective+inhibitor+of+cyclin-dependent+kinase+4%2F6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6</span></div><div class="casAuthors">Toogood, Peter L.; Harvey, Patricia J.; Repine, Joseph T.; Sheehan, Derek J.; VanderWel, Scott N.; Zhou, Hairong; Keller, Paul R.; McNamara, Dennis J.; Sherry, Debra; Zhu, Tong; Brodfuehrer, Joanne; Choi, Chung; Barvian, Mark R.; Fry, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2388-2406</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A pharmacol. approach to inhibition of cyclin-dependent kinases 4 and 6 (Cdk4/6) using highly selective small mol. inhibitors has the potential to provide novel cancer therapies for clin. use.  Achieving high levels of selectivity for Cdk4/6, vs. other ATP-dependent kinases, presents a significant challenge.  The pyrido[2,3-d]pyrimidin-7-one template provides an effective platform for the inhibition of a broad cross-section of kinases, including Cdks.  It is now demonstrated that the modification of pyrido[2,3-d]pyrimidin-7-ones to include a 2-aminopyridine side chain at the C2-position provides inhibitors with exquisite selectivity for Cdk4/6 in vitro.  This selectivity profile is recapitulated in cells where the most selective inhibitors create a G1 block at concns. up to 100-fold the IC50 for cell proliferation.  On the basis of its selectivity profile and pharmacokinetic profile, compd. I (PD 0332991) was identified as a drug candidate for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX577J5U0r97Vg90H21EOLACvtfcHk0liHKuVbilriCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVGisL0%253D&md5=23cbe58426ff1975695712db7c1b128a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm049354h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049354h%26sid%3Dliteratum%253Aachs%26aulast%3DToogood%26aufirst%3DP.%2BL.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DRepine%26aufirst%3DJ.%2BT.%26aulast%3DSheehan%26aufirst%3DD.%2BJ.%26aulast%3DVanderWel%26aufirst%3DS.%2BN.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DSherry%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DBrodfuehrer%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DC.%26aulast%3DBarvian%26aufirst%3DM.%2BR.%26aulast%3DFry%26aufirst%3DD.%2BW.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520cyclin-dependent%2520kinase%25204%252F6%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D2388%26epage%3D2406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Tetsu, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCormick, F.</span><span> </span><span class="NLM_article-title">Proliferation of cancer cells despite CDK2 inhibition</span> <span class="citation_source-journal">Cancer Cell.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">233</span><span class="NLM_x">–</span> <span class="NLM_lpage">245</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=233-245&author=O.+Tetsuauthor=F.+McCormick&title=Proliferation+of+cancer+cells+despite+CDK2+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTetsu%26aufirst%3DO.%26aulast%3DMcCormick%26aufirst%3DF.%26atitle%3DProliferation%2520of%2520cancer%2520cells%2520despite%2520CDK2%2520inhibition%26jtitle%3DCancer%2520Cell.%26date%3D2003%26volume%3D3%26spage%3D233%26epage%3D245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Martin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Odajima, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubus, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortega, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malumbres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span> </span><span class="NLM_article-title">CDK2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27<sup>Kip1</sup> and p21<sup>Cip1</sup></span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">591</span><span class="NLM_x">–</span> <span class="NLM_lpage">598</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=591-598&author=A.+Martinauthor=J.+Odajimaauthor=S.+L.+Huntauthor=P.+Dubusauthor=S.+Ortegaauthor=M.+Malumbresauthor=M.+Barbacid&title=CDK2+is+dispensable+for+cell+cycle+inhibition+and+tumor+suppression+mediated+by+p27Kip1+and+p21Cip1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DA.%26aulast%3DOdajima%26aufirst%3DJ.%26aulast%3DHunt%26aufirst%3DS.%2BL.%26aulast%3DDubus%26aufirst%3DP.%26aulast%3DOrtega%26aufirst%3DS.%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DCDK2%2520is%2520dispensable%2520for%2520cell%2520cycle%2520inhibition%2520and%2520tumor%2520suppression%2520mediated%2520by%2520p27Kip1%2520and%2520p21Cip1%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D591%26epage%3D598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hirai, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawanishi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwasawa, Y.</span><span> </span><span class="NLM_article-title">Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">167</span><span class="NLM_x">–</span> <span class="NLM_lpage">179</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=16&amp;doi=10.1021%2Fjm901710h&amp;key=10.2174%2F1568026053507688" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=8&amp;doi=10.1021%2Fjm901710h&amp;key=15853645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=32&amp;doi=10.1021%2Fjm901710h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFyksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=167-179&author=H.+Hiraiauthor=N.+Kawanishiauthor=Y.+Iwasawa&title=Recent+advances+in+the+development+of+selective+small+molecule+inhibitors+for+cyclin-dependent+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12cR"><div class="casContent"><span class="casTitleNuber">12c</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the development of selective small molecule inhibitors for Cyclin-dependent kinases</span></div><div class="casAuthors">Hirai, Hiroshi; Kawanishi, Nobuhiko; Iwasawa, Yoshikazu</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-179</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Loss of normal cell cycle regulation is the hallmark of human cancers, and alteration of the components involved in cell cycle regulation occurs in most human tumors.  This suggests that Cyclin dependent kinases (CDKs) are an attractive target for the development of pharmacol. agents for the treatment of cancer.  Recently, CDK family members that are not directly involved in cell cycle regulation were identified.  This includes CDK7, CDK8, and CDK9, which participate in transcription regulation, and CDK5, which plays a role in neuronal and secretory functions.  Given the involvement of CDKs in multiple cellular processes, development of selective small mol. inhibitors for specific CDKs is expected to help clarify whether improved specificity of cell cycle CDK inhibitors will enhance their therapeutic potential in cancer treatment.  Selective inhibitors are also needed as tools to explore the biol. of diseases in which CDKs may participate and to help develop therapeutics to treat them.  Intensive screening and drug design based on CDK/inhibitor co-crystal structure and SAR studies have led to the identification of a large variety of chem. inhibitors of CDKs.  Although they are competitive with ATP at the catalytic site, their kinase selectivity varies greatly, and inhibitors selective for certain CDKs have begun to be identified.  There are currently 2 categories of selective CDK inhibitors: those that are selective for CDK2 and CDK1 and those that are selective for CDK4/6.  These 2 types of inhibitors have different effects on tumor cells and are expected to be useful in the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooiAF6UAza_7Vg90H21EOLACvtfcHk0liHKuVbilriCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFyksbw%253D&md5=2fceab02ebbaaca45061a80884571ef7</span></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.2174%2F1568026053507688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026053507688%26sid%3Dliteratum%253Aachs%26aulast%3DHirai%26aufirst%3DH.%26aulast%3DKawanishi%26aufirst%3DN.%26aulast%3DIwasawa%26aufirst%3DY.%26atitle%3DRecent%2520advances%2520in%2520the%2520development%2520of%2520selective%2520small%2520molecule%2520inhibitors%2520for%2520cyclin-dependent%2520kinases%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2005%26volume%3D5%26spage%3D167%26epage%3D179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Cai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Latham, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span> </span><span class="NLM_article-title">Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">9270</span><span class="NLM_x">–</span> <span class="NLM_lpage">9280</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=9270-9280&author=D.+Caiauthor=V.+M.+Lathamauthor=X.+Zhangauthor=G.+I.+Shapiro&title=Combined+depletion+of+cell+cycle+and+transcriptional+cyclin-dependent+kinase+activities+induces+apoptosis+in+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DD.%26aulast%3DLatham%26aufirst%3DV.%2BM.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DCombined%2520depletion%2520of%2520cell%2520cycle%2520and%2520transcriptional%2520cyclin-dependent%2520kinase%2520activities%2520induces%2520apoptosis%2520in%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D9270%26epage%3D9280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Wyatt, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodhead, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulstridge, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devine, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Early, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feltell, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMenamin, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navarro, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Reilly, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reule, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saxty, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seavers, L. C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Squires, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trewartha, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woolford, A. J.-A.</span><span> </span><span class="NLM_article-title">Identification of <i>N</i>-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1<i>H</i>-pyrazole-3-carboxamide (AT7519), a novel cyclin-dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4986</span><span class="NLM_x">–</span> <span class="NLM_lpage">4999</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800382h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4986-4999&author=P.+G.+Wyattauthor=A.+J.+Woodheadauthor=V.+Berdiniauthor=J.+A.+Boulstridgeauthor=M.+G.+Carrauthor=D.+M.+Crossauthor=D.+J.+Davisauthor=L.+A.+Devineauthor=T.+R.+Earlyauthor=R.+E.+Feltellauthor=E.+J.+Lewisauthor=R.+L.+McMenaminauthor=E.+F.+Navarroauthor=M.+A.+O%E2%80%99Brienauthor=M.+O%E2%80%99Reillyauthor=M.+Reuleauthor=G.+Saxtyauthor=L.+C.+A.+Seaversauthor=D.+M.+Smithauthor=M.+S.+Squiresauthor=G.+Trewarthaauthor=M.+T.+Walkerauthor=A.+J.-A.+Woolford&title=Identification+of+N-%284-piperidinyl%29-4-%282%2C6-dichlorobenzoylamino%29-1H-pyrazole-3-carboxamide+%28AT7519%29%2C+a+novel+cyclin-dependent+kinase+inhibitor+using+fragment-based+X-ray+crystallography+and+structure+based+drug+design"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm800382h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800382h%26sid%3Dliteratum%253Aachs%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DWoodhead%26aufirst%3DA.%2BJ.%26aulast%3DBerdini%26aufirst%3DV.%26aulast%3DBoulstridge%26aufirst%3DJ.%2BA.%26aulast%3DCarr%26aufirst%3DM.%2BG.%26aulast%3DCross%26aufirst%3DD.%2BM.%26aulast%3DDavis%26aufirst%3DD.%2BJ.%26aulast%3DDevine%26aufirst%3DL.%2BA.%26aulast%3DEarly%26aufirst%3DT.%2BR.%26aulast%3DFeltell%26aufirst%3DR.%2BE.%26aulast%3DLewis%26aufirst%3DE.%2BJ.%26aulast%3DMcMenamin%26aufirst%3DR.%2BL.%26aulast%3DNavarro%26aufirst%3DE.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DM.%2BA.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DM.%26aulast%3DReule%26aufirst%3DM.%26aulast%3DSaxty%26aufirst%3DG.%26aulast%3DSeavers%26aufirst%3DL.%2BC.%2BA.%26aulast%3DSmith%26aufirst%3DD.%2BM.%26aulast%3DSquires%26aufirst%3DM.%2BS.%26aulast%3DTrewartha%26aufirst%3DG.%26aulast%3DWalker%26aufirst%3DM.%2BT.%26aulast%3DWoolford%26aufirst%3DA.%2BJ.-A.%26atitle%3DIdentification%2520of%2520N-%25284-piperidinyl%2529-4-%25282%252C6-dichlorobenzoylamino%2529-1H-pyrazole-3-carboxamide%2520%2528AT7519%2529%252C%2520a%2520novel%2520cyclin-dependent%2520kinase%2520inhibitor%2520using%2520fragment-based%2520X-ray%2520crystallography%2520and%2520structure%2520based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4986%26epage%3D4999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Chu, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DePinto, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartkowitz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">So, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vu, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Packman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukacs, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goelzer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, B. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moliterni, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graves, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fotouhi, N.</span><span> </span><span class="NLM_article-title">Discovery of [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6-methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6549</span><span class="NLM_x">–</span> <span class="NLM_lpage">6560</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0606138" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6549-6560&author=X.+J.+Chuauthor=W.+DePintoauthor=D.+Bartkowitzauthor=S.+S.+Soauthor=B.+T.+Vuauthor=K.+Packmanauthor=C.+Lukacsauthor=Q.+Dingauthor=N.+Jiangauthor=K.+Wangauthor=P.+Goelzerauthor=X.+Yinauthor=M.+A.+Smithauthor=B.+X.+Higginsauthor=Y.+Chenauthor=Q.+Xiangauthor=J.+Moliterniauthor=G.+Kaplanauthor=B.+Gravesauthor=A.+Loveyauthor=N.+Fotouhi&title=Discovery+of+%5B4-amino-2-%281-methanesulfonylpiperidin-4-ylamino%29pyrimidin-5-yl%5D%282%2C3-difluoro-6-methoxyphenyl%29methanone+%28R547%29%2C+a+potent+and+selective+cyclin-dependent+kinase+inhibitor+with+significant+in+vivo+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm0606138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0606138%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DX.%2BJ.%26aulast%3DDePinto%26aufirst%3DW.%26aulast%3DBartkowitz%26aufirst%3DD.%26aulast%3DSo%26aufirst%3DS.%2BS.%26aulast%3DVu%26aufirst%3DB.%2BT.%26aulast%3DPackman%26aufirst%3DK.%26aulast%3DLukacs%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DGoelzer%26aufirst%3DP.%26aulast%3DYin%26aufirst%3DX.%26aulast%3DSmith%26aufirst%3DM.%2BA.%26aulast%3DHiggins%26aufirst%3DB.%2BX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DQ.%26aulast%3DMoliterni%26aufirst%3DJ.%26aulast%3DKaplan%26aufirst%3DG.%26aulast%3DGraves%26aufirst%3DB.%26aulast%3DLovey%26aufirst%3DA.%26aulast%3DFotouhi%26aufirst%3DN.%26atitle%3DDiscovery%2520of%2520%255B4-amino-2-%25281-methanesulfonylpiperidin-4-ylamino%2529pyrimidin-5-yl%255D%25282%252C3-difluoro-6-methoxyphenyl%2529methanone%2520%2528R547%2529%252C%2520a%2520potent%2520and%2520selective%2520cyclin-dependent%2520kinase%2520inhibitor%2520with%2520significant%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6549%26epage%3D6560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Parry, D.; Guzi, T.; Seghezzi, W.; Paruch, K.; Doll, R.; Nomeir, A.; Wang, Y.; Oft, M.; Kirschmeier, P.; Chen, T.; Lees, E.</span>In vitro and in vivo characterization of SCH727965, a novel potent cyclin-dependent kinase inhibitor. Presented at AACR Conference, Los Angeles, CA, April 14−18,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span>Poster No. 4371.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=D.+Parry&author=T.+Guzi&author=W.+Seghezzi&author=K.+Paruch&author=R.+Doll&author=A.+Nomeir&author=Y.+Wang&author=M.+Oft&author=P.+Kirschmeier&author=T.+Chen&author=E.+Lees&title=In+vitro+and+in+vivo+characterization+of+SCH727965%2C+a+novel+potent+cyclin-dependent+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DParry%26aufirst%3DD.%26jtitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520characterization%2520of%2520SCH727965%252C%2520a%2520novel%2520potent%2520cyclin-dependent%2520kinase%2520inhibitor%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Jones, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrew, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blades, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daunt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">East, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geh, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loddick, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFarland, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGregor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudge, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simpson, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swain, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tucker, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, M.</span><span> </span><span class="NLM_article-title">The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">6369</span><span class="NLM_x">–</span> <span class="NLM_lpage">6373</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm901710h&amp;key=10.1016%2Fj.bmcl.2008.10.102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm901710h&amp;key=18996007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm901710h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWjs7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=6369-6373&author=C.+D.+Jonesauthor=D.+M.+Andrewauthor=A.+J.+Barkerauthor=K.+Bladesauthor=P.+Dauntauthor=S.+Eastauthor=C.+Gehauthor=M.+A.+Grahamauthor=K.+M.+Johnsonauthor=S.+A.+Loddickauthor=H.+M.+McFarlandauthor=A.+McGregorauthor=L.+Mossauthor=D.+A.+Rudgeauthor=P.+B.+Simpsonauthor=M.+L.+Swainauthor=K.+Y.+Tamauthor=J.+A.+Tuckerauthor=M.+Walker&title=The+discovery+of+AZD5597%2C+a+potent+imidazole+pyrimidine+amide+CDK+inhibitor+suitable+for+intravenous+dosing"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing</span></div><div class="casAuthors">Jones, Clifford D.; Andrews, David M.; Barker, Andrew J.; Blades, Kevin; Daunt, Paula; East, Simon; Geh, Catherine; Graham, Mark A.; Johnson, Keith M.; Loddick, Sarah A.; McFarland, Heather M.; McGregor, Alexandra; Moss, Louise; Rudge, David A.; Simpson, Peter B.; Swain, Michael L.; Tam, Kin Y.; Tucker, Julie A.; Walker, Mike</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6369-6373</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The development of a novel series of imidazole pyrimidine amides as cyclin-dependent kinase (CDK) inhibitors is described.  Optimization of inhibitory potency against multiple CDK's (1, 2 and 9) resulted in imidazole pyrimidine amides with potent in vitro anti-proliferative effects against a range of cancer cell lines.  Excellent physiochem. properties and large margins against inhibition of CYP isoforms and the hERG ion channel were achieved by modification of lipophilicity and amine basicity.  A candidate with disease model activity in human cancer cell line xenografts and with suitable physiochem. and pharmacokinetic profiles for i.v. (iv) dosing was selected for further development as AZD5597 (I).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnX9-GP03dzbVg90H21EOLACvtfcHk0lgQLfO6m1EGhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWjs7bP&md5=084ed54076134c7173953ebbdb23fd86</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.10.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.10.102%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DC.%2BD.%26aulast%3DAndrew%26aufirst%3DD.%2BM.%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DBlades%26aufirst%3DK.%26aulast%3DDaunt%26aufirst%3DP.%26aulast%3DEast%26aufirst%3DS.%26aulast%3DGeh%26aufirst%3DC.%26aulast%3DGraham%26aufirst%3DM.%2BA.%26aulast%3DJohnson%26aufirst%3DK.%2BM.%26aulast%3DLoddick%26aufirst%3DS.%2BA.%26aulast%3DMcFarland%26aufirst%3DH.%2BM.%26aulast%3DMcGregor%26aufirst%3DA.%26aulast%3DMoss%26aufirst%3DL.%26aulast%3DRudge%26aufirst%3DD.%2BA.%26aulast%3DSimpson%26aufirst%3DP.%2BB.%26aulast%3DSwain%26aufirst%3DM.%2BL.%26aulast%3DTam%26aufirst%3DK.%2BY.%26aulast%3DTucker%26aufirst%3DJ.%2BA.%26aulast%3DWalker%26aufirst%3DM.%26atitle%3DThe%2520discovery%2520of%2520AZD5597%252C%2520a%2520potent%2520imidazole%2520pyrimidine%2520amide%2520CDK%2520inhibitor%2520suitable%2520for%2520intravenous%2520dosing%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D6369%26epage%3D6373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Brasca, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amboldi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballinari, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cervi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colotta, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croci, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Alessio, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiorentini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercurio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moretti, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panzeri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pastori, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pevarello, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quartieri, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roletto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traquandi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vianello, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vulpetti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciomei, M.</span><span> </span><span class="NLM_article-title">Identification of <i>N</i>-1,4,4-tetramethyl-8-{[(4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin-dependent kinase inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">5152</span><span class="NLM_x">–</span> <span class="NLM_lpage">5163</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9006559" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5152-5163&author=M.+G.+Brascaauthor=N.+Amboldiauthor=D.+Ballinariauthor=A.+Cameronauthor=E.+Casaleauthor=G.+Cerviauthor=M.+Colomboauthor=F.+Colottaauthor=V.+Crociauthor=R.+D%E2%80%99Alessioauthor=F.+Fiorentiniauthor=A.+Isacchiauthor=C.+Mercurioauthor=W.+Morettiauthor=A.+Panzeriauthor=W.+Pastoriauthor=P.+Pevarelloauthor=F.+Quartieriauthor=F.+Rolettoauthor=G.+Traquandiauthor=P.+Vianelloauthor=A.+Vulpettiauthor=M.+Ciomei&title=Identification+of+N-1%2C4%2C4-tetramethyl-8-%7B%5B%284-%284-methylpiperazin-1-yl%29phenyl%5Damino%7D-4%2C5-dihydro-1H-pyrazolo%5B4%2C3-h%5Dquinazoline-3-carboxamide+%28PHA-848125%29%2C+a+potent%2C+orally+available+cyclin-dependent+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm9006559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9006559%26sid%3Dliteratum%253Aachs%26aulast%3DBrasca%26aufirst%3DM.%2BG.%26aulast%3DAmboldi%26aufirst%3DN.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DCameron%26aufirst%3DA.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DCervi%26aufirst%3DG.%26aulast%3DColombo%26aufirst%3DM.%26aulast%3DColotta%26aufirst%3DF.%26aulast%3DCroci%26aufirst%3DV.%26aulast%3DD%25E2%2580%2599Alessio%26aufirst%3DR.%26aulast%3DFiorentini%26aufirst%3DF.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DMercurio%26aufirst%3DC.%26aulast%3DMoretti%26aufirst%3DW.%26aulast%3DPanzeri%26aufirst%3DA.%26aulast%3DPastori%26aufirst%3DW.%26aulast%3DPevarello%26aufirst%3DP.%26aulast%3DQuartieri%26aufirst%3DF.%26aulast%3DRoletto%26aufirst%3DF.%26aulast%3DTraquandi%26aufirst%3DG.%26aulast%3DVianello%26aufirst%3DP.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DCiomei%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520N-1%252C4%252C4-tetramethyl-8-%257B%255B%25284-%25284-methylpiperazin-1-yl%2529phenyl%255Damino%257D-4%252C5-dihydro-1H-pyrazolo%255B4%252C3-h%255Dquinazoline-3-carboxamide%2520%2528PHA-848125%2529%252C%2520a%2520potent%252C%2520orally%2520available%2520cyclin-dependent%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5152%26epage%3D5163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Traquandi, G.; Brasca, M. G.; D’Alessio, R.; Polucci, P.; Roletto, F.; Vulpetti, A.; Pevarello, P.; Panzeri, A.; Quartieri, F.; Ferguson, R.; Vianello, P.; Fancelli, D.</span>; <span> </span><span class="NLM_article-title">Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors</span>. Patent WO2004/104007,<span class="NLM_x"> </span><span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=G.+Traquandi&author=M.+G.+Brasca&author=R.+D%E2%80%99Alessio&author=P.+Polucci&author=F.+Roletto&author=A.+Vulpetti&author=P.+Pevarello&author=A.+Panzeri&author=F.+Quartieri&author=R.+Ferguson&author=P.+Vianello&author=D.+Fancelli&title=Pyrazolo-quinazoline+derivatives%2C+process+for+their+preparation+and+their+use+as+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTraquandi%26aufirst%3DG.%26atitle%3DPyrazolo-quinazoline%2520derivatives%252C%2520process%2520for%2520their%2520preparation%2520and%2520their%2520use%2520as%2520kinase%2520inhibitors%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Pevarello, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fancelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vulpetti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amici, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pittalà, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vianello, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciomei, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercurio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bischoff, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roletto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varasi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brasca, M. G.</span><span> </span><span class="NLM_article-title">3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-<i>c</i>]pyrazoles: A new class of CDK2 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1084</span><span class="NLM_x">–</span> <span class="NLM_lpage">1090</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=1084-1090&author=P.+Pevarelloauthor=D.+Fancelliauthor=A.+Vulpettiauthor=R.+Amiciauthor=M.+Villaauthor=V.+Pittal%C3%A0author=P.+Vianelloauthor=A.+Cameronauthor=M.+Ciomeiauthor=C.+Mercurioauthor=J.+R.+Bischoffauthor=F.+Rolettoauthor=M.+Varasiauthor=M.+G.+Brasca&title=3-Amino-1%2C4%2C5%2C6-tetrahydropyrrolo%5B3%2C4-c%5Dpyrazoles%3A+A+new+class+of+CDK2+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPevarello%26aufirst%3DP.%26aulast%3DFancelli%26aufirst%3DD.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DAmici%26aufirst%3DR.%26aulast%3DVilla%26aufirst%3DM.%26aulast%3DPittal%25C3%25A0%26aufirst%3DV.%26aulast%3DVianello%26aufirst%3DP.%26aulast%3DCameron%26aufirst%3DA.%26aulast%3DCiomei%26aufirst%3DM.%26aulast%3DMercurio%26aufirst%3DC.%26aulast%3DBischoff%26aufirst%3DJ.%2BR.%26aulast%3DRoletto%26aufirst%3DF.%26aulast%3DVarasi%26aufirst%3DM.%26aulast%3DBrasca%26aufirst%3DM.%2BG.%26atitle%3D3-Amino-1%252C4%252C5%252C6-tetrahydropyrrolo%255B3%252C4-c%255Dpyrazoles%253A%2520A%2520new%2520class%2520of%2520CDK2%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D1084%26epage%3D1090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Colombo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riccardi-Sirtori, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzo, V.</span><span> </span><span class="NLM_article-title">A fully automated method for accurate mass determination using high-performance liquid chromatography with a quadrupole/orthogonal acceleration time-of-flight mass spectrometer</span> <span class="citation_source-journal">Rapid Commun. Mass Spectrom.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">511</span><span class="NLM_x">–</span> <span class="NLM_lpage">517</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm901710h&amp;key=10.1002%2Frcm.1368" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm901710h&amp;key=14966861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm901710h&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhs1equr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2004&pages=511-517&author=M.+Colomboauthor=F.+Riccardi-Sirtoriauthor=V.+Rizzo&title=A+fully+automated+method+for+accurate+mass+determination+using+high-performance+liquid+chromatography+with+a+quadrupole%2Forthogonal+acceleration+time-of-flight+mass+spectrometer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A fully automated method for accurate mass determination using high-performance liquid chromatography with a quadrupole/orthogonal acceleration time-of-flight mass spectrometer</span></div><div class="casAuthors">Colombo, Maristella; Sirtori, Federico Riccardi; Rizzo, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Rapid Communications in Mass Spectrometry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">511-517</span>CODEN:
                <span class="NLM_cas:coden">RCMSEF</span>;
        ISSN:<span class="NLM_cas:issn">0951-4198</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A generic LC/ESI(+)-oaTOFMS method has been developed for routine automated high accuracy mass detns. of different classes of substances.  The system makes use of micro-high-performance liq. chromatog. and a hybrid quadrupole/orthogonal acceleration time-of-flight (Q-oaTOF) mass spectrometer.  Reproducible and accurate mass measurements were obtained using an electrospray dual sprayer with reserpine as ref. compd., introduced into the mass spectrometer alternating with the samples.  Expts. were performed to optimize analyte/ref. response ratio, statistical algorithm correction setting, and analyte concn.  In these expts., a clear dependence of the mass measurement error on the analyte/ref. response ratio was obsd.  The dependence of av. mass error vs. different dead time correction algorithm settings (Np factors) was also explored.  In the final automated procedure, verified for a statistically significant set of compds. (∼550) obtained from a medicinal chem. department, about 70% of the analyzed samples satisfied the acceptance criteria fixed at a max. error of ±5 ppm (mass range 150-800 Da).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro5JNVhGdzjrVg90H21EOLACvtfcHk0lhed96gmbETKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhs1equr8%253D&md5=6f1f93c5e2fb4e24257b77f5ce6dfa37</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Frcm.1368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frcm.1368%26sid%3Dliteratum%253Aachs%26aulast%3DColombo%26aufirst%3DM.%26aulast%3DRiccardi-Sirtori%26aufirst%3DF.%26aulast%3DRizzo%26aufirst%3DV.%26atitle%3DA%2520fully%2520automated%2520method%2520for%2520accurate%2520mass%2520determination%2520using%2520high-performance%2520liquid%2520chromatography%2520with%2520a%2520quadrupole%252Forthogonal%2520acceleration%2520time-of-flight%2520mass%2520spectrometer%26jtitle%3DRapid%2520Commun.%2520Mass%2520Spectrom.%26date%3D2004%26volume%3D18%26spage%3D511%26epage%3D517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Pevarello, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brasca, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amici, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traquandi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piutti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sansonna, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulici, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martina, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritzen, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nugent, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciomei, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roletto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogliatto, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesenti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pastori, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsiglio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clare, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiorentini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varasi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vulpetti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warpehoski, M. A.</span><span> </span><span class="NLM_article-title">3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">3367</span><span class="NLM_x">–</span> <span class="NLM_lpage">3380</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm031145u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=3367-3380&author=P.+Pevarelloauthor=M.+G.+Brascaauthor=R.+Amiciauthor=P.+Orsiniauthor=G.+Traquandiauthor=L.+Cortiauthor=C.+Piuttiauthor=P.+Sansonnaauthor=M.+Villaauthor=B.+S.+Pierceauthor=M.+Puliciauthor=P.+Giordanoauthor=K.+Martinaauthor=E.+L.+Fritzenauthor=R.+A.+Nugentauthor=E.+Casaleauthor=A.+Cameronauthor=M.+Ciomeiauthor=F.+Rolettoauthor=A.+Isacchiauthor=G.+Fogliattoauthor=E.+Pesentiauthor=W.+Pastoriauthor=A.+Marsiglioauthor=K.+L.+Leachauthor=P.+M.+Clareauthor=F.+Fiorentiniauthor=M.+Varasiauthor=A.+Vulpettiauthor=M.+A.+Warpehoski&title=3-Aminopyrazole+inhibitors+of+CDK2%2Fcyclin+A+as+antitumor+agents.+1.+Lead+finding"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm031145u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm031145u%26sid%3Dliteratum%253Aachs%26aulast%3DPevarello%26aufirst%3DP.%26aulast%3DBrasca%26aufirst%3DM.%2BG.%26aulast%3DAmici%26aufirst%3DR.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DTraquandi%26aufirst%3DG.%26aulast%3DCorti%26aufirst%3DL.%26aulast%3DPiutti%26aufirst%3DC.%26aulast%3DSansonna%26aufirst%3DP.%26aulast%3DVilla%26aufirst%3DM.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DPulici%26aufirst%3DM.%26aulast%3DGiordano%26aufirst%3DP.%26aulast%3DMartina%26aufirst%3DK.%26aulast%3DFritzen%26aufirst%3DE.%2BL.%26aulast%3DNugent%26aufirst%3DR.%2BA.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DCameron%26aufirst%3DA.%26aulast%3DCiomei%26aufirst%3DM.%26aulast%3DRoletto%26aufirst%3DF.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DFogliatto%26aufirst%3DG.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DPastori%26aufirst%3DW.%26aulast%3DMarsiglio%26aufirst%3DA.%26aulast%3DLeach%26aufirst%3DK.%2BL.%26aulast%3DClare%26aufirst%3DP.%2BM.%26aulast%3DFiorentini%26aufirst%3DF.%26aulast%3DVarasi%26aufirst%3DM.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DWarpehoski%26aufirst%3DM.%2BA.%26atitle%3D3-Aminopyrazole%2520inhibitors%2520of%2520CDK2%252Fcyclin%2520A%2520as%2520antitumor%2520agents.%25201.%2520Lead%2520finding%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D3367%26epage%3D3380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Bissery, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vrignaud, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavelle, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chabot, G. G.</span><span> </span><span class="NLM_article-title">Experimental anitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice</span> <span class="citation_source-journal">Anticancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">437</span><span class="NLM_x">–</span> <span class="NLM_lpage">460</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1996&pages=437-460&author=M.+C.+Bisseryauthor=P.+Vrignaudauthor=F.+Lavelleauthor=G.+G.+Chabot&title=Experimental+anitumor+activity+and+pharmacokinetics+of+the+camptothecin+analog+irinotecan+%28CPT-11%29+in+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBissery%26aufirst%3DM.%2BC.%26aulast%3DVrignaud%26aufirst%3DP.%26aulast%3DLavelle%26aufirst%3DF.%26aulast%3DChabot%26aufirst%3DG.%2BG.%26atitle%3DExperimental%2520anitumor%2520activity%2520and%2520pharmacokinetics%2520of%2520the%2520camptothecin%2520analog%2520irinotecan%2520%2528CPT-11%2529%2520in%2520mice%26jtitle%3DAnticancer%2520Drugs%26date%3D1996%26volume%3D7%26spage%3D437%26epage%3D460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2a','cit2b'],'ref3':['cit3a','cit3b','cit3c'],'ref4':['cit4a','cit4b'],'ref5':['cit5a','cit5b','cit5c'],'ref6':['cit6a','cit6b','cit6c'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12a','cit12b','cit12c','cit12d'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 26 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Gunasekaran Balamurugan, Rengan Ramesh, <span class="NLM_string-name hlFld-ContribAuthor">Jan Grzegorz Malecki</span>. </span><span class="cited-content_cbyCitation_article-title">Nickel(II)–NΛNΛO Pincer Type Complex-Catalyzed N-alkylation of Amines with Alcohols via the Hydrogen Autotransfer Reaction. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (11)
                                     , 7125-7135. <a href="https://doi.org/10.1021/acs.joc.0c00530" title="DOI URL">https://doi.org/10.1021/acs.joc.0c00530</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c00530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c00530%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DNickel%252528II%252529%2525E2%252580%252593N%2525CE%25259BN%2525CE%25259BO%252BPincer%252BType%252BComplex-Catalyzed%252BN-alkylation%252Bof%252BAmines%252Bwith%252BAlcohols%252Bvia%252Bthe%252BHydrogen%252BAutotransfer%252BReaction%26aulast%3DBalamurugan%26aufirst%3DGunasekaran%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D28022020%26date%3D19052020%26date%3D08052020%26volume%3D85%26issue%3D11%26spage%3D7125%26epage%3D7135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Priya  Mahajan</span>, <span class="hlFld-ContribAuthor ">Gousia  Chashoo</span>, <span class="hlFld-ContribAuthor ">Monika  Gupta</span>, <span class="hlFld-ContribAuthor ">Amit  Kumar</span>, <span class="hlFld-ContribAuthor ">Parvinder Pal  Singh</span>, and <span class="hlFld-ContribAuthor ">Amit  Nargotra</span>  . </span><span class="cited-content_cbyCitation_article-title">Fusion of Structure and Ligand Based Methods for Identification of Novel CDK2 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2017,</strong> <em>57 </em>
                                    (8)
                                     , 1957-1969. <a href="https://doi.org/10.1021/acs.jcim.7b00293" title="DOI URL">https://doi.org/10.1021/acs.jcim.7b00293</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.7b00293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.7b00293%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DFusion%252Bof%252BStructure%252Band%252BLigand%252BBased%252BMethods%252Bfor%252BIdentification%252Bof%252BNovel%252BCDK2%252BInhibitors%26aulast%3DMahajan%26aufirst%3DPriya%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D22052017%26date%3D03082017%26date%3D28082017%26date%3D19072017%26volume%3D57%26issue%3D8%26spage%3D1957%26epage%3D1969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lewis D.  Pennington</span> and <span class="hlFld-ContribAuthor ">Demetri T.  Moustakas</span>  . </span><span class="cited-content_cbyCitation_article-title">The Necessary Nitrogen Atom: A Versatile High-Impact Design Element for Multiparameter Optimization. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (9)
                                     , 3552-3579. <a href="https://doi.org/10.1021/acs.jmedchem.6b01807" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01807</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01807%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252BNecessary%252BNitrogen%252BAtom%25253A%252BA%252BVersatile%252BHigh-Impact%252BDesign%252BElement%252Bfor%252BMultiparameter%252BOptimization%26aulast%3DPennington%26aufirst%3DLewis%2BD.%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D09122016%26date%3D08022017%26date%3D11052017%26volume%3D60%26issue%3D9%26spage%3D3552%26epage%3D3579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mala  Sharma</span>, <span class="hlFld-ContribAuthor ">Neha  Sharma</span>, <span class="hlFld-ContribAuthor ">Mohd  Muddassir</span>, <span class="hlFld-ContribAuthor ">Qazi Inamur  Rahman</span>, <span class="hlFld-ContribAuthor ">U. N.  Dwivedi</span>, <span class="hlFld-ContribAuthor ">Salman  Akhtar</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based pharmacophore modeling, virtual screening and simulation studies for the identification of potent anticancerous phytochemical lead targeting cyclin-dependent kinase 2. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2021,</strong> <em>24 </em>, 1-18. <a href="https://doi.org/10.1080/07391102.2021.1936178" title="DOI URL">https://doi.org/10.1080/07391102.2021.1936178</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2021.1936178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2021.1936178%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DStructure-based%252Bpharmacophore%252Bmodeling%25252C%252Bvirtual%252Bscreening%252Band%252Bsimulation%252Bstudies%252Bfor%252Bthe%252Bidentification%252Bof%252Bpotent%252Banticancerous%252Bphytochemical%252Blead%252Btargeting%252Bcyclin-dependent%252Bkinase%252B2%26aulast%3DSharma%26aufirst%3DMala%26date%3D2021%26date%3D2021%26volume%3D24%26spage%3D1%26epage%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter  Bloomingdale</span>, <span class="hlFld-ContribAuthor ">Donald E.  Mager</span>. </span><span class="cited-content_cbyCitation_article-title">Machine Learning Models for the Prediction of Chemotherapy-Induced Peripheral Neuropathy. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutical Research</span><span> <strong>2019,</strong> <em>36 </em>
                                    (2)
                                     <a href="https://doi.org/10.1007/s11095-018-2562-7" title="DOI URL">https://doi.org/10.1007/s11095-018-2562-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11095-018-2562-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11095-018-2562-7%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutical%2520Research%26atitle%3DMachine%252BLearning%252BModels%252Bfor%252Bthe%252BPrediction%252Bof%252BChemotherapy-Induced%252BPeripheral%252BNeuropathy%26aulast%3DBloomingdale%26aufirst%3DPeter%26date%3D2019%26date%3D2019%26volume%3D36%26issue%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Weiyan  Cheng</span>, <span class="hlFld-ContribAuthor ">Zhiheng  Yang</span>, <span class="hlFld-ContribAuthor ">Suhua  Wang</span>, <span class="hlFld-ContribAuthor ">Ying  Li</span>, <span class="hlFld-ContribAuthor ">Han  Wei</span>, <span class="hlFld-ContribAuthor ">Xin  Tian</span>, <span class="hlFld-ContribAuthor ">Quancheng  Kan</span>. </span><span class="cited-content_cbyCitation_article-title">Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>164 </em>, 615-639. <a href="https://doi.org/10.1016/j.ejmech.2019.01.003" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.01.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.01.003%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bdevelopment%252Bof%252BCDK%252Binhibitors%25253A%252BAn%252Boverview%252Bof%252BCDK%25252Finhibitor%252Bco-crystal%252Bstructures%26aulast%3DCheng%26aufirst%3DWeiyan%26date%3D2019%26volume%3D164%26spage%3D615%26epage%3D639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mostafa M.  Ghorab</span>, <span class="hlFld-ContribAuthor ">Fatma A.  Ragab</span>, <span class="hlFld-ContribAuthor ">Helmy I.  Heiba</span>, <span class="hlFld-ContribAuthor ">Mohamed S.A.  Elsayed</span>, <span class="hlFld-ContribAuthor ">Walid M.  Ghorab</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and molecular modeling study of certain 4-Methylbenzenesulfonamides with CDK2 inhibitory activity as anticancer and radio-sensitizing agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2018,</strong> <em>80 </em>, 276-287. <a href="https://doi.org/10.1016/j.bioorg.2018.06.010" title="DOI URL">https://doi.org/10.1016/j.bioorg.2018.06.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2018.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2018.06.010%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bmolecular%252Bmodeling%252Bstudy%252Bof%252Bcertain%252B4-Methylbenzenesulfonamides%252Bwith%252BCDK2%252Binhibitory%252Bactivity%252Bas%252Banticancer%252Band%252Bradio-sensitizing%252Bagents%26aulast%3DGhorab%26aufirst%3DMostafa%2BM.%26date%3D2018%26volume%3D80%26spage%3D276%26epage%3D287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yousry A.  Ammar</span>, <span class="hlFld-ContribAuthor ">Eman A.  Fayed</span>, <span class="hlFld-ContribAuthor ">Ashraf H.  Bayoumi</span>, <span class="hlFld-ContribAuthor ">Rogy R.  Ezz</span>, <span class="hlFld-ContribAuthor ">Mansour S.  Alsaid</span>, <span class="hlFld-ContribAuthor ">Aiten M.  Soliman</span>, <span class="hlFld-ContribAuthor ">Mostafa M.  Ghorab</span>. </span><span class="cited-content_cbyCitation_article-title">New chalcones bearing isatin scaffold: synthesis, molecular modeling and biological evaluation as anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Research on Chemical Intermediates</span><span> <strong>2017,</strong> <em>43 </em>
                                    (12)
                                     , 6765-6786. <a href="https://doi.org/10.1007/s11164-017-3019-z" title="DOI URL">https://doi.org/10.1007/s11164-017-3019-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11164-017-3019-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11164-017-3019-z%26sid%3Dliteratum%253Aachs%26jtitle%3DResearch%2520on%2520Chemical%2520Intermediates%26atitle%3DNew%252Bchalcones%252Bbearing%252Bisatin%252Bscaffold%25253A%252Bsynthesis%25252C%252Bmolecular%252Bmodeling%252Band%252Bbiological%252Bevaluation%252Bas%252Banticancer%252Bagents%26aulast%3DAmmar%26aufirst%3DYousry%2BA.%26date%3D2017%26date%3D2017%26volume%3D43%26issue%3D12%26spage%3D6765%26epage%3D6786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Virginia  Spanò</span>, <span class="hlFld-ContribAuthor ">Ilaria  Frasson</span>, <span class="hlFld-ContribAuthor ">Daniele  Giallombardo</span>, <span class="hlFld-ContribAuthor ">Filippo  Doria</span>, <span class="hlFld-ContribAuthor ">Barbara  Parrino</span>, <span class="hlFld-ContribAuthor ">Anna  Carbone</span>, <span class="hlFld-ContribAuthor ">Alessandra  Montalbano</span>, <span class="hlFld-ContribAuthor ">Matteo  Nadai</span>, <span class="hlFld-ContribAuthor ">Patrizia  Diana</span>, <span class="hlFld-ContribAuthor ">Girolamo  Cirrincione</span>, <span class="hlFld-ContribAuthor ">Mauro  Freccero</span>, <span class="hlFld-ContribAuthor ">Sara N.  Richter</span>, <span class="hlFld-ContribAuthor ">Paola  Barraja</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and antiproliferative mechanism of action of pyrrolo[3′,2′:6,7] cyclohepta[1,2- d ]pyrimidin-2-amines as singlet oxygen photosensitizers. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>123 </em>, 447-461. <a href="https://doi.org/10.1016/j.ejmech.2016.07.051" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.07.051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.07.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.07.051%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bantiproliferative%252Bmechanism%252Bof%252Baction%252Bof%252Bpyrrolo%25255B3%2525E2%252580%2525B2%25252C2%2525E2%252580%2525B2%25253A6%25252C7%25255D%252Bcyclohepta%25255B1%25252C2-%252Bd%252B%25255Dpyrimidin-2-amines%252Bas%252Bsinglet%252Boxygen%252Bphotosensitizers%26aulast%3DSpan%25C3%25B2%26aufirst%3DVirginia%26date%3D2016%26volume%3D123%26spage%3D447%26epage%3D461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">V.  Ganga Reddy</span>, <span class="hlFld-ContribAuthor ">T.  Srinivasa Reddy</span>, <span class="hlFld-ContribAuthor ">V.  Lakshma Nayak</span>, <span class="hlFld-ContribAuthor ">Budaganaboyina  Prasad</span>, <span class="hlFld-ContribAuthor ">Adiyala Praveen  Reddy</span>, <span class="hlFld-ContribAuthor ">A.  Ravikumar</span>, <span class="hlFld-ContribAuthor ">Shaik  Taj</span>, <span class="hlFld-ContribAuthor ">Ahmed  Kamal</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of N -((1-benzyl-1 H -1,2,3-triazol-4-yl)methyl)-1,3-diphenyl-1 H -pyrazole-4-carboxamides as CDK1/Cdc2 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>122 </em>, 164-177. <a href="https://doi.org/10.1016/j.ejmech.2016.06.011" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.06.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.06.011%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252BN%252B-%252528%2525281-benzyl-1%252BH%252B-1%25252C2%25252C3-triazol-4-yl%252529methyl%252529-1%25252C3-diphenyl-1%252BH%252B-pyrazole-4-carboxamides%252Bas%252BCDK1%25252FCdc2%252Binhibitors%26aulast%3DGanga%2BReddy%26aufirst%3DV.%26date%3D2016%26volume%3D122%26spage%3D164%26epage%3D177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nasser S.M.  Ismail</span>, <span class="hlFld-ContribAuthor ">Eslam M.H.  Ali</span>, <span class="hlFld-ContribAuthor ">Diaa A.  Ibrahim</span>, <span class="hlFld-ContribAuthor ">Rabah A.T.  Serya</span>, <span class="hlFld-ContribAuthor ">Dalal A.  Abou El Ella</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrazolo[3,4-d]pyrimidine based scaffold derivatives targeting kinases as anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Future Journal of Pharmaceutical Sciences</span><span> <strong>2016,</strong> <em>2 </em>
                                    (1)
                                     , 20-30. <a href="https://doi.org/10.1016/j.fjps.2016.02.002" title="DOI URL">https://doi.org/10.1016/j.fjps.2016.02.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.fjps.2016.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.fjps.2016.02.002%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Journal%2520of%2520Pharmaceutical%2520Sciences%26atitle%3DPyrazolo%25255B3%25252C4-d%25255Dpyrimidine%252Bbased%252Bscaffold%252Bderivatives%252Btargeting%252Bkinases%252Bas%252Banticancer%252Bagents%26aulast%3DIsmail%26aufirst%3DNasser%2BS.M.%26date%3D2016%26volume%3D2%26issue%3D1%26spage%3D20%26epage%3D30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Asterios I.  Grigoroudis</span>, <span class="hlFld-ContribAuthor ">George  Kontopidis</span>. </span><span class="cited-content_cbyCitation_article-title">Preparation of CDK/Cyclin Inhibitor Complexes for Structural Determination. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 29-45. <a href="https://doi.org/10.1007/978-1-4939-2926-9_4" title="DOI URL">https://doi.org/10.1007/978-1-4939-2926-9_4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-1-4939-2926-9_4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-1-4939-2926-9_4%26sid%3Dliteratum%253Aachs%26atitle%3DPreparation%252Bof%252BCDK%25252FCyclin%252BInhibitor%252BComplexes%252Bfor%252BStructural%252BDetermination%26aulast%3DGrigoroudis%26aufirst%3DAsterios%2BI.%26date%3D2016%26spage%3D29%26epage%3D45%26pub%3DSpringer%2520New%2520York%26atitle%3DCyclin-Dependent%252BKinase%252B%252528CDK%252529%252BInhibitors%26aulast%3DOrz%25C3%25A1ez%26aufirst%3DMar%26date%3D2016%26volume%3D1336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Soňa  Jantová</span>, <span class="hlFld-ContribAuthor ">Martina  Melušová</span>, <span class="hlFld-ContribAuthor ">Miroslav  Pánik</span>, <span class="hlFld-ContribAuthor ">Vlasta  Brezová</span>, <span class="hlFld-ContribAuthor ">Zuzana  Barbieriková</span>. </span><span class="cited-content_cbyCitation_article-title">UVA-induced effects of 2,6-disubstituted 4-anilinoquinazolines on cancer cell lines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Photochemistry and Photobiology B: Biology</span><span> <strong>2016,</strong> <em>154 </em>, 77-88. <a href="https://doi.org/10.1016/j.jphotobiol.2015.11.014" title="DOI URL">https://doi.org/10.1016/j.jphotobiol.2015.11.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jphotobiol.2015.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jphotobiol.2015.11.014%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Photochemistry%2520and%2520Photobiology%2520B%253A%2520Biology%26atitle%3DUVA-induced%252Beffects%252Bof%252B2%25252C6-disubstituted%252B4-anilinoquinazolines%252Bon%252Bcancer%252Bcell%252Blines%26aulast%3DJantov%25C3%25A1%26aufirst%3DSo%25C5%2588a%26date%3D2016%26volume%3D154%26spage%3D77%26epage%3D88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Asterios I.  Grigoroudis</span>, <span class="hlFld-ContribAuthor ">Campbell  McInnes</span>, <span class="hlFld-ContribAuthor ">Padmavathy Nandha  Premnath</span>, <span class="hlFld-ContribAuthor ">George  Kontopidis</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient soluble expression of active recombinant human cyclin A2 mediated by E. coli molecular chaperones. </span><span class="cited-content_cbyCitation_journal-name">Protein Expression and Purification</span><span> <strong>2015,</strong> <em>113 </em>, 8-16. <a href="https://doi.org/10.1016/j.pep.2015.01.013" title="DOI URL">https://doi.org/10.1016/j.pep.2015.01.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pep.2015.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pep.2015.01.013%26sid%3Dliteratum%253Aachs%26jtitle%3DProtein%2520Expression%2520and%2520Purification%26atitle%3DEfficient%252Bsoluble%252Bexpression%252Bof%252Bactive%252Brecombinant%252Bhuman%252Bcyclin%252BA2%252Bmediated%252Bby%252BE.%252Bcoli%252Bmolecular%252Bchaperones%26aulast%3DGrigoroudis%26aufirst%3DAsterios%2BI.%26date%3D2015%26volume%3D113%26spage%3D8%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmed M.  Alafeefy</span>, <span class="hlFld-ContribAuthor ">Amani S.  Awaad</span>, <span class="hlFld-ContribAuthor ">Hatem A.  Abdel-Aziz</span>, <span class="hlFld-ContribAuthor ">Reham M.  El-Meligy</span>, <span class="hlFld-ContribAuthor ">Mohamed E.  Zain</span>, <span class="hlFld-ContribAuthor ">Mounerah R.  Al-Outhman</span>, <span class="hlFld-ContribAuthor ">Abir B.  Bacha</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of certain 3-substituted benzylideneamino-2-(4-nitrophenyl)quinazolin-4(3
              H
              )-one derivatives. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2015,</strong> <em>30 </em>
                                    (2)
                                     , 270-276. <a href="https://doi.org/10.3109/14756366.2014.915398" title="DOI URL">https://doi.org/10.3109/14756366.2014.915398</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3109/14756366.2014.915398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3109%2F14756366.2014.915398%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bcertain%252B3-substituted%252Bbenzylideneamino-2-%2525284-nitrophenyl%252529quinazolin-4%2525283%252BH%252B%252529-one%252Bderivatives%26aulast%3DAlafeefy%26aufirst%3DAhmed%2BM.%26date%3D2015%26date%3D2014%26volume%3D30%26issue%3D2%26spage%3D270%26epage%3D276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Meng  Li</span>, <span class="hlFld-ContribAuthor ">Bao-Xiang  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Progress of the synthesis of condensed pyrazole derivatives (from 2010 to mid-2013). </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>85 </em>, 311-340. <a href="https://doi.org/10.1016/j.ejmech.2014.07.102" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.07.102</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.07.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.07.102%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DProgress%252Bof%252Bthe%252Bsynthesis%252Bof%252Bcondensed%252Bpyrazole%252Bderivatives%252B%252528from%252B2010%252Bto%252Bmid-2013%252529%26aulast%3DLi%26aufirst%3DMeng%26date%3D2014%26volume%3D85%26spage%3D311%26epage%3D340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simpal  Kumari</span>, <span class="hlFld-ContribAuthor ">Sarvesh  Paliwal</span>, <span class="hlFld-ContribAuthor ">Rajani  Chauhan</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Pyrazole Derivatives Possessing Anticancer Activity: Current Status. </span><span class="cited-content_cbyCitation_journal-name">Synthetic Communications</span><span> <strong>2014,</strong> <em>44 </em>
                                    (11)
                                     , 1521-1578. <a href="https://doi.org/10.1080/00397911.2013.828757" title="DOI URL">https://doi.org/10.1080/00397911.2013.828757</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00397911.2013.828757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00397911.2013.828757%26sid%3Dliteratum%253Aachs%26jtitle%3DSynthetic%2520Communications%26atitle%3DSynthesis%252Bof%252BPyrazole%252BDerivatives%252BPossessing%252BAnticancer%252BActivity%25253A%252BCurrent%252BStatus%26aulast%3DKumari%26aufirst%3DSimpal%26date%3D2014%26date%3D2014%26volume%3D44%26issue%3D11%26spage%3D1521%26epage%3D1578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dong-Sheng  Chen</span>, <span class="hlFld-ContribAuthor ">Mei-Mei  Zhang</span>, <span class="hlFld-ContribAuthor ">Yu-Ling  Li</span>, <span class="hlFld-ContribAuthor ">Yun  Liu</span>, <span class="hlFld-ContribAuthor ">Xiang-Shan  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Copper(I)-catalyzed synthesis of 1-arylpyrazolo[5,1-b]quinazolin-9(1H)-one via intramolecular alkyne hydroamination. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2014,</strong> <em>70 </em>
                                    (18)
                                     , 2889-2893. <a href="https://doi.org/10.1016/j.tet.2014.03.048" title="DOI URL">https://doi.org/10.1016/j.tet.2014.03.048</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2014.03.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2014.03.048%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DCopper%252528I%252529-catalyzed%252Bsynthesis%252Bof%252B1-arylpyrazolo%25255B5%25252C1-b%25255Dquinazolin-9%2525281H%252529-one%252Bvia%252Bintramolecular%252Balkyne%252Bhydroamination%26aulast%3DChen%26aufirst%3DDong-Sheng%26date%3D2014%26volume%3D70%26issue%3D18%26spage%3D2889%26epage%3D2893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Virginia  Spanò</span>, <span class="hlFld-ContribAuthor ">Alessandra  Montalbano</span>, <span class="hlFld-ContribAuthor ">Anna  Carbone</span>, <span class="hlFld-ContribAuthor ">Barbara  Parrino</span>, <span class="hlFld-ContribAuthor ">Patrizia  Diana</span>, <span class="hlFld-ContribAuthor ">Girolamo  Cirrincione</span>, <span class="hlFld-ContribAuthor ">Ignazio  Castagliuolo</span>, <span class="hlFld-ContribAuthor ">Paola  Brun</span>, <span class="hlFld-ContribAuthor ">Olaf-Georg  Issinger</span>, <span class="hlFld-ContribAuthor ">Silvia  Tisi</span>, <span class="hlFld-ContribAuthor ">Irina  Primac</span>, <span class="hlFld-ContribAuthor ">Daniela  Vedaldi</span>, <span class="hlFld-ContribAuthor ">Alessia  Salvador</span>, <span class="hlFld-ContribAuthor ">Paola  Barraja</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of a new class of pyrrolo[3,4-h]quinazolines with antimitotic activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>74 </em>, 340-357. <a href="https://doi.org/10.1016/j.ejmech.2013.10.014" title="DOI URL">https://doi.org/10.1016/j.ejmech.2013.10.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2013.10.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2013.10.014%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Bof%252Ba%252Bnew%252Bclass%252Bof%252Bpyrrolo%25255B3%25252C4-h%25255Dquinazolines%252Bwith%252Bantimitotic%252Bactivity%26aulast%3DSpan%25C3%25B2%26aufirst%3DVirginia%26date%3D2014%26volume%3D74%26spage%3D340%26epage%3D357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feng  Li</span>, <span class="hlFld-ContribAuthor ">Lin  Chen</span>, <span class="hlFld-ContribAuthor ">Qikai  Kang</span>, <span class="hlFld-ContribAuthor ">Jianguang  Cai</span>, <span class="hlFld-ContribAuthor ">Guangjun  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Regioselective N-alkylation with alcohols for the preparation of 2-(N-alkylamino)quinazolines and 2-(N-alkylamino)pyrimidines. </span><span class="cited-content_cbyCitation_journal-name">New J. Chem.</span><span> <strong>2013,</strong> <em>37 </em>
                                    (3)
                                     , 624-631. <a href="https://doi.org/10.1039/C2NJ41021D" title="DOI URL">https://doi.org/10.1039/C2NJ41021D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C2NJ41021D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC2NJ41021D%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520J.%2520Chem.%26atitle%3DRegioselective%252BN-alkylation%252Bwith%252Balcohols%252Bfor%252Bthe%252Bpreparation%252Bof%252B2-%252528N-alkylamino%252529quinazolines%252Band%252B2-%252528N-alkylamino%252529pyrimidines%26aulast%3DLi%26aufirst%3DFeng%26date%3D2013%26date%3D2013%26volume%3D37%26issue%3D3%26spage%3D624%26epage%3D631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eduard R.  Felder</span>, <span class="hlFld-ContribAuthor ">Alessandra  Badari</span>, <span class="hlFld-ContribAuthor ">Teresa  Disingrini</span>, <span class="hlFld-ContribAuthor ">Sergio  Mantegani</span>, <span class="hlFld-ContribAuthor ">Christian  Orrenius</span>, <span class="hlFld-ContribAuthor ">Nilla  Avanzi</span>, <span class="hlFld-ContribAuthor ">Antonella  Isacchi</span>, <span class="hlFld-ContribAuthor ">Barbara  Salom</span>. </span><span class="cited-content_cbyCitation_article-title">The generation of purinome-targeted libraries as a means to diversify ATP-mimetic chemical classes for lead finding. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diversity</span><span> <strong>2012,</strong> <em>16 </em>
                                    (1)
                                     , 27-51. <a href="https://doi.org/10.1007/s11030-012-9361-6" title="DOI URL">https://doi.org/10.1007/s11030-012-9361-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11030-012-9361-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11030-012-9361-6%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diversity%26atitle%3DThe%252Bgeneration%252Bof%252Bpurinome-targeted%252Blibraries%252Bas%252Ba%252Bmeans%252Bto%252Bdiversify%252BATP-mimetic%252Bchemical%252Bclasses%252Bfor%252Blead%252Bfinding%26aulast%3DFelder%26aufirst%3DEduard%2BR.%26date%3D2012%26date%3D2012%26volume%3D16%26issue%3D1%26spage%3D27%26epage%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marco  Derudas</span>, <span class="hlFld-ContribAuthor ">Nicolino  Pala</span>, <span class="hlFld-ContribAuthor ">Vanna  Sanna</span>, <span class="hlFld-ContribAuthor ">Roberto  Dallocchio</span>, <span class="hlFld-ContribAuthor ">Alessandro  Dessì</span>, <span class="hlFld-ContribAuthor ">Anna Maria  Roggio</span>, <span class="hlFld-ContribAuthor ">Mario  Sechi</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of novel polycycles based on the 3H-pyrrolo/6,7-dihydropyrido[1,2-a]indole scaffold as templates for pharmaceutical development. </span><span class="cited-content_cbyCitation_journal-name">Journal of Heterocyclic Chemistry</span><span> <strong>2011,</strong> <em>48 </em>
                                    (5)
                                     , 1161-1168. <a href="https://doi.org/10.1002/jhet.710" title="DOI URL">https://doi.org/10.1002/jhet.710</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jhet.710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjhet.710%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Heterocyclic%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bnovel%252Bpolycycles%252Bbased%252Bon%252Bthe%252B3H-pyrrolo%25252F6%25252C7-dihydropyrido%25255B1%25252C2-a%25255Dindole%252Bscaffold%252Bas%252Btemplates%252Bfor%252Bpharmaceutical%252Bdevelopment%26aulast%3DDerudas%26aufirst%3DMarco%26date%3D2011%26date%3D2011%26volume%3D48%26issue%3D5%26spage%3D1161%26epage%3D1168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jian  Wang</span>, <span class="hlFld-ContribAuthor ">Ya-Dong  Chen</span>, <span class="hlFld-ContribAuthor ">Hai-Chun  Liu</span>, <span class="hlFld-ContribAuthor ">Guo-Wu  Lin</span>, <span class="hlFld-ContribAuthor ">Tao-Tao  Yang</span>, <span class="hlFld-ContribAuthor ">Hao-Liang  Yuan</span>, <span class="hlFld-ContribAuthor ">Ting  Ran</span>, <span class="hlFld-ContribAuthor ">Shuai  Lu</span>, <span class="hlFld-ContribAuthor ">Wei-Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">Ying  Leng</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">De novo
              design of quinazoline derivatives as CDK2 inhibitors: 3D-QSAR, molecular fragment replacement and Volsurf predictions. </span><span class="cited-content_cbyCitation_journal-name">Molecular Simulation</span><span> <strong>2011,</strong> <em>37 </em>
                                    (10)
                                     , 824-836. <a href="https://doi.org/10.1080/08927022.2011.563302" title="DOI URL">https://doi.org/10.1080/08927022.2011.563302</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/08927022.2011.563302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F08927022.2011.563302%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Simulation%26atitle%3DDe%252Bnovo%252Bdesign%252Bof%252Bquinazoline%252Bderivatives%252Bas%252BCDK2%252Binhibitors%25253A%252B3D-QSAR%25252C%252Bmolecular%252Bfragment%252Breplacement%252Band%252BVolsurf%252Bpredictions%26aulast%3DWang%26aufirst%3DJian%26date%3D2011%26volume%3D37%26issue%3D10%26spage%3D824%26epage%3D836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael M.  Miller</span>, <span class="hlFld-ContribAuthor ">Albert J.  DelMonte</span>. </span><span class="cited-content_cbyCitation_article-title">Six-Membered Ring Systems. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2011,</strong>,, 371-402. <a href="https://doi.org/10.1016/B978-0-08-096805-6.00013-9" title="DOI URL">https://doi.org/10.1016/B978-0-08-096805-6.00013-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-096805-6.00013-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-096805-6.00013-9%26sid%3Dliteratum%253Aachs%26atitle%3DSix-Membered%252BRing%252BSystems%26aulast%3DMiller%26aufirst%3DMichael%2BM.%26date%3D2011%26spage%3D371%26epage%3D402%26pub%3DElsevier%26date%3D2011%26volume%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ping  Lan</span>, <span class="hlFld-ContribAuthor ">Wan-Na  Chen</span>, <span class="hlFld-ContribAuthor ">Gao-Keng  Xiao</span>, <span class="hlFld-ContribAuthor ">Ping-Hua  Sun</span>, <span class="hlFld-ContribAuthor ">Wei-Min  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">3D-QSAR and docking studies on pyrazolo[4,3-h]qinazoline-3-carboxamides as cyclin-dependent kinase 2 (CDK2) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2010,</strong> <em>20 </em>
                                    (22)
                                     , 6764-6772. <a href="https://doi.org/10.1016/j.bmcl.2010.08.131" title="DOI URL">https://doi.org/10.1016/j.bmcl.2010.08.131</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2010.08.131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2010.08.131%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3D3D-QSAR%252Band%252Bdocking%252Bstudies%252Bon%252Bpyrazolo%25255B4%25252C3-h%25255Dqinazoline-3-carboxamides%252Bas%252Bcyclin-dependent%252Bkinase%252B2%252B%252528CDK2%252529%252Binhibitors%26aulast%3DLan%26aufirst%3DPing%26date%3D2010%26volume%3D20%26issue%3D22%26spage%3D6764%26epage%3D6772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mauro  Angiolini</span>, <span class="hlFld-ContribAuthor ">Patrizia  Banfi</span>, <span class="hlFld-ContribAuthor ">Elena  Casale</span>, <span class="hlFld-ContribAuthor ">Francesco  Casuscelli</span>, <span class="hlFld-ContribAuthor ">Claudio  Fiorelli</span>, <span class="hlFld-ContribAuthor ">Maria B.  Saccardo</span>, <span class="hlFld-ContribAuthor ">Marco  Silvagni</span>, <span class="hlFld-ContribAuthor ">Fabio  Zuccotto</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based optimization of potent PDK1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2010,</strong> <em>20 </em>
                                    (14)
                                     , 4095-4099. <a href="https://doi.org/10.1016/j.bmcl.2010.05.070" title="DOI URL">https://doi.org/10.1016/j.bmcl.2010.05.070</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2010.05.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2010.05.070%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DStructure-based%252Boptimization%252Bof%252Bpotent%252BPDK1%252Binhibitors%26aulast%3DAngiolini%26aufirst%3DMauro%26date%3D2010%26volume%3D20%26issue%3D14%26spage%3D4095%26epage%3D4099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/medium/jm-2009-01710h_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901710h&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/medium/jm-2009-01710h_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of pyrazolo[4,3-<i>h</i>]quinazoline scaffold and hit compound <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901710h&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/medium/jm-2009-01710h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Final Compounds <b>1</b>, <b>14</b>, <b>19</b>−<b>26</b>, and <b>28</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901710h&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>S</i>-methylisothiourea, AcOK, DMF, 90 °C, 74%; (b) NH<sub>4</sub>OH, MeOH-DMF, 80 °C, 52%; (c) oxone, DMF, rt, 80%; (d) R<sup>3</sup>NH<sub>2</sub>, DMSO, 50−120 °C, 40−72%.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/medium/jm-2009-01710h_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Final Compounds <b>18</b>, <b>27</b>,<b> 29</b>, <b>30</b>, and <b>47</b>−<b>49</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901710h&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>O</i>-methylisourea, K<sub>2</sub>CO<sub>3</sub>, acetonitrile, reflux, 16 h, 80%; (b) trimethylsilyl chloride, NaI, rt, 8 h, 78%; (c) trifluoromethansulfonic anhydride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, from −78 °C to rt, 5 h, 67%; (d) R<sup>3</sup>NH<sub>2</sub>, dioxane, rt, 70−85%; (e) EtOH, KOH, reflux, 75−80%; HOBT·NH<sub>3</sub>, EDC, DIPEA, DMF-THF, rt, 61−73%; (f) NH<sub>4</sub>OH, MeOH-DMF, 70 °C, 60%; (g) CH<sub>3</sub>NH<sub>2</sub>, EtOH, 60 °C, 50−78%.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/medium/jm-2009-01710h_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Final Compounds <b>15</b>−<b>17</b>, <b>31</b>−<b>36</b>, and <b>50</b>−<b>61</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901710h&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) guanidine hydrochloride, EtONa, EtOH, reflux, 12 h, 85%; (b) NH<sub>4</sub>OH, MeOH-DMF, 70 °C, 50−65%; (c) CH<sub>3</sub>NH<sub>2</sub>, EtOH, 60 °C, 78%; (d) ArCHO, NaBH<sub>3</sub>CN, AcOH−MeOH−H<sub>2</sub>O 1/1/1, rt, 58−62%; (e) cycloalkylketone, NaBH(OAc)<sub>3</sub>, TFA, DMF, rt, 50−73%; (f) KOH, EtOH, reflux; R<sup>1</sup>NH<sub>2</sub>, EDC, HOBT, DIPEA, DMF-THF, rt, 31−51%; (g) KOH, EtOH, reflux; HOBT·NH<sub>3</sub>, EDC, DIPEA, DMF-THF, rt, 43−49%; (h) KOH, EtOH, reflux; (COCl)<sub>2</sub>, R<sup>1</sup>NHOH, rt, 36−62%.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/medium/jm-2009-01710h_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Final Compounds <b>37</b>−<b>46</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901710h&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) R<sup>2</sup>NHNH<sub>2</sub>, AcOH, rt, 63−80%; (b) dimethylformamide di-<i>tert</i>-butylacetale, DMF, 60 °C; guanidine hydrochloride, EtONa, EtOH, reflux, 45−72%; (c) cyclopentylketone, NaBH(OAc)<sub>3</sub>, TFA, DMF, rt, 65−80%; (d) NH<sub>4</sub>OH, MeOH-DMF, 70 °C, 75−80%; (e) CH<sub>3</sub>NH<sub>2</sub>, EtOH, 60 °C, 78%.</p></p></figure><figure data-id="fig2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/medium/jm-2009-01710h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Crystal structure of selected compound <b>59</b> in complex with CDK2/CyA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901710h&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/medium/jm-2009-01710h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effects of compound <b>59</b> on cell cycle progression and DNA synthesis after 24 h treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901710h&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/medium/jm-2009-01710h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Decrease of pRb phosphorylation induced by compound <b>59</b> in cells after 24 h treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901710h&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/medium/jm-2009-01710h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>59</b> shows 38, 46, and 75% tumor growth inhibition (TGI) against a human ovarian cancer model (A2780) transplanted into nude mice when orally administered respectively at doses of 5 (square), 10 (triangle), and 20 (cross) mg/kg bid for 10 consecutive days. Vehicle-treated (control) curve is reported with open circles.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901710h/production/images/large/jm-2009-01710h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901710h&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i104">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38756" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38756" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 22 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Massagué, J.</span><span> </span><span class="NLM_article-title">G1 cell cycle and cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">432</span><span class="NLM_x">, </span> <span class="NLM_fpage">298</span><span class="NLM_x">–</span> <span class="NLM_lpage">306</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=432&publication_year=2004&pages=298-306&author=J.+Massagu%C3%A9&title=G1+cell+cycle+and+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMassagu%25C3%25A9%26aufirst%3DJ.%26atitle%3DG1%2520cell%2520cycle%2520and%2520cancer%26jtitle%3DNature%26date%3D2004%26volume%3D432%26spage%3D298%26epage%3D306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Grana, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span> </span><span class="NLM_article-title">Cell cycle control in mammalian cells: role of cyclins, cyclin-dependent kinases (CDKs), growth suppressor genes, and cyclin-dependent kinase inhibitors (CKIs)</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1995&pages=211-219&author=X.+Granaauthor=E.+P.+Reddy&title=Cell+cycle+control+in+mammalian+cells%3A+role+of+cyclins%2C+cyclin-dependent+kinases+%28CDKs%29%2C+growth+suppressor+genes%2C+and+cyclin-dependent+kinase+inhibitors+%28CKIs%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGrana%26aufirst%3DX.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DCell%2520cycle%2520control%2520in%2520mammalian%2520cells%253A%2520role%2520of%2520cyclins%252C%2520cyclin-dependent%2520kinases%2520%2528CDKs%2529%252C%2520growth%2520suppressor%2520genes%252C%2520and%2520cyclin-dependent%2520kinase%2520inhibitors%2520%2528CKIs%2529%26jtitle%3DOncogene%26date%3D1995%26volume%3D11%26spage%3D211%26epage%3D219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Morgan, D. O.</span><span> </span><span class="NLM_article-title">Principles of CDK regulation</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">374</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">134</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Fjm901710h&amp;key=10.1038%2F374131a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Fjm901710h&amp;key=7877684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Fjm901710h&amp;key=1%3ACAS%3A528%3ADyaK2MXkt1yju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=1995&pages=131-134&author=D.+O.+Morgan&title=Principles+of+CDK+regulation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Principles of CDK regulation</span></div><div class="casAuthors">Morgan, David O.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">6518</span>),
    <span class="NLM_cas:pages">131-4</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">A review with 77 refs.  As key regulators of the cell cycle, the cyclin-dependent kinases (CDKs) must be tightly regulated by extra- and intracellular signals.  The activity of cyclin-dependent kinases is controlled by four highly conserved biochem. mechanisms, forming a web of regulatory pathways unmatched in its elegance and intricacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrQWC7U9kpj7Vg90H21EOLACvtfcHk0lg802mPMDox_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXkt1yju7s%253D&md5=3dafa23aec02e4887757b100abb52d89</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1038%2F374131a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F374131a0%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DD.%2BO.%26atitle%3DPrinciples%2520of%2520CDK%2520regulation%26jtitle%3DNature%26date%3D1995%26volume%3D374%26spage%3D131%26epage%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Dynlacht, B.</span><span> </span><span class="NLM_article-title">Regulation of transcription during the cell cycle</span> <span class="citation_source-journal">Transcription Factors</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_fpage">85</span><span class="NLM_x">–</span> <span class="NLM_lpage">112</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Fjm901710h&amp;key=1%3ACAS%3A528%3ADC%252BD3cXovFWgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&pages=85-112&author=B.+Dynlacht&title=Regulation+of+transcription+during+the+cell+cycle"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of transcription during the cell cycle</span></div><div class="casAuthors">Dynlacht, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Transcription Factors</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">85-112</span>CODEN:
                <span class="NLM_cas:coden">69ATCS</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">BIOS Scientific Publishers Ltd.</span>)
        </div><div class="casAbstract">A review with 198 refs emphasizing recent advances in understanding of factors regulating transcription during cell-cycle progression in mammalian cells.  Studies in this system are providing a unified view of the regulatory controls based on the sequential activation of CDKs during G1 phase and S phase entry.  These kinases progressively inhibit the retinoblastoma (pRB) tumor-sup- pressor protein and initially promote, and then inhibit, E2F, a transcription factor that displays the properties of an oncogene and tumor suppressor.  This leads to the timely activation of genes required for cell-cycle progression.  Similarly, cyclin B/Cdc2 activity inhibits a no. of transcriptional regulators during M phase.  Two other CDK complexes that have less clear roles in cell-cycle regulation, cyclin H/Cdk7 and cyclin C/Cdk8, modify pol II thereby regulating the initiation and progression of transcription.  Recent results further suggest intriguing parallels between the mechanisms that regulate transcription by all three RNA polymerases during the cell cycle and conservation of transcriptional controls between yeast and mammalian cells.  Thus, an intricate balance of transcriptional and post-translational controls govern the activity of transcription factors that propel the cell cycle in a unidirectional manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6rja6WN4tk7Vg90H21EOLACvtfcHk0lg802mPMDox_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXovFWgtL4%253D&md5=f98c23b9cec17dd2a25ddcf84d3a9b56</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDynlacht%26aufirst%3DB.%26atitle%3DRegulation%2520of%2520transcription%2520during%2520the%2520cell%2520cycle%26jtitle%3DTranscription%2520Factors%26date%3D2001%26spage%3D85%26epage%3D112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">De Falco, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, A.</span><span> </span><span class="NLM_article-title">CDK9: from basal transcription to cancer and AIDS</span> <span class="citation_source-journal">Cancer Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">342</span><span class="NLM_x">–</span> <span class="NLM_lpage">347</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Fjm901710h&amp;key=12432243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Fjm901710h&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlsFygsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=342-347&author=G.+De+Falcoauthor=A.+Giordano&title=CDK9%3A+from+basal+transcription+to+cancer+and+AIDS"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">CDK9: from basal transcription to cancer and AIDS</span></div><div class="casAuthors">De Falco, Giulia; Giordano, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">342-347</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  Cdk9 is a member of the Cdc2-like family of kinases.  Its cyclin partners are members of the family of cyclin T (T1, T2a and T2b) and cyclin K.  The Cdk9/cyclin T complexes appear to be involved in regulating several physiol. processes.  Cdk9/cyclin T1 belongs to the P-TEFb complex, and is responsible for the phosphorylation of the carboxyl-terminal domain (CTD) of the RNA Polymerase II, thus promoting general elongation.  Cdk9 has also been described as the kinase of the TAK complex, which is homologous to the P-TEFb complex and involved in HIV replication.  Cdk9 also appears to be involved in the differentiation program of several cell types, such as muscle cells, monocytes and neurons, suggesting that it may have a function in controlling specific differentiative pathways.  In addn., Cdk9 seems to have an anti-apoptotic function in monocytes, that may be related to its control over differentiation of monocytes.  This data suggests the involvement of Cdk9 in several physiol. processes in the cell, the deregulation of which may be related to the genesis of transforming events, that may in turn lead to the onset of cancer.  In addn., since the complex Cdk9/cyclin T1 is able to bind to the HIV-1 product Tat, the study of the functions of Cdk9/cyclin T may be of interest in understanding the basal mechanisms that regulate HIV replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-K3Ihi8BcqLVg90H21EOLACvtfcHk0li2z4kbh9l9jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlsFygsQ%253D%253D&md5=27ca2c40fa916694ef9d8e8dadfc7bf9</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BFalco%26aufirst%3DG.%26aulast%3DGiordano%26aufirst%3DA.%26atitle%3DCDK9%253A%2520from%2520basal%2520transcription%2520to%2520cancer%2520and%2520AIDS%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2002%26volume%3D1%26spage%3D342%26epage%3D347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Cruz, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, L. A.</span><span> </span><span class="NLM_article-title">Jekyll and Hyde kinase: roles for Cdk5 in brain development and disease</span> <span class="citation_source-journal">Curr. Opin. Neurobiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">390</span><span class="NLM_x">–</span> <span class="NLM_lpage">394</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=390-394&author=J.+C.+Cruzauthor=L.+A.+Tsai&title=Jekyll+and+Hyde+kinase%3A+roles+for+Cdk5+in+brain+development+and+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCruz%26aufirst%3DJ.%2BC.%26aulast%3DTsai%26aufirst%3DL.%2BA.%26atitle%3DJekyll%2520and%2520Hyde%2520kinase%253A%2520roles%2520for%2520Cdk5%2520in%2520brain%2520development%2520and%2520disease%26jtitle%3DCurr.%2520Opin.%2520Neurobiol.%26date%3D2004%26volume%3D14%26spage%3D390%26epage%3D394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span> </span><span class="NLM_article-title">Cyclin-dependent kinase pathways as targets for cancer treatment</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1770</span><span class="NLM_x">–</span> <span class="NLM_lpage">1783</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Fjm901710h&amp;key=10.1200%2FJCO.2005.03.7689" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Fjm901710h&amp;key=16603719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Fjm901710h&amp;key=1%3ACAS%3A528%3ADC%252BD28XksVKgtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=1770-1783&author=G.+I.+Shapiro&title=Cyclin-dependent+kinase+pathways+as+targets+for+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase pathways as targets for cancer treatment</span></div><div class="casAuthors">Shapiro, Geoffrey I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1770-1783</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Cyclin-dependent kinases (cdks) are crit. regulators of cell cycle progression and RNA transcription.  A variety of genetic and epigenetic events cause universal overactivity of the cell cycle cdks in human cancer, and their inhibition can lead to both cell cycle arrest and apoptosis.  However, built-in redundancy may limit the effects of highly selective cdk inhibition.  Cdk4/6 inhibition has been shown to induce potent G1 arrest in vitro and tumor regression in vivo; cdk2/1 inhibition has the most potent effects during the S and G2 phases and induces E2F transcription factor-dependent cell death.  Modulation of cdk2 and cdk1 activities also affects survival checkpoint responses after exposure to DNA-damaging and microtubule-stabilizing agents.  The transcriptional cdks phosphorylate the carboxy-terminal domain of RNA polymerase II, facilitating efficient transcriptional initiation and elongation.  Inhibition of these cdks primarily affects the accumulation of transcripts with short half-lives, including those encoding antiapoptosis family members, cell cycle regulators, as well as p53 and nuclear factor-kappa B-responsive gene targets.  These effects may account for apoptosis induced by cdk9 inhibitors, esp. in malignant hematopoietic cells, and may also potentiate cytotoxicity mediated by disruption of a variety of pathways in many transformed cell types.  Current work is focusing on overcoming pharmacokinetic barriers that hindered development of flavopiridol, a pan-cdk inhibitor, as well as assessing novel classes of compds. potently targeting groups of cell cycle cdks (cdk4/6 or cdk2/1) with variable effects on the transcriptional cdks 7 and 9.  These efforts will establish whether the strategy of cdk inhibition is able to produce therapeutic benefit in the majority of human tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYfmCpSfvpTbVg90H21EOLACvtfcHk0li2z4kbh9l9jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksVKgtbg%253D&md5=420a31b47f6600625f7d499a4b8a5fc9</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.03.7689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.03.7689%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DCyclin-dependent%2520kinase%2520pathways%2520as%2520targets%2520for%2520cancer%2520treatment%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D1770%26epage%3D1783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Dyson, N.</span><span> </span><span class="NLM_article-title">The regulation of E2F by pRb-family proteins</span> <span class="citation_source-journal">Gene Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2245</span><span class="NLM_x">–</span> <span class="NLM_lpage">2262</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Fjm901710h&amp;key=10.1101%2Fgad.12.15.2245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Fjm901710h&amp;key=9694791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Fjm901710h&amp;key=1%3ACAS%3A528%3ADyaK1cXltlagu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1998&pages=2245-2262&author=N.+Dyson&title=The+regulation+of+E2F+by+pRb-family+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">The regulation of E2F by pRB-family proteins</span></div><div class="casAuthors">Dyson, Nicholas</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2245-2262</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">A review with over 100 refs.  Topics include: Introduction to the families of E2F and DP proteins (free E2F, complexed E2F), E2F-binding sites mediate both transcriptional activation and repression (E2F as a transcriptional activator, E2F-mediated repression), Activation of E2F-dependent transcription (phosphorylation of pRB-family members, phosphorylation of E2F-1, changes in the subcellular localization of specific E2F complexes, synthesis of new E2Fs), Inactivation of E2F (E2F/DP phosphorylation, degrdn. of free E2F, E2F-repressors), Consequences of elevated E2F activity-ectopic S-phase entry and apoptosis, Is E2F required for S-phase entry, What are the key targets of E2F activity, What is the role of pRB in E2F regulation, Is the ability of pRB to bind E2F important for pRB's role as a tumor suppressor, and How can E2F-1 be both an oncogene and a tumor suppressor gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeXAl9aLvm5bVg90H21EOLACvtfcHk0lh6N7KzZRcosw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXltlagu74%253D&md5=755af21d258487f59a09899698e860e8</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1101%2Fgad.12.15.2245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.12.15.2245%26sid%3Dliteratum%253Aachs%26aulast%3DDyson%26aufirst%3DN.%26atitle%3DThe%2520regulation%2520of%2520E2F%2520by%2520pRb-family%2520proteins%26jtitle%3DGene%2520Dev.%26date%3D1998%26volume%3D12%26spage%3D2245%26epage%3D2262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hanahan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, R. A.</span><span> </span><span class="NLM_article-title">The hallmarks of cancer</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">–</span> <span class="NLM_lpage">70</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Fjm901710h&amp;key=10.1016%2FS0092-8674%2800%2981683-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Fjm901710h&amp;key=10647931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Fjm901710h&amp;key=1%3ACAS%3A528%3ADC%252BD3cXks1CktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2000&pages=57-70&author=D.+Hanahanauthor=R.+A.+Weinberg&title=The+hallmarks+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">The hallmarks of cancer</span></div><div class="casAuthors">Hanahan, Douglas; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-70</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review is given with many refs. on principles governing the transformation of normal human cells into malignant cancers.  The authors suggest that research over the past decades has revealed a small no. of mol., biochem., and cellular traits (acquired capabilities) shared by most and perhaps all types of cancer.  Topics included are the acquired capabilities self-sufficiency in growth signals, insensitivity to antigrowth signals, evading apoptosis, limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis followed by genome instability as an enabling characteristic and alternative pathways to cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooXmGqKjM1C7Vg90H21EOLACvtfcHk0lh6N7KzZRcosw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXks1CktA%253D%253D&md5=1d23c4400dad34c7f32d4a0c41890349</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981683-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981683-9%26sid%3Dliteratum%253Aachs%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DThe%2520hallmarks%2520of%2520cancer%26jtitle%3DCell%26date%3D2000%26volume%3D100%26spage%3D57%26epage%3D70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Malumbres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span> </span><span class="NLM_article-title">Cell cycle, CDKs and cancer: a changing paradigm</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">166</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Fjm901710h&amp;key=10.1038%2Fnrc2602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Fjm901710h&amp;key=19238148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Fjm901710h&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=153-166&author=M.+Malumbresauthor=M.+Barbacid&title=Cell+cycle%2C+CDKs+and+cancer%3A+a+changing+paradigm"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle, CDKs and cancer: a changing paradigm</span></div><div class="casAuthors">Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">153-166</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor-assocd. cell cycle defects are often mediated by alterations in cyclin-dependent kinase (CDK) activity.  Misregulated CDKs induce unscheduled proliferation as well as genomic and chromosomal instability.  According to current models, mammalian CDKs are essential for driving each cell cycle phase, so therapeutic strategies that block CDK activity are unlikely to selectively target tumor cells.  However, recent genetic evidence has revealed that, whereas CDK1 is required for the cell cycle, interphase CDKs are only essential for proliferation of specialized cells.  Emerging evidence suggests that tumor cells may also require specific interphase CDKs for proliferation.  Thus, selective CDK inhibition may provide therapeutic benefit against certain human neoplasias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzlIKlbCPWnLVg90H21EOLACvtfcHk0lh6N7KzZRcosw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D&md5=2a7eb34b2381e288b3f43ec1bffc0aec</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1038%2Fnrc2602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2602%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DCell%2520cycle%252C%2520CDKs%2520and%2520cancer%253A%2520a%2520changing%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D153%26epage%3D166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Malumbres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span> </span><span class="NLM_article-title">Milestones in cell division: to cycle or not to cycle: a critical decision in cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">222</span><span class="NLM_x">–</span> <span class="NLM_lpage">231</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=16&amp;doi=10.1021%2Fjm901710h&amp;key=10.1038%2F35106065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=8&amp;doi=10.1021%2Fjm901710h&amp;key=11902577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=32&amp;doi=10.1021%2Fjm901710h&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvF2qtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=222-231&author=M.+Malumbresauthor=M.+Barbacid&title=Milestones+in+cell+division%3A+to+cycle+or+not+to+cycle%3A+a+critical+decision+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5cR"><div class="casContent"><span class="casTitleNuber">5c</span><div class="casTitle"><span class="NLM_cas:atitle">Milestones in cell division: to cycle or not to cycle: a critical decision in cancer</span></div><div class="casAuthors">Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">222-231</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor cells undergo uncontrolled proliferation, yet tumors most often originate from adult tissues, in which most cells are quiescent.  So, the proliferative advantage of tumor cells arises from their ability to bypass quiescence.  This can be due to increased mitogenic signaling and/or alterations that lower the threshold required for cell-cycle commitment.  Understanding the mol. mechanisms that underlie this commitment should provide important insights into how normal cells become tumorigenic and how new anticancer strategies can be devised.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI2EOLFB2ULbVg90H21EOLACvtfcHk0lj6yiuh-_e3UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvF2qtrg%253D&md5=2bd8961854332a30c814f8ac2f9bd6f4</span></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=10.1038%2F35106065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35106065%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DMilestones%2520in%2520cell%2520division%253A%2520to%2520cycle%2520or%2520not%2520to%2520cycle%253A%2520a%2520critical%2520decision%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2001%26volume%3D1%26spage%3D222%26epage%3D231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sherr, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, J. M.</span><span> </span><span class="NLM_article-title">Inhibitors of mammalian G1 cyclin-dependent kinases</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1149</span><span class="NLM_x">–</span> <span class="NLM_lpage">1163</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1995&pages=1149-1163&author=C.+J.+Sherrauthor=J.+M.+Robert&title=Inhibitors+of+mammalian+G1+cyclin-dependent+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSherr%26aufirst%3DC.%2BJ.%26aulast%3DRobert%26aufirst%3DJ.%2BM.%26atitle%3DInhibitors%2520of%2520mammalian%2520G1%2520cyclin-dependent%2520kinases%26jtitle%3DGenes%2520Dev.%26date%3D1995%26volume%3D9%26spage%3D1149%26epage%3D1163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sherr, C. J.</span><span> </span><span class="NLM_article-title">Cancer cell cycles</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">274</span><span class="NLM_x">, </span> <span class="NLM_fpage">1672</span><span class="NLM_x">–</span> <span class="NLM_lpage">1677</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1996&pages=1672-1677&author=C.+J.+Sherr&title=Cancer+cell+cycles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSherr%26aufirst%3DC.%2BJ.%26atitle%3DCancer%2520cell%2520cycles%26jtitle%3DScience%26date%3D1996%26volume%3D274%26spage%3D1672%26epage%3D1677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, G.</span><span> </span><span class="NLM_article-title">Genetic alterations of cyclins, cyclin-dependent kinases and Cdk inhibitors in human cancer</span> <span class="citation_source-journal">Adv. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">67</span><span class="NLM_x">–</span> <span class="NLM_lpage">108</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=1996&pages=67-108&author=M.+Hallauthor=G.+Peters&title=Genetic+alterations+of+cyclins%2C+cyclin-dependent+kinases+and+Cdk+inhibitors+in+human+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DM.%26aulast%3DPeters%26aufirst%3DG.%26atitle%3DGenetic%2520alterations%2520of%2520cyclins%252C%2520cyclin-dependent%2520kinases%2520and%2520Cdk%2520inhibitors%2520in%2520human%2520cancer%26jtitle%3DAdv.%2520Cancer%2520Res.%26date%3D1996%26volume%3D68%26spage%3D67%26epage%3D108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Christian, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grever, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrd, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T. S.</span><span> </span><span class="NLM_article-title">Flavopiridol in the treatment of chronic lymphocytic leukemia</span> <span class="citation_source-journal">Curr. Opin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">573</span><span class="NLM_x">–</span> <span class="NLM_lpage">578</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm901710h&amp;key=10.1097%2FCCO.0b013e3282efb9da" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm901710h&amp;key=17906454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm901710h&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSnu7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2007&pages=573-578&author=B.+A.+Christianauthor=M.+R.+Greverauthor=J.+C.+Byrdauthor=T.+S.+Lin&title=Flavopiridol+in+the+treatment+of+chronic+lymphocytic+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Flavopiridol in the treatment of chronic lymphocytic leukemia</span></div><div class="casAuthors">Christian, Beth A.; Grever, Michael R.; Byrd, John C.; Lin, Thomas S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">573-578</span>CODEN:
                <span class="NLM_cas:coden">CUOOE8</span>;
        ISSN:<span class="NLM_cas:issn">1040-8746</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: The synthetic flavone flavopiridol induces apoptosis of chronic lymphocytic leukemia cells in vitro; however, initial studies administering flavopiridol by a 24- to 72-h continuous i.v. infusion demonstrated no clin. activity.  This review focuses on a novel dosing regimen that has achieved significant clin. activity in relapsed, poor-risk chronic lymphocytic leukemia.  Recent findings: Binding to human plasma proteins reduces free flavopiridol concn. and makes continuous i.v. infusion dosing ineffective.  Pharmacokinetic modeling indicated that administering flavopiridol by a 30-min i.v. bolus followed by a 4-h continuous i.v. infusion would achieve serum concns. necessary to induce in-vivo apoptosis.  Our institution conducted a phase I study in relapsed chronic lymphocytic leukemia.  Dose-limiting toxicity was acute tumor lysis syndrome resulting in fatal hyperkalemia.  Careful monitoring and aggressive intervention for hyperkalemia, including hemodialysis if necessary, allowed flavopiridol to be given safely.  Nineteen of 42 patients responded (45%), including five of 12 patients (42%) with del(17p13) and 13 of 18 patients (72%) with del(11q22).  Summary: Flavopiridol, when administered by a 30-min i.v. bolus followed by a 4-h continuous i.v. infusion, is active in high-risk, refractory chronic lymphocytic leukemia.  Careful monitoring and aggressive intervention for tumor lysis syndrome and hyperkalemia is necessary for safe drug administration.  Further studies to optimize the dose and schedule of administration, and to study this drug in other hematol. malignancies, are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6YGpEb0iAxLVg90H21EOLACvtfcHk0li18drYYBflKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSnu7zL&md5=9682028742de790c116d8e99a9aa60c5</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1097%2FCCO.0b013e3282efb9da&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCCO.0b013e3282efb9da%26sid%3Dliteratum%253Aachs%26aulast%3DChristian%26aufirst%3DB.%2BA.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DLin%26aufirst%3DT.%2BS.%26atitle%3DFlavopiridol%2520in%2520the%2520treatment%2520of%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DCurr.%2520Opin.%2520Oncol.%26date%3D2007%26volume%3D19%26spage%3D573%26epage%3D578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Fuse, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuwabara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sparreboom, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sausville, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figg, W. D.</span><span> </span><span class="NLM_article-title">Review of UCN-01 development: A lesson in the importance of clinical pharmacology</span> <span class="citation_source-journal">J. Clin. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">394</span><span class="NLM_x">–</span> <span class="NLM_lpage">403</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm901710h&amp;key=10.1177%2F0091270005274549" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm901710h&amp;key=15778420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm901710h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXksFyhtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2005&pages=394-403&author=E.+Fuseauthor=T.+Kuwabaraauthor=A.+Sparreboomauthor=E.+A.+Sausvilleauthor=W.+D.+Figg&title=Review+of+UCN-01+development%3A+A+lesson+in+the+importance+of+clinical+pharmacology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Review of UCN-01 development: A lesson in the importance of clinical pharmacology</span></div><div class="casAuthors">Fuse, Eiichi; Kuwabara, Takashi; Sparreboom, Alex; Sausville, Edward A.; Figg, William D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">394-403</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  UCN-01 is a protein kinase inhibitor under development as a novel anticancer drug.  The initial pharmacol. features in patients were not predicted from preclin. expts.  The distribution vol. and the systemic clearance were much lower than those in exptl. animals (mice, rats, and dogs), and the elimination half-life was unusually long (> 200 h).  The unbound fraction in human plasma was also much smaller than that in dogs, rats and mice, as was the binding of UCN-01 to human alpha-1 acid glycoprotein much stronger than that to human serum albumin or human γ-globulin.  The assocn. consts. for alpha-1 acid glycoprotein and human plasma were approx. 8 × 108 (mol/L)-1, indicating extremely high affinity.  In this review article, the authors discuss the pharmacol. features of UCN-01 across species and provide a perspective on how this information could be applied prospectively to the future development of this agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn8zC_DOvaOrVg90H21EOLACvtfcHk0li18drYYBflKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXksFyhtL8%253D&md5=094cb6a7f568b8f74a05356c6b2d15d6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1177%2F0091270005274549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270005274549%26sid%3Dliteratum%253Aachs%26aulast%3DFuse%26aufirst%3DE.%26aulast%3DKuwabara%26aufirst%3DT.%26aulast%3DSparreboom%26aufirst%3DA.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DFigg%26aufirst%3DW.%2BD.%26atitle%3DReview%2520of%2520UCN-01%2520development%253A%2520A%2520lesson%2520in%2520the%2520importance%2520of%2520clinical%2520pharmacology%26jtitle%3DJ.%2520Clin.%2520Pharm.%26date%3D2005%26volume%3D45%26spage%3D394%26epage%3D403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Meijer, L.; Bettayeb, K.; Galons, H.</span><span> </span><span class="NLM_article-title">(<i>R</i>)-Roscovitine (CYC202, Seliciclib)</span>.  <span class="citation_source-book">Inhibitors of Cyclin-Dependent Kinases as Anti-Tumor Agents</span>; <span class="NLM_publisher-name">CRC</span>: <span class="NLM_publisher-loc">Boca Raton, FL</span>,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">187</span>− <span class="NLM_lpage">225</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&pages=187-225&author=L.+Meijer&author=K.+Bettayeb&author=H.+Galons&title=Inhibitors+of+Cyclin-Dependent+Kinases+as+Anti-Tumor+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMeijer%26aufirst%3DL.%26atitle%3D%2528R%2529-Roscovitine%2520%2528CYC202%252C%2520Seliciclib%2529%26btitle%3DInhibitors%2520of%2520Cyclin-Dependent%2520Kinases%2520as%2520Anti-Tumor%2520Agents%26pub%3DCRC%26date%3D2007%26spage%3D187%26epage%3D225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Misra, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rawlins, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, S. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bednarz, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kellar, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulheron, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batorsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roongta, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranadive, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavletich, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimball, S. D.</span><span> </span><span class="NLM_article-title"><i>N</i>-(Cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. <i>N</i>-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1719</span><span class="NLM_x">–</span> <span class="NLM_lpage">1728</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0305568" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1719-1728&author=R.+N.+Misraauthor=H.+Xiaoauthor=K.+S.+Kimauthor=S.+Luauthor=W.+Hanauthor=S.+A.+Barbosaauthor=J.+T.+Huntauthor=D.+B.+Rawlinsauthor=W.+Shanauthor=S.+Z.+Ahmedauthor=L.+Qianauthor=B.+Chenauthor=R.+Zhaoauthor=M.+S.+Bednarzauthor=K.+A.+Kellarauthor=J.+G.+Mulheronauthor=R.+Batorskyauthor=U.+Roongtaauthor=A.+Kamathauthor=P.+Maratheauthor=S.+A.+Ranadiveauthor=J.+S.+Sackauthor=J.+S.+Tokarskiauthor=N.+P.+Pavletichauthor=F.+Y.+F.+Leeauthor=K.+R.+Websterauthor=S.+D.+Kimball&title=N-%28Cycloalkylamino%29acyl-2-aminothiazole+inhibitors+of+cyclin-dependent+kinase+2.+N-%5B5-%5B%5B%5B5-%281%2C1-Dimethylethyl%29-2-oxazolyl%5Dmethyl%5Dthio%5D-2-thiazolyl%5D-4-piperidinecarboxamide+%28BMS-387032%29%2C+a+highly+efficacious+and+selective+antitumor+agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm0305568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0305568%26sid%3Dliteratum%253Aachs%26aulast%3DMisra%26aufirst%3DR.%2BN.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DK.%2BS.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DHan%26aufirst%3DW.%26aulast%3DBarbosa%26aufirst%3DS.%2BA.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DRawlins%26aufirst%3DD.%2BB.%26aulast%3DShan%26aufirst%3DW.%26aulast%3DAhmed%26aufirst%3DS.%2BZ.%26aulast%3DQian%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DBednarz%26aufirst%3DM.%2BS.%26aulast%3DKellar%26aufirst%3DK.%2BA.%26aulast%3DMulheron%26aufirst%3DJ.%2BG.%26aulast%3DBatorsky%26aufirst%3DR.%26aulast%3DRoongta%26aufirst%3DU.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DRanadive%26aufirst%3DS.%2BA.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26aulast%3DLee%26aufirst%3DF.%2BY.%2BF.%26aulast%3DWebster%26aufirst%3DK.%2BR.%26aulast%3DKimball%26aufirst%3DS.%2BD.%26atitle%3DN-%2528Cycloalkylamino%2529acyl-2-aminothiazole%2520inhibitors%2520of%2520cyclin-dependent%2520kinase%25202.%2520N-%255B5-%255B%255B%255B5-%25281%252C1-Dimethylethyl%2529-2-oxazolyl%255Dmethyl%255Dthio%255D-2-thiazolyl%255D-4-piperidinecarboxamide%2520%2528BMS-387032%2529%252C%2520a%2520highly%2520efficacious%2520and%2520selective%2520antitumor%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1719%26epage%3D1728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Toogood, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Repine, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehan, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VanderWel, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodfuehrer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barvian, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span> </span><span class="NLM_article-title">Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">2388</span><span class="NLM_x">–</span> <span class="NLM_lpage">2406</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049354h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm901710h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVGisL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2388-2406&author=P.+L.+Toogoodauthor=P.+J.+Harveyauthor=J.+T.+Repineauthor=D.+J.+Sheehanauthor=S.+N.+VanderWelauthor=H.+Zhouauthor=P.+R.+Kellerauthor=D.+J.+McNamaraauthor=D.+Sherryauthor=T.+Zhuauthor=J.+Brodfuehrerauthor=C.+Choiauthor=M.+R.+Barvianauthor=D.+W.+Fry&title=Discovery+of+a+potent+and+selective+inhibitor+of+cyclin-dependent+kinase+4%2F6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6</span></div><div class="casAuthors">Toogood, Peter L.; Harvey, Patricia J.; Repine, Joseph T.; Sheehan, Derek J.; VanderWel, Scott N.; Zhou, Hairong; Keller, Paul R.; McNamara, Dennis J.; Sherry, Debra; Zhu, Tong; Brodfuehrer, Joanne; Choi, Chung; Barvian, Mark R.; Fry, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2388-2406</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A pharmacol. approach to inhibition of cyclin-dependent kinases 4 and 6 (Cdk4/6) using highly selective small mol. inhibitors has the potential to provide novel cancer therapies for clin. use.  Achieving high levels of selectivity for Cdk4/6, vs. other ATP-dependent kinases, presents a significant challenge.  The pyrido[2,3-d]pyrimidin-7-one template provides an effective platform for the inhibition of a broad cross-section of kinases, including Cdks.  It is now demonstrated that the modification of pyrido[2,3-d]pyrimidin-7-ones to include a 2-aminopyridine side chain at the C2-position provides inhibitors with exquisite selectivity for Cdk4/6 in vitro.  This selectivity profile is recapitulated in cells where the most selective inhibitors create a G1 block at concns. up to 100-fold the IC50 for cell proliferation.  On the basis of its selectivity profile and pharmacokinetic profile, compd. I (PD 0332991) was identified as a drug candidate for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX577J5U0r97Vg90H21EOLACvtfcHk0lgW2QrKH9o_Bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVGisL0%253D&md5=23cbe58426ff1975695712db7c1b128a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm049354h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049354h%26sid%3Dliteratum%253Aachs%26aulast%3DToogood%26aufirst%3DP.%2BL.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DRepine%26aufirst%3DJ.%2BT.%26aulast%3DSheehan%26aufirst%3DD.%2BJ.%26aulast%3DVanderWel%26aufirst%3DS.%2BN.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DSherry%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DBrodfuehrer%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DC.%26aulast%3DBarvian%26aufirst%3DM.%2BR.%26aulast%3DFry%26aufirst%3DD.%2BW.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520cyclin-dependent%2520kinase%25204%252F6%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D2388%26epage%3D2406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Tetsu, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCormick, F.</span><span> </span><span class="NLM_article-title">Proliferation of cancer cells despite CDK2 inhibition</span> <span class="citation_source-journal">Cancer Cell.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">233</span><span class="NLM_x">–</span> <span class="NLM_lpage">245</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=233-245&author=O.+Tetsuauthor=F.+McCormick&title=Proliferation+of+cancer+cells+despite+CDK2+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTetsu%26aufirst%3DO.%26aulast%3DMcCormick%26aufirst%3DF.%26atitle%3DProliferation%2520of%2520cancer%2520cells%2520despite%2520CDK2%2520inhibition%26jtitle%3DCancer%2520Cell.%26date%3D2003%26volume%3D3%26spage%3D233%26epage%3D245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Martin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Odajima, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubus, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortega, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malumbres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span> </span><span class="NLM_article-title">CDK2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27<sup>Kip1</sup> and p21<sup>Cip1</sup></span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">591</span><span class="NLM_x">–</span> <span class="NLM_lpage">598</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=591-598&author=A.+Martinauthor=J.+Odajimaauthor=S.+L.+Huntauthor=P.+Dubusauthor=S.+Ortegaauthor=M.+Malumbresauthor=M.+Barbacid&title=CDK2+is+dispensable+for+cell+cycle+inhibition+and+tumor+suppression+mediated+by+p27Kip1+and+p21Cip1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DA.%26aulast%3DOdajima%26aufirst%3DJ.%26aulast%3DHunt%26aufirst%3DS.%2BL.%26aulast%3DDubus%26aufirst%3DP.%26aulast%3DOrtega%26aufirst%3DS.%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DCDK2%2520is%2520dispensable%2520for%2520cell%2520cycle%2520inhibition%2520and%2520tumor%2520suppression%2520mediated%2520by%2520p27Kip1%2520and%2520p21Cip1%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D591%26epage%3D598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hirai, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawanishi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwasawa, Y.</span><span> </span><span class="NLM_article-title">Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">167</span><span class="NLM_x">–</span> <span class="NLM_lpage">179</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=16&amp;doi=10.1021%2Fjm901710h&amp;key=10.2174%2F1568026053507688" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=8&amp;doi=10.1021%2Fjm901710h&amp;key=15853645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=32&amp;doi=10.1021%2Fjm901710h&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFyksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=167-179&author=H.+Hiraiauthor=N.+Kawanishiauthor=Y.+Iwasawa&title=Recent+advances+in+the+development+of+selective+small+molecule+inhibitors+for+cyclin-dependent+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12cR"><div class="casContent"><span class="casTitleNuber">12c</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the development of selective small molecule inhibitors for Cyclin-dependent kinases</span></div><div class="casAuthors">Hirai, Hiroshi; Kawanishi, Nobuhiko; Iwasawa, Yoshikazu</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-179</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Loss of normal cell cycle regulation is the hallmark of human cancers, and alteration of the components involved in cell cycle regulation occurs in most human tumors.  This suggests that Cyclin dependent kinases (CDKs) are an attractive target for the development of pharmacol. agents for the treatment of cancer.  Recently, CDK family members that are not directly involved in cell cycle regulation were identified.  This includes CDK7, CDK8, and CDK9, which participate in transcription regulation, and CDK5, which plays a role in neuronal and secretory functions.  Given the involvement of CDKs in multiple cellular processes, development of selective small mol. inhibitors for specific CDKs is expected to help clarify whether improved specificity of cell cycle CDK inhibitors will enhance their therapeutic potential in cancer treatment.  Selective inhibitors are also needed as tools to explore the biol. of diseases in which CDKs may participate and to help develop therapeutics to treat them.  Intensive screening and drug design based on CDK/inhibitor co-crystal structure and SAR studies have led to the identification of a large variety of chem. inhibitors of CDKs.  Although they are competitive with ATP at the catalytic site, their kinase selectivity varies greatly, and inhibitors selective for certain CDKs have begun to be identified.  There are currently 2 categories of selective CDK inhibitors: those that are selective for CDK2 and CDK1 and those that are selective for CDK4/6.  These 2 types of inhibitors have different effects on tumor cells and are expected to be useful in the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooiAF6UAza_7Vg90H21EOLACvtfcHk0liaXX5hHRdwtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFyksbw%253D&md5=2fceab02ebbaaca45061a80884571ef7</span></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.2174%2F1568026053507688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026053507688%26sid%3Dliteratum%253Aachs%26aulast%3DHirai%26aufirst%3DH.%26aulast%3DKawanishi%26aufirst%3DN.%26aulast%3DIwasawa%26aufirst%3DY.%26atitle%3DRecent%2520advances%2520in%2520the%2520development%2520of%2520selective%2520small%2520molecule%2520inhibitors%2520for%2520cyclin-dependent%2520kinases%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2005%26volume%3D5%26spage%3D167%26epage%3D179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Cai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Latham, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span> </span><span class="NLM_article-title">Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">9270</span><span class="NLM_x">–</span> <span class="NLM_lpage">9280</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=9270-9280&author=D.+Caiauthor=V.+M.+Lathamauthor=X.+Zhangauthor=G.+I.+Shapiro&title=Combined+depletion+of+cell+cycle+and+transcriptional+cyclin-dependent+kinase+activities+induces+apoptosis+in+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DD.%26aulast%3DLatham%26aufirst%3DV.%2BM.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DCombined%2520depletion%2520of%2520cell%2520cycle%2520and%2520transcriptional%2520cyclin-dependent%2520kinase%2520activities%2520induces%2520apoptosis%2520in%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D9270%26epage%3D9280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Wyatt, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodhead, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulstridge, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devine, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Early, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feltell, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMenamin, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navarro, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Reilly, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reule, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saxty, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seavers, L. C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Squires, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trewartha, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woolford, A. J.-A.</span><span> </span><span class="NLM_article-title">Identification of <i>N</i>-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1<i>H</i>-pyrazole-3-carboxamide (AT7519), a novel cyclin-dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4986</span><span class="NLM_x">–</span> <span class="NLM_lpage">4999</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800382h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4986-4999&author=P.+G.+Wyattauthor=A.+J.+Woodheadauthor=V.+Berdiniauthor=J.+A.+Boulstridgeauthor=M.+G.+Carrauthor=D.+M.+Crossauthor=D.+J.+Davisauthor=L.+A.+Devineauthor=T.+R.+Earlyauthor=R.+E.+Feltellauthor=E.+J.+Lewisauthor=R.+L.+McMenaminauthor=E.+F.+Navarroauthor=M.+A.+O%E2%80%99Brienauthor=M.+O%E2%80%99Reillyauthor=M.+Reuleauthor=G.+Saxtyauthor=L.+C.+A.+Seaversauthor=D.+M.+Smithauthor=M.+S.+Squiresauthor=G.+Trewarthaauthor=M.+T.+Walkerauthor=A.+J.-A.+Woolford&title=Identification+of+N-%284-piperidinyl%29-4-%282%2C6-dichlorobenzoylamino%29-1H-pyrazole-3-carboxamide+%28AT7519%29%2C+a+novel+cyclin-dependent+kinase+inhibitor+using+fragment-based+X-ray+crystallography+and+structure+based+drug+design"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm800382h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800382h%26sid%3Dliteratum%253Aachs%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DWoodhead%26aufirst%3DA.%2BJ.%26aulast%3DBerdini%26aufirst%3DV.%26aulast%3DBoulstridge%26aufirst%3DJ.%2BA.%26aulast%3DCarr%26aufirst%3DM.%2BG.%26aulast%3DCross%26aufirst%3DD.%2BM.%26aulast%3DDavis%26aufirst%3DD.%2BJ.%26aulast%3DDevine%26aufirst%3DL.%2BA.%26aulast%3DEarly%26aufirst%3DT.%2BR.%26aulast%3DFeltell%26aufirst%3DR.%2BE.%26aulast%3DLewis%26aufirst%3DE.%2BJ.%26aulast%3DMcMenamin%26aufirst%3DR.%2BL.%26aulast%3DNavarro%26aufirst%3DE.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DM.%2BA.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DM.%26aulast%3DReule%26aufirst%3DM.%26aulast%3DSaxty%26aufirst%3DG.%26aulast%3DSeavers%26aufirst%3DL.%2BC.%2BA.%26aulast%3DSmith%26aufirst%3DD.%2BM.%26aulast%3DSquires%26aufirst%3DM.%2BS.%26aulast%3DTrewartha%26aufirst%3DG.%26aulast%3DWalker%26aufirst%3DM.%2BT.%26aulast%3DWoolford%26aufirst%3DA.%2BJ.-A.%26atitle%3DIdentification%2520of%2520N-%25284-piperidinyl%2529-4-%25282%252C6-dichlorobenzoylamino%2529-1H-pyrazole-3-carboxamide%2520%2528AT7519%2529%252C%2520a%2520novel%2520cyclin-dependent%2520kinase%2520inhibitor%2520using%2520fragment-based%2520X-ray%2520crystallography%2520and%2520structure%2520based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4986%26epage%3D4999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Chu, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DePinto, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartkowitz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">So, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vu, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Packman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukacs, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goelzer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, B. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moliterni, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graves, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fotouhi, N.</span><span> </span><span class="NLM_article-title">Discovery of [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6-methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6549</span><span class="NLM_x">–</span> <span class="NLM_lpage">6560</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0606138" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6549-6560&author=X.+J.+Chuauthor=W.+DePintoauthor=D.+Bartkowitzauthor=S.+S.+Soauthor=B.+T.+Vuauthor=K.+Packmanauthor=C.+Lukacsauthor=Q.+Dingauthor=N.+Jiangauthor=K.+Wangauthor=P.+Goelzerauthor=X.+Yinauthor=M.+A.+Smithauthor=B.+X.+Higginsauthor=Y.+Chenauthor=Q.+Xiangauthor=J.+Moliterniauthor=G.+Kaplanauthor=B.+Gravesauthor=A.+Loveyauthor=N.+Fotouhi&title=Discovery+of+%5B4-amino-2-%281-methanesulfonylpiperidin-4-ylamino%29pyrimidin-5-yl%5D%282%2C3-difluoro-6-methoxyphenyl%29methanone+%28R547%29%2C+a+potent+and+selective+cyclin-dependent+kinase+inhibitor+with+significant+in+vivo+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm0606138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0606138%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DX.%2BJ.%26aulast%3DDePinto%26aufirst%3DW.%26aulast%3DBartkowitz%26aufirst%3DD.%26aulast%3DSo%26aufirst%3DS.%2BS.%26aulast%3DVu%26aufirst%3DB.%2BT.%26aulast%3DPackman%26aufirst%3DK.%26aulast%3DLukacs%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DGoelzer%26aufirst%3DP.%26aulast%3DYin%26aufirst%3DX.%26aulast%3DSmith%26aufirst%3DM.%2BA.%26aulast%3DHiggins%26aufirst%3DB.%2BX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DQ.%26aulast%3DMoliterni%26aufirst%3DJ.%26aulast%3DKaplan%26aufirst%3DG.%26aulast%3DGraves%26aufirst%3DB.%26aulast%3DLovey%26aufirst%3DA.%26aulast%3DFotouhi%26aufirst%3DN.%26atitle%3DDiscovery%2520of%2520%255B4-amino-2-%25281-methanesulfonylpiperidin-4-ylamino%2529pyrimidin-5-yl%255D%25282%252C3-difluoro-6-methoxyphenyl%2529methanone%2520%2528R547%2529%252C%2520a%2520potent%2520and%2520selective%2520cyclin-dependent%2520kinase%2520inhibitor%2520with%2520significant%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6549%26epage%3D6560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Parry, D.; Guzi, T.; Seghezzi, W.; Paruch, K.; Doll, R.; Nomeir, A.; Wang, Y.; Oft, M.; Kirschmeier, P.; Chen, T.; Lees, E.</span>In vitro and in vivo characterization of SCH727965, a novel potent cyclin-dependent kinase inhibitor. Presented at AACR Conference, Los Angeles, CA, April 14−18,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span>Poster No. 4371.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=D.+Parry&author=T.+Guzi&author=W.+Seghezzi&author=K.+Paruch&author=R.+Doll&author=A.+Nomeir&author=Y.+Wang&author=M.+Oft&author=P.+Kirschmeier&author=T.+Chen&author=E.+Lees&title=In+vitro+and+in+vivo+characterization+of+SCH727965%2C+a+novel+potent+cyclin-dependent+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DParry%26aufirst%3DD.%26jtitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520characterization%2520of%2520SCH727965%252C%2520a%2520novel%2520potent%2520cyclin-dependent%2520kinase%2520inhibitor%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Jones, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrew, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blades, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daunt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">East, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geh, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loddick, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFarland, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGregor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudge, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simpson, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swain, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tucker, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, M.</span><span> </span><span class="NLM_article-title">The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">6369</span><span class="NLM_x">–</span> <span class="NLM_lpage">6373</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm901710h&amp;key=10.1016%2Fj.bmcl.2008.10.102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm901710h&amp;key=18996007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm901710h&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWjs7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=6369-6373&author=C.+D.+Jonesauthor=D.+M.+Andrewauthor=A.+J.+Barkerauthor=K.+Bladesauthor=P.+Dauntauthor=S.+Eastauthor=C.+Gehauthor=M.+A.+Grahamauthor=K.+M.+Johnsonauthor=S.+A.+Loddickauthor=H.+M.+McFarlandauthor=A.+McGregorauthor=L.+Mossauthor=D.+A.+Rudgeauthor=P.+B.+Simpsonauthor=M.+L.+Swainauthor=K.+Y.+Tamauthor=J.+A.+Tuckerauthor=M.+Walker&title=The+discovery+of+AZD5597%2C+a+potent+imidazole+pyrimidine+amide+CDK+inhibitor+suitable+for+intravenous+dosing"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing</span></div><div class="casAuthors">Jones, Clifford D.; Andrews, David M.; Barker, Andrew J.; Blades, Kevin; Daunt, Paula; East, Simon; Geh, Catherine; Graham, Mark A.; Johnson, Keith M.; Loddick, Sarah A.; McFarland, Heather M.; McGregor, Alexandra; Moss, Louise; Rudge, David A.; Simpson, Peter B.; Swain, Michael L.; Tam, Kin Y.; Tucker, Julie A.; Walker, Mike</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6369-6373</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The development of a novel series of imidazole pyrimidine amides as cyclin-dependent kinase (CDK) inhibitors is described.  Optimization of inhibitory potency against multiple CDK's (1, 2 and 9) resulted in imidazole pyrimidine amides with potent in vitro anti-proliferative effects against a range of cancer cell lines.  Excellent physiochem. properties and large margins against inhibition of CYP isoforms and the hERG ion channel were achieved by modification of lipophilicity and amine basicity.  A candidate with disease model activity in human cancer cell line xenografts and with suitable physiochem. and pharmacokinetic profiles for i.v. (iv) dosing was selected for further development as AZD5597 (I).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnX9-GP03dzbVg90H21EOLACvtfcHk0lhzfIlYdki7wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWjs7bP&md5=084ed54076134c7173953ebbdb23fd86</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.10.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.10.102%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DC.%2BD.%26aulast%3DAndrew%26aufirst%3DD.%2BM.%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DBlades%26aufirst%3DK.%26aulast%3DDaunt%26aufirst%3DP.%26aulast%3DEast%26aufirst%3DS.%26aulast%3DGeh%26aufirst%3DC.%26aulast%3DGraham%26aufirst%3DM.%2BA.%26aulast%3DJohnson%26aufirst%3DK.%2BM.%26aulast%3DLoddick%26aufirst%3DS.%2BA.%26aulast%3DMcFarland%26aufirst%3DH.%2BM.%26aulast%3DMcGregor%26aufirst%3DA.%26aulast%3DMoss%26aufirst%3DL.%26aulast%3DRudge%26aufirst%3DD.%2BA.%26aulast%3DSimpson%26aufirst%3DP.%2BB.%26aulast%3DSwain%26aufirst%3DM.%2BL.%26aulast%3DTam%26aufirst%3DK.%2BY.%26aulast%3DTucker%26aufirst%3DJ.%2BA.%26aulast%3DWalker%26aufirst%3DM.%26atitle%3DThe%2520discovery%2520of%2520AZD5597%252C%2520a%2520potent%2520imidazole%2520pyrimidine%2520amide%2520CDK%2520inhibitor%2520suitable%2520for%2520intravenous%2520dosing%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D6369%26epage%3D6373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Brasca, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amboldi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballinari, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cervi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colotta, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croci, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Alessio, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiorentini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercurio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moretti, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panzeri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pastori, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pevarello, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quartieri, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roletto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traquandi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vianello, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vulpetti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciomei, M.</span><span> </span><span class="NLM_article-title">Identification of <i>N</i>-1,4,4-tetramethyl-8-{[(4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin-dependent kinase inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">5152</span><span class="NLM_x">–</span> <span class="NLM_lpage">5163</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9006559" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5152-5163&author=M.+G.+Brascaauthor=N.+Amboldiauthor=D.+Ballinariauthor=A.+Cameronauthor=E.+Casaleauthor=G.+Cerviauthor=M.+Colomboauthor=F.+Colottaauthor=V.+Crociauthor=R.+D%E2%80%99Alessioauthor=F.+Fiorentiniauthor=A.+Isacchiauthor=C.+Mercurioauthor=W.+Morettiauthor=A.+Panzeriauthor=W.+Pastoriauthor=P.+Pevarelloauthor=F.+Quartieriauthor=F.+Rolettoauthor=G.+Traquandiauthor=P.+Vianelloauthor=A.+Vulpettiauthor=M.+Ciomei&title=Identification+of+N-1%2C4%2C4-tetramethyl-8-%7B%5B%284-%284-methylpiperazin-1-yl%29phenyl%5Damino%7D-4%2C5-dihydro-1H-pyrazolo%5B4%2C3-h%5Dquinazoline-3-carboxamide+%28PHA-848125%29%2C+a+potent%2C+orally+available+cyclin-dependent+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm9006559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9006559%26sid%3Dliteratum%253Aachs%26aulast%3DBrasca%26aufirst%3DM.%2BG.%26aulast%3DAmboldi%26aufirst%3DN.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DCameron%26aufirst%3DA.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DCervi%26aufirst%3DG.%26aulast%3DColombo%26aufirst%3DM.%26aulast%3DColotta%26aufirst%3DF.%26aulast%3DCroci%26aufirst%3DV.%26aulast%3DD%25E2%2580%2599Alessio%26aufirst%3DR.%26aulast%3DFiorentini%26aufirst%3DF.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DMercurio%26aufirst%3DC.%26aulast%3DMoretti%26aufirst%3DW.%26aulast%3DPanzeri%26aufirst%3DA.%26aulast%3DPastori%26aufirst%3DW.%26aulast%3DPevarello%26aufirst%3DP.%26aulast%3DQuartieri%26aufirst%3DF.%26aulast%3DRoletto%26aufirst%3DF.%26aulast%3DTraquandi%26aufirst%3DG.%26aulast%3DVianello%26aufirst%3DP.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DCiomei%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520N-1%252C4%252C4-tetramethyl-8-%257B%255B%25284-%25284-methylpiperazin-1-yl%2529phenyl%255Damino%257D-4%252C5-dihydro-1H-pyrazolo%255B4%252C3-h%255Dquinazoline-3-carboxamide%2520%2528PHA-848125%2529%252C%2520a%2520potent%252C%2520orally%2520available%2520cyclin-dependent%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5152%26epage%3D5163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Traquandi, G.; Brasca, M. G.; D’Alessio, R.; Polucci, P.; Roletto, F.; Vulpetti, A.; Pevarello, P.; Panzeri, A.; Quartieri, F.; Ferguson, R.; Vianello, P.; Fancelli, D.</span>; <span> </span><span class="NLM_article-title">Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors</span>. Patent WO2004/104007,<span class="NLM_x"> </span><span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=G.+Traquandi&author=M.+G.+Brasca&author=R.+D%E2%80%99Alessio&author=P.+Polucci&author=F.+Roletto&author=A.+Vulpetti&author=P.+Pevarello&author=A.+Panzeri&author=F.+Quartieri&author=R.+Ferguson&author=P.+Vianello&author=D.+Fancelli&title=Pyrazolo-quinazoline+derivatives%2C+process+for+their+preparation+and+their+use+as+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTraquandi%26aufirst%3DG.%26atitle%3DPyrazolo-quinazoline%2520derivatives%252C%2520process%2520for%2520their%2520preparation%2520and%2520their%2520use%2520as%2520kinase%2520inhibitors%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Pevarello, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fancelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vulpetti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amici, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pittalà, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vianello, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciomei, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercurio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bischoff, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roletto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varasi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brasca, M. G.</span><span> </span><span class="NLM_article-title">3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-<i>c</i>]pyrazoles: A new class of CDK2 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1084</span><span class="NLM_x">–</span> <span class="NLM_lpage">1090</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=1084-1090&author=P.+Pevarelloauthor=D.+Fancelliauthor=A.+Vulpettiauthor=R.+Amiciauthor=M.+Villaauthor=V.+Pittal%C3%A0author=P.+Vianelloauthor=A.+Cameronauthor=M.+Ciomeiauthor=C.+Mercurioauthor=J.+R.+Bischoffauthor=F.+Rolettoauthor=M.+Varasiauthor=M.+G.+Brasca&title=3-Amino-1%2C4%2C5%2C6-tetrahydropyrrolo%5B3%2C4-c%5Dpyrazoles%3A+A+new+class+of+CDK2+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPevarello%26aufirst%3DP.%26aulast%3DFancelli%26aufirst%3DD.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DAmici%26aufirst%3DR.%26aulast%3DVilla%26aufirst%3DM.%26aulast%3DPittal%25C3%25A0%26aufirst%3DV.%26aulast%3DVianello%26aufirst%3DP.%26aulast%3DCameron%26aufirst%3DA.%26aulast%3DCiomei%26aufirst%3DM.%26aulast%3DMercurio%26aufirst%3DC.%26aulast%3DBischoff%26aufirst%3DJ.%2BR.%26aulast%3DRoletto%26aufirst%3DF.%26aulast%3DVarasi%26aufirst%3DM.%26aulast%3DBrasca%26aufirst%3DM.%2BG.%26atitle%3D3-Amino-1%252C4%252C5%252C6-tetrahydropyrrolo%255B3%252C4-c%255Dpyrazoles%253A%2520A%2520new%2520class%2520of%2520CDK2%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D1084%26epage%3D1090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Colombo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riccardi-Sirtori, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzo, V.</span><span> </span><span class="NLM_article-title">A fully automated method for accurate mass determination using high-performance liquid chromatography with a quadrupole/orthogonal acceleration time-of-flight mass spectrometer</span> <span class="citation_source-journal">Rapid Commun. Mass Spectrom.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">511</span><span class="NLM_x">–</span> <span class="NLM_lpage">517</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm901710h&amp;key=10.1002%2Frcm.1368" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm901710h&amp;key=14966861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm901710h&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhs1equr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2004&pages=511-517&author=M.+Colomboauthor=F.+Riccardi-Sirtoriauthor=V.+Rizzo&title=A+fully+automated+method+for+accurate+mass+determination+using+high-performance+liquid+chromatography+with+a+quadrupole%2Forthogonal+acceleration+time-of-flight+mass+spectrometer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A fully automated method for accurate mass determination using high-performance liquid chromatography with a quadrupole/orthogonal acceleration time-of-flight mass spectrometer</span></div><div class="casAuthors">Colombo, Maristella; Sirtori, Federico Riccardi; Rizzo, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Rapid Communications in Mass Spectrometry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">511-517</span>CODEN:
                <span class="NLM_cas:coden">RCMSEF</span>;
        ISSN:<span class="NLM_cas:issn">0951-4198</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A generic LC/ESI(+)-oaTOFMS method has been developed for routine automated high accuracy mass detns. of different classes of substances.  The system makes use of micro-high-performance liq. chromatog. and a hybrid quadrupole/orthogonal acceleration time-of-flight (Q-oaTOF) mass spectrometer.  Reproducible and accurate mass measurements were obtained using an electrospray dual sprayer with reserpine as ref. compd., introduced into the mass spectrometer alternating with the samples.  Expts. were performed to optimize analyte/ref. response ratio, statistical algorithm correction setting, and analyte concn.  In these expts., a clear dependence of the mass measurement error on the analyte/ref. response ratio was obsd.  The dependence of av. mass error vs. different dead time correction algorithm settings (Np factors) was also explored.  In the final automated procedure, verified for a statistically significant set of compds. (∼550) obtained from a medicinal chem. department, about 70% of the analyzed samples satisfied the acceptance criteria fixed at a max. error of ±5 ppm (mass range 150-800 Da).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro5JNVhGdzjrVg90H21EOLACvtfcHk0ljhMf1HEgaERA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhs1equr8%253D&md5=6f1f93c5e2fb4e24257b77f5ce6dfa37</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Frcm.1368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frcm.1368%26sid%3Dliteratum%253Aachs%26aulast%3DColombo%26aufirst%3DM.%26aulast%3DRiccardi-Sirtori%26aufirst%3DF.%26aulast%3DRizzo%26aufirst%3DV.%26atitle%3DA%2520fully%2520automated%2520method%2520for%2520accurate%2520mass%2520determination%2520using%2520high-performance%2520liquid%2520chromatography%2520with%2520a%2520quadrupole%252Forthogonal%2520acceleration%2520time-of-flight%2520mass%2520spectrometer%26jtitle%3DRapid%2520Commun.%2520Mass%2520Spectrom.%26date%3D2004%26volume%3D18%26spage%3D511%26epage%3D517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Pevarello, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brasca, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amici, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traquandi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piutti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sansonna, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulici, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martina, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritzen, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nugent, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciomei, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roletto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogliatto, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesenti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pastori, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsiglio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clare, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiorentini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varasi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vulpetti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warpehoski, M. A.</span><span> </span><span class="NLM_article-title">3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">3367</span><span class="NLM_x">–</span> <span class="NLM_lpage">3380</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm031145u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=3367-3380&author=P.+Pevarelloauthor=M.+G.+Brascaauthor=R.+Amiciauthor=P.+Orsiniauthor=G.+Traquandiauthor=L.+Cortiauthor=C.+Piuttiauthor=P.+Sansonnaauthor=M.+Villaauthor=B.+S.+Pierceauthor=M.+Puliciauthor=P.+Giordanoauthor=K.+Martinaauthor=E.+L.+Fritzenauthor=R.+A.+Nugentauthor=E.+Casaleauthor=A.+Cameronauthor=M.+Ciomeiauthor=F.+Rolettoauthor=A.+Isacchiauthor=G.+Fogliattoauthor=E.+Pesentiauthor=W.+Pastoriauthor=A.+Marsiglioauthor=K.+L.+Leachauthor=P.+M.+Clareauthor=F.+Fiorentiniauthor=M.+Varasiauthor=A.+Vulpettiauthor=M.+A.+Warpehoski&title=3-Aminopyrazole+inhibitors+of+CDK2%2Fcyclin+A+as+antitumor+agents.+1.+Lead+finding"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm031145u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm031145u%26sid%3Dliteratum%253Aachs%26aulast%3DPevarello%26aufirst%3DP.%26aulast%3DBrasca%26aufirst%3DM.%2BG.%26aulast%3DAmici%26aufirst%3DR.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DTraquandi%26aufirst%3DG.%26aulast%3DCorti%26aufirst%3DL.%26aulast%3DPiutti%26aufirst%3DC.%26aulast%3DSansonna%26aufirst%3DP.%26aulast%3DVilla%26aufirst%3DM.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DPulici%26aufirst%3DM.%26aulast%3DGiordano%26aufirst%3DP.%26aulast%3DMartina%26aufirst%3DK.%26aulast%3DFritzen%26aufirst%3DE.%2BL.%26aulast%3DNugent%26aufirst%3DR.%2BA.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DCameron%26aufirst%3DA.%26aulast%3DCiomei%26aufirst%3DM.%26aulast%3DRoletto%26aufirst%3DF.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DFogliatto%26aufirst%3DG.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DPastori%26aufirst%3DW.%26aulast%3DMarsiglio%26aufirst%3DA.%26aulast%3DLeach%26aufirst%3DK.%2BL.%26aulast%3DClare%26aufirst%3DP.%2BM.%26aulast%3DFiorentini%26aufirst%3DF.%26aulast%3DVarasi%26aufirst%3DM.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DWarpehoski%26aufirst%3DM.%2BA.%26atitle%3D3-Aminopyrazole%2520inhibitors%2520of%2520CDK2%252Fcyclin%2520A%2520as%2520antitumor%2520agents.%25201.%2520Lead%2520finding%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D3367%26epage%3D3380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Bissery, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vrignaud, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavelle, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chabot, G. G.</span><span> </span><span class="NLM_article-title">Experimental anitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice</span> <span class="citation_source-journal">Anticancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">437</span><span class="NLM_x">–</span> <span class="NLM_lpage">460</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1996&pages=437-460&author=M.+C.+Bisseryauthor=P.+Vrignaudauthor=F.+Lavelleauthor=G.+G.+Chabot&title=Experimental+anitumor+activity+and+pharmacokinetics+of+the+camptothecin+analog+irinotecan+%28CPT-11%29+in+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBissery%26aufirst%3DM.%2BC.%26aulast%3DVrignaud%26aufirst%3DP.%26aulast%3DLavelle%26aufirst%3DF.%26aulast%3DChabot%26aufirst%3DG.%2BG.%26atitle%3DExperimental%2520anitumor%2520activity%2520and%2520pharmacokinetics%2520of%2520the%2520camptothecin%2520analog%2520irinotecan%2520%2528CPT-11%2529%2520in%2520mice%26jtitle%3DAnticancer%2520Drugs%26date%3D1996%26volume%3D7%26spage%3D437%26epage%3D460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WXV" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2WXV','PDB','2WXV'); return false;">PDB: 2WXV</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i103"><a href="/doi/suppl/10.1021/jm901710h">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_71363"></div></div></div></div></div><hr /></hr><p class="last">X-ray crystallographic studies of compound <b>59</b>; Elemental analysis results of compounds <b>1</b>, <b>14</b>, <b>17</b>, <b>19</b>−<b>27</b>, <b>34</b>, <b>35</b>, <b>40</b>, <b>41</b>, <b>43</b>, <b>56</b>, and <b>59</b>. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm901710h/suppl_file/jm901710h_si_001.pdf">jm901710h_si_001.pdf (133.24 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm901710h&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm901710h%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2010.53.issue-5%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm901710h" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677b0a6f3f5222c0","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
